Complementary analyses in economic evaluation of health care by Koopmanschap, M.A. (Marc)
Complementary analyses in economic 
evaluation of health care 
Colophon 
Complementary analyses in economic evaluation of health care 
Marc Koopmanschap 
Key words: economic evaluation, cost of illness, indirect costs 
Photography: V. NykJ, A VC, Erasmus University Rotterdam 
Printer: Pasmans offsetdrukkerij B.V., Den Haag 
Layout: Angelique Visser 
Complementary analyses in economic 
evaluation of health care 
Complementaire analyses in economische 
evaluatie van de gezondheidszorg 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof. dr. P.W.C. Akkermans M. Lit. 
en volgens besluit van het College van Dekanen. 
De openbare verdediging zal plaatsvinden op 
woensdag 15 juni 1994 om 13.45 uur 
door 
Marcus Anthonius Koopmanschap 
geboren te Amsterdam 
Promotiecommissie 
Promotores 
Overige leden 
Prof. dr. F.F.H. Rutten 
Prof. dr. P.J. van der Maas 
Prof. dr. L.J. Gunning-Schepers 
Prof.dr. R. Leidl 
'Doubt is the beginning of wisdom, and complacency the major obstacle to 
change, so it is essential to keep exposing the inadequacies of the present 
situation' 
(Alan Williams. Priorities and research strategy in health economics for the 
1990s. Health Economics 1993;2:295-302.) 

Complementary analyses in economic evaluation of health care 
Contents 
1 Introduction 
Economic evaluation 
Level of aggregation 
Costs to be included 
Key questions 
Reading guidance 
Part I Detailed analysis 
2 
3 
Economic aspects of cervical cancer screening 
Summary 
Introduction 
Material and methods 
Results 
Sensitivity analysis 
Discussion 
Conclusions 
Cervical cancer screening: attendance and cost-effectiveness 
Summary 
Introduction 
Methods 
Results 
Discussion 
Conclusions 
Supplementary co=ent 
Part II Aggregate analysis 
4 Cost of disease in international perspective 
Su=ary 
Introduction 
Methods 
Results 
Discussion 
1 
1 
1 
4 
5 
7 
11 
11 
11 
12 
17 
22 
23 
24 
27 
27 
27 
28 
29 
40 
42 
44 
47 
47 
47 
48 
53 
62 
Complementary analyses in economic evaluation of health care 
5 Current and future costs of cancer 
Sununary 
Introduction 
Material and methods 
Results 
Discussion 
Pan III Indirect costs of disease 
6 Indirect costs in economic studies: confronting the confusion 
Sununary 
Introduction 
A literature review 
Some controversies 
Why and how to include indirect costs 
Indirect costs and health policy 
The agenda for futnre research 
7 Towards a new approach for estimating indirect costs of disease 
Sununary 
Introduction 
The concept of indirect costs 
Operationalisation 
Results 
Discussion 
Conclusion 
8 The friction cost method for measuring indirect costs of disease 
Sununary 
Introduction 
The friction cost method 
Operationalisation of concepts 
Data and methods for the Netherlands 
Results 
Discussion 
65 
65 
65 
66 
70 
77 
81 
81 
81 
83 
84 
85 
90 
90 
93 
93 
94 
94 
97 
101 
102 
103 
105 
105 
105 
106 
110 
113 
116 
121 
Complementary analyses in economic evaluation oj health care 
9 
10 
The impact of indirect costs on outcomes of 
health care programs 
Summary 
Introduction 
Methods 
Health care programs 
Results 
Analysis of impact of indirect costs 
Discussion 
Conclusions 
Detailed analysis 
Aggregate analysis 
Iodirect costs 
Literature 
Summary 
Samenvatting 
Appendices 
Acknowledgements 
Curriculum vitae 
125 
125 
125 
126 
128 
131 
134 
136 
139 
139 
140 
141 
145 
157 
161 
165 
Complementary analyses in economic evaluation oj health care 
Publications 
Chapters 2-9 are based on the following articles: 
Ch. 2 Economic aspects of cervical cancer screening. Koopmanschap MA, 
Lubbe, JThN, Oortmarssen van GJ, Agt van HME, BaUegooijen van 
M, Habbema IDF. Soc Sci Med 1990; 30: 1081-10871 
Ch. 3 Cervical cancer screening: attendance and cost-effectiveness. Koop-
manschap MA, Oortmarssen van GJ, Agt van HME, BaUegooijen van 
M, Habbema IDF, Lubbe JThN. Int J Cancer 1990; 45: 410-415.2 
Ch. 4 Cost of diseases in international perspective. Koopmanschap MA, 
Roijen L van, Bonneux L, Bonsel GJ, Rutten FFH, Maas PJ van der. 
EJPH (in press).' 
Ch. 5 Current and future costs of cancer. Koopmanschap MA, Roijen L van, 
Bonneux L, Barendregt JJ. Eur J Cancer 1994; 30A(1): 60-65.' 
Ch. 6 Indirect costs in economic studies: Confronting the confusion. Koop-
manschap MA and Rutten FFH. PharmacoEcon 1993; 4(6): 446-454." 
Ch. 7 Towards a new approach for estimating indirect costs of disease. 
Koopmanschap MA and van Ineveld BM. Soc Sci Med 1992; 34: 
1005-1010.' 
Ch. 8 The friction cost method for measuring indirect costs of disease. 
Koopmanschap MA, Rutten FFH, Ineveld BM van and Roijen L van. 
J Health Economics (in press).' 
Ch. 9 The impact of indirect costs on outcomes of health care programs. 
Koopmanschap MA and Rutten FFH (submitted). 
Reproduced with permission of ' Pergamon Press Ltd, 2 Wiley-Liss 
Division, 3 Oxford University Press, 4 Adis International and 5 Else-
vier Science Publishers. 
1 Introduction 
Econonllcevruuation 
The steady increase in health care costs and the continuous emergence of new 
medical technologies have forced policy makers in health care to reconsider 
the current resource allocation and to become more selective with investing in 
new health care programs. Economic evaluations can support the decision 
making process, by providing systematic information on the costs and the 
consequences for health of investing in alternative health care programs. 
Needless to say, economic evaluations of health care should be method-
ologically sound, the outcomes should be relevant for health policy and 
comparable to results of studies concerning other health care programs. With 
respect to the policy relevance it is important that the aggregation level of the 
analysis matches the specificity of the policy question: a study of costs and 
health effects of for example air pollution control will not need to be as 
detailed as an analysis of the cost-effectiveness of cimetidine versus surgery in 
peptic ulcer. 
Economic evaluations may never become entirely comparable, but 
incomparabilities due to different methodologies can be reduced considerably. 
This raises two questions: 
- what is the appropriate level of aggregation in the economic evaluation of 
health care? 
- which cost items are to be included in economic evaluations and how should 
these be measured and valued, in particular the indirect costs of disease? 
Level of aggregation 
In economic evaluation, health care is usually analyzed on one of the fOllow-
ing levels of aggregation: 
- a specific health care intervention or program: 'the detailed level'; 
- total health care, a specific sector of health care or a disease category: 'the 
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aggregate level'. 
Either level of analysis has advantages and limitations. The detailed 
analysis can provide a thorough and complete overview of the relevant aspects 
of a specific program. It is the appropriate level of analysis, if the policy 
decision is to choose among specific programs for a specific patient group. 
However, focusing on cost-effectiveness of individual programs bears the risk 
of overlooking interactions with other health care programs (Birch and Gafni, 
1992; Drummond et aI., 1993). A specific program may have a favourable 
balance of costs and health effects, if added to an already existing program 
which itself is not cost-effective. In case of end stage renal disease, the 
introduction of kidney transplantation involves cost savings as well as gains in 
length and quality of life. Candidates for kidney transplantation can only stay 
alive due to expensive facilities for haemodialysis (Rutten and van Hout, 
1991). The decision to adopt the transplantation program should be based on 
an economic appraisal of the combination of the two medical technologies as 
compared to the situation without both technologies. 
A second type of interaction is caused by common risk factors for 
different diseases. If the treatment of lung cancer would improve, thereby 
reducing lung cancer mortality, more smokers would stay alive, causing a 
more than proportional increase in prevalence and costs of cardiovascular 
disease and chronic lung disease. Another example of interaction is hormone 
suppletion for perimenopausal women in order to prevent osteoporosis, which 
may increase the prevalence of breast cancer, which in turn may improve the 
cost-effectiveness of breast cancer screening (Tosteson et aI., 1990). Hence, 
the neglect of possible interactions between health care programs may invoke 
non-optimal resource allocation. 
Furthermore, health care programs may influence the distribution of 
health (care). These equity consequences should preferably be considered in 
the context of all interventions for a specific disease or patient group, instead 
of being analyzed separately. The detailed type of analysis has a second, more 
practical limitation. It is simply not feasible to conduct economic evaluations 
of all existing and new health care programs within a reasonable time-span and 
research budget. As a consequence, existing health care programs are 
seldomly analyzed, so we lack information on costs and health effects of a 
substantial part of health care. 
It follows that somehow economic evaluation on a more aggregate level 
is needed to provide a consistent and complete overview of costs and health 
effects in health care. Such overview could serve as a starting point for more 
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detailed analysis in specific parts of health care that need closer investigation 
of costs and health effects. This aggregate approach also has some drawbacks. 
An estimate of costs and health effects of all interventions related to a certain 
disease always represents the combination of cost-effective and cost-ineffective 
programs. Withdrawing resources from specific subsectors or broad disease 
categories, based on unfavourable aggregate cost-effectiveness, may result in 
abolisbing or reducing specific cost-effective programs. In addition, the 
estimation of the effectiveness of a bundle of interventions directed to a 
disease is a formidable task since it requires knowledge about the health status 
of patients in the situation without the existing health care programs. 
The arguments above suggest that economic evaluation should be 
performed on both levels of analysis, as either provides relevant information 
for health policy. Economic evaluation on the detailed level is common -
practice in the form of cost-effectiveness analysis, cost-utility analysis and 
cost-benefit analysis. Thus far, aggregate economic evaluation is (usually) 
restricted to estimates of the current and future cost and morbidity and 
mortality of diseases, as we lack evidence on the total effectiveness of the 
programs involved. Shiell et al. argued that the relevance of such "cost of 
illness (or burden of illness) estimates" for allocation decisions is rather 
limited, because the costs of a disease may only represent the 'benefits of the 
unattainable': the savings as a result of eradicating that disease (Shiell et aI., 
1987). Furthermore, these cost of illness estimates do not take into account the 
costs of possible remaining comorbidity or the costs of competing diseases that 
will emerge after eradication of the specific disease studied. 
However, in the absence of reliable evidence on aggregate effective-
ness, information on costs and epidemiology can be incorporated in a disease 
model, in order to estimate future costs, morbidity and mortality of diseases. 
The disease model should contain the main elements of costs by disease phase 
or -stage. The model-based predictions can indicate the possible consequences 
of expected demographic, epidemiologic or technological scenarios. This type 
of scenario analysis is a form of partial economic evaluation that will not 
allow answering efficiency questions (Drummond et aI., 1987), but it may still 
serve several purposes. First, it may be relevant for planning the capacity of 
specific health care services. Second, it provides an estimate of the growth 
rate of health care costs if health policy remains unchanged, indicating the 
need for cost reduction or the room for extending health care. Third, 
modelling several diseases simultaneously, as described by Bonneux and 
Barendregt (1992), facilitates a correct estimation of the future medical 
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consumption of patients whose life has been extended (or its quality 
improved), due to an intervention, taking into account the possible higher risk 
for other diseases. 
In case of comorbidity, things become even more complicated, as cost 
of illness estimates generally (this thesis is no exception) assign all costs to the 
primary diagnosis, whereas part of these costs may be related to comorbidity. 
Further analysis of the magnitude of comorbidity costs, especially for elderly 
patients, is urgently needed. Detailed comparison of the costs for patient-
groups (age- and sex-specific) with the same primary diagnosis, with and 
without comorbidity, could shed more light on this matter. 
If estimates of effectiveness of bundles of interventions will become 
available, the disease model can also produce results on aggregate cost-
effectiveness. If the latter are unfavourable, it seems appropriate to conduct a 
critical analysis of the costs and health effects of the constituent interventions. 
As a matter of fact, application of cost-effectiveness as ouly criterium 
for evaluation of health care is not to be recommended, because eqnity and 
ethical considerations should also be taken into account. It is to be expected 
that for example care for mentally retarded, parts of nursing home care and 
palliative care for advanced cancer would not pass the pure cost-effectiveness 
test. However, a civilized society would not withhold its citizens such basic 
care, irrespective of its cost-effectiveness. 
Costs to be included 
The literature on economic evaluation distinguishes 4 types of costs with 
respect to health care programs: 
- direct medical costs (usually referred to as health care costs); 
- direct non-medical costs (e.g. patient's travel costs); 
- indirect medical costs (the costs of medical consumption during life-years 
saved as a result of an intervention); 
- indirect non-medical costs (the value of production loss and/or the extra costs 
to continue production, due to illness or its treatment). 
Health economists generally agree that the first and second type of costs 
should be included in economic evaluation. The issue of indirect medical costs 
will not be considered in this thesis, but authors tend to agree that inclusion of 
indirect medical costs depends on the specific research question. They may be 
not relevant for the costs and effects of a specific intervention (Drummond et 
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al .• 1987), but tbey should definitely be included in scenario-analysis, as tbey 
may represent an important part of tbe future costs of disease. 
At tbe moment, tbe relevance of tbe indirect non-medical costs (further 
referred to as indirect costs) is subject to considerable debate. The discussion 
relates to tbe issue whetber economic consequences of disease beyond tbe 
healtb care sector should have implications for healtb policy. Anotber import-
ant topic is tbe possible influence of including indirect costs on equity witb 
respect to employed and not employed citizens. 
If indirect costs are included in economic evaluation, tbe next question 
relates to tbe appropriate metbodology to estimate tbese costs. The basic idea 
as proposed in this tbesis is that indirect costs should represent tbe expected 
level of economic consequences in tbe real world, instead of estimating tbe 
potential consequences in a tbeoretical state of full employment equilibrium, 
according to tbe human capital approach. In tbis respect, tbree issues are 
crucial: tbe short term impact of absence from work on production and costs, 
tbe time-span during which production and costs are affected directly and tbe 
medium term macro-economic consequences of absence from work and 
disability. These issues will be discussed extensively in this tbesis. 
Key questions 
Summarizing tbe previous discussion, tbe following questions are to be 
answered in this tbesis: 
- What can be concluded for healtb policy from a detailed economic evaluation 
of an individual healtb care program, as illustrated by a cost-effectiveness 
analysis of cervical cancer screening? 
- What is tbe role of more aggregate economic evaluation of healtb care? To 
what extent may cost estimates, incorporated in disease models, permit 
conclusions on future costs and cost-effectiveness of healtb care? 
- What is tbe relevance of indirect non-medical costs of disease in economic 
evaluation? 
- If tbe indirect costs are important for healtb policy, how can reliable and 
realistic estimates of indirect costs be derived and what is tbeir impact on tbe 
results of economic evaluations of specific healtb care programs? 
Not all issues raised i.."1. this introduction are studied in this tbesis. For 
example, tbe problem of taking into account tbe costs of comorbidity and 
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estimates of cost-effectiveness of bundles of interventions will remain unsolved 
here. Table 1.1 gives an overview of the subjects analyzed in each part of this 
thesis: the detailed analysis (part I). the aggregate analysis (part m and the 
indirect costs of disease (part ill). 
Table 1.1 The consideration of issues in economic evaluation in this thesis. 
Issue Detailed analysis Aggregate Indirect non-medical 
(cervical cancer analysis costs of disease 
screening) 
Total current costs yes yes yes 
Total costs per patient yes Cancer: yes some diseases: yes 
Other dis.: no 
Future direct medical yes yes n.a. 
costs, dernographical 
scenario 
Future direct medical yes Colorectal ca: yes n.a. 
costs, epidemiological Other dis.: nO 
scenario 
Direct non-medical yes no n.a. 
costs 
Costs of comorbidity no no no 
Indirect costs of n.a. n.a. no 
unpaid work 
Efficiency of health yes no no 
care program 
(Cost)-effectiveness of yes no yes (theoretical 
health care program intervention) 
Competing mortality yes Cancer: yes no 
Other dis.: no 
Competing morbidity no no no 
n.a.: not applicable 
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Reading guidance 
In this thesis it will be suggested that both the detailed and the more aggregate 
level of analysis are useful in conducting economic evaluations of health care 
programs. 
In part I a detailed cost-effectiveness analysis of cervical cancer 
screening is performed. Chapter 2 focuses on the costs of screening and its 
impact on the costs of diagnosis and treatment, the selection of efficient 
screening policies and the diminishing returns of extending the screening 
program, whereas chapter 3 shows the role of the screening attendance rate 
for the cost-effectiveness of cervical cancer screening. 
Part II describes the aggregate point of view in economic evaluation. In 
chapter 4 total health care costs for the Netherlands in 1988 are estimated by 
disease category, age-group and sex and compared to results for Sweden and 
the United States of America. The estimated costs for 1988 are used to predict 
the cost consequences of ageing. For six types of cancer the aforementioned 
cost estimates are refined and assigned to disease phases in the cancer disease 
model, as described in chapter 5. The future costs of cancer are predicted for 
a demographical scenario and, in case of colorectal cancer, also for several 
epidemiological scenarios, involving expected trends in incidence and survival. 
The indirect costs of disease are discussed in part III. Chapter 6 
reviews the empirical literature on indirect costs of disease and discusses the 
main methodological issues at stake. The exact concept of indirect costs as 
used in this thesis is defined. It is argued that indirect costs should be included 
in economic evaluation, provided that the real amouut and value of the 
production lost andlor extra costs to continue production is to be estimated. A 
new concept for estimating the indirect costs of disease, the friction cost 
method, is introduced in chapter 7. This method. is developed further in 
chapter 8, paying attention to the relation between short term absence from 
work and labour productivity, the situation on the labour market and the 
macro-economic consequences of absence from work and disability. 
Chapter 9 describes the impact of including indirect costs, according to 
the friction cost method, on the results of several health care programs, 
including cervical cancer screening. The variation in impact of indirect costs 
across programs will be explained in terms of the type of health care program, 
the disease involved and the population aimed at. The conclusions are pres-
ented in chapter 10. 
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Part I Detailed Analysis 

2 Economic aspects of cervical cancer 
screening! 
Summary 
The results of a cost-effectiveness analysis of cervical cancer screening in the 
Netherlands are reported, emphasizing the analysis of the costs of screening 
and consequent diagnosis and treannent, Many organized screening policies 
are evaluated, differing in age-range and interval between screens, The cost 
estimates are based on organization cbarts, file smdies and tariffs, The costs of 
screening itself are by far the most important cost component, Screening 
increases the costs of diagnosis, Costs for primary treannent ouly rise for 
large screening policies, Screening causes savings in costs of terminal treat-
ment, but these are small compared with the costs of screening, The costs per 
life-year gained for the most efficient policies amount to Dfl 24,000 for the 
policy with 7 invitations per woman in a lifetime and rise considerably in case 
of more than 10 invitations. Cervical cancer screening appears to be less cost" 
effective than breast cancer screening, but compared with other services the 
results are comparatively good. Implementing one of the efficient organized 
screening policies and discouraging spontaneous screening beyond that 
schedule leads to considerable savings. Moreover, many organized policies 
which are not efficient are still superior to spontaneous screening. 
Introduction 
In the Netherlands 300 women per year die from cervical cancer, i.e. 0.5% of 
total female mortality. Symptoms of cervical cancer ouly occur when the 
cancer is already invasive. The pre-invasive stages of cervical cancer last on 
average about 15 years and can be detected by taking a Pap-smear. Almost 
100% of the women with early detected pre-invasive stages can be cured. 
1 Chapter based on Koopmanschap et aI., Soc Sci Med, 1990 
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A considerable part of the pre-invasive stages will not become invasive 
but will disappear (regress) spontaneously, especially in younger ages. Neither 
the smear nor further diagnosis can discern regressive from progressive pre-
invasive stages, so any screening policy inevitably causes diagnosis and 
treatment and costs for women who would never have developed invasive 
cervical cancer. 
Taking Pap-smears has proved to be effective from the medical point of 
view: it can reduce cervical cancer mortality (Day, 1984). Discussion remains 
about the best screening policy: At what ages should women be screened? 
What is the appropriate interval between successive screens? Should women be 
invited? Who must take the smears, specially trained women or general 
practitioners and gynaecologists? To answer these questions it is necessary to 
estimate both health effects and costs of all possible courses of action. Moreo-
ver, costs and health effects of screening for cervical cancer should be evalu-
ated in relation with other health services, given limited resources. 
The study on which this article has been based aims at detemtining 
which policies of cervical cancer screening in the Netherlands generate the 
best results in terms of health effects and costs. (Habbema et al., 1988). To 
this end a prospective cost-effectiveness analysis has been carried out in which 
epidemiological, medical and economic aspects were studied. This article 
describes the economic part and focuses on the following items: 
- the costs of screening itself for various policies; 
- the influence of screening on costs of diagnosis and treannent; 
- the cost-effectiveness of the most favourable policies, as compared with 
other health care services. 
Material and methods 
In general 
During the last decade in The Netherlands, as in many other countries, early 
detection of cervical cancer was achieved in two ways. A screening program 
was in operation for all women aged 35-54, who were invited at 3-year 
intervals. At the same time gynaecologists and general practitioners have taken 
many smears, especially from younger women, without fixed intervals. As a 
result many women were screened very often. The efficiency of this combina-
tion of organized and spontaneous screening has been questioned. 
In order to make recommendations about age-groups and intervals it is 
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necessary to estimate costs and health effects of strategies in which only 
"organized" screening is performed. This means that women are invited 
regularly. The screening is performed exclusively by trained female personnel. 
No further smears are taken. To estimate the impact of "organization". costs 
and effects were also calculated for cases in which only spontaneous screening 
was performed. Early detection was carried out by general practitioners and 
gynaecologists only. according to the distribution and frequency of smears as 
observed in The Netherlands during 1985-1987. 
With respect to organized screening, cost and health effects were 
calculated for about 100 policies. The number of invitations per woman varied 
between 3 and 25, the interval between two invitations ranged from 15 to 2 
years. The age-group invited varied, between the ages of 20 and 75. The 
results were compared with the estimated costs and effects for the (hypotheti-
cal) situation where no early detection takes place: the zero-option. 
A model for cervical cancer and the impact of screening on morbidity 
and mortality was developed. The micro-simulation program MISCAN was 
used to calculate screening results and the effects of screening (Habberna et 
al., 1984 and 1987). First, the model was fitted to data from the three Dutch 
pilot regions where organized screening took place during 1976-1984. Model 
assumptions about sensitivity of the Pap-smear and regression and duration of 
the pre-invasive disease stages were derived which offered a satisfactory fit 
with data concerning screen detected pre-invasive and invasive cases, interval 
cancers and mortality. 
Next, the model was used to predict the health effects and costs of the 
policies. Data for the assumptions concerning organization and costs were 
collected by numerous interviews and analysis of cost accounts. They were 
integrated into the model by combining the predicted numbers of screens and 
the impact on diagnosis and treatment with the relevant cost-estimates. 
The most important health effect of cervical cancer screening is the 
reduction in mortality, expressed in the number of life-years gained compared 
with the zero-option. From the total set of policies those with a maximum of 
life-years gained for a given level of costs were identified as efficient policies. 
Figure 2.1 shows the incremental costs and the life-years gained for all 
simulated policies. The marked points indicate efficient policies. The upper-
left quadrant of these points is empty with neither policies producing more 
life-years gained for the same costs nor policies saving more life-years less 
expensively. 
In the rest of this chapter results will only be presented for a limited 
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number of efficient organized screening policies and one variant of spontane-
ous screening. 
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Incremental social costs and life-years gained for about 100 different orgarllzed 
cervical cancer screening policies. Screening during 1988-2015. Discount rate 5%. 
The marked points indicate the subset of efficient policies. 
Cost calculations 
All possible costs and savings that screening policies bring about were 
identified and measured, taking the concept of social costs as point of departu-
re. This included non-financial costs and costs which do not fall upon the 
medical sector, but excluded value added tax. The costs of screening itself 
were derived by estimating the quantities and costs of each input of the screen-
ing program. This resulted in cost functions reflecting the influence of fixed 
and variable costs and economies of scale. 
The costs of diagnosis and treatment have been approximated by the 
tariffs charged (1987) in The Netherlands. An analysis of the true resource 
costs was beyond the scope of this study. For each policy MISCAN calculated 
for each year the number of women invited, the number of women screened 
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and the number of women needing diagnosis and/or therapy in various 
degrees. These outcomes combined with the cost functions and tariffs produ-
ced the annual costs. 
Only after a considerable period the health effects of screening on 
cervical cancer become visible while the costs of screening are important from 
the start. To permit adequate evaluation, the screening program was assumed 
to be in operation during 1988-2015. After the year 2015, the terminated 
program will still cause health effects and changes in costs of diagnosis and 
treatment; these were calculated until 2088. Costs and effects were discounted 
to present values for 1988 with a discount rate of 5 %, stipulated by the Dutch 
gove=ent (Klaassen, 1985) and several health economists (Russell, 1987). 
The estimated annual financial costs for gove=ent and insurers, including 
value added tax, will be presented too. 
A fraction of the women screened has a suspicious smear, leading to 
diagnosis and, if necessary, treatment. Therefore three categories of costs are 
relevant: costs for screening, diagnosis and treatment. 
Costs of screening 
The organization of the cervical mass screening in the three Dutch pilot re-
gions and expert opinions about future developments were used to draw the 
outline of an efficient nationwide organization. This outline is only a tool to 
assess all relevant costs. The activities are carried out at three levels: local, 
regional and national. 
Local level 
Each municipality sent a first invitation to the women in turn, by means of the 
up to date population registry. The women were screened in their municipality 
by a team of three trained smear-takers. The yearly capacity per team ranged 
from 19,000 (mobile unit) to 20,000 (static centre) smears. For a static centre 
the material costs are relatively low; use of a mobile unit increases the cost of 
taking smears by at least 25 %. The number of static and mobile units depends 
on the population density and the number of women screened. The time and 
travel costs of the women attending were relevant social costs (see table 2.2). 
The average time for travelling and screening was estimated at 50 min and 
was valued by 25 % of the average net labour income per labour hour per 
household, according to binding advices (COBA, 1975). Travel costs were es-
timated on the basis of public transport tariffs. 
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Regional level 
With respect to cancer prevention The Netherlands was divided ioto 9 regions, 
each with on average about 800,000 female iohabitants. One coordioation 
centre per region managed the screeniog teams, took care of local publicity 
and informed municipalities about the iovitations. The centre sent test results 
to all women participatiog and re-iovited non-participants. In cooperation with 
the cytological laboratory, quality control of the smears and traioiog of the 
smear-takers was carried out. The centre was staffed by a manager, a medical 
consultant and administrative personnel. The workload and the costs varied 
accordiog to the size of the program. 
The cytological laboratory evaluated the smears and registered the test 
results io a local data-base connected to a national data-base. On average, full 
time analysts evaluated approx. 7,200 smears annually. Per 50,000 smears one 
senior analyst, one pathologist and two admioistrative employees are needed. 
Economies of scale existed for the costs of supervisiog and administrative 
personnel and part of the material costs. 
National level 
One centre took care of the national coordioation and public relations. Usiog 
regional reports the policy was monitored and adapted if necessary. These 
costs were not related to the program size. The costs of registration consisted 
of costs for the national database, costs of traioiog the laboratory personnel 
and costs of local computer facilities. The national data-base also registered 
results of other pathological examioations, so these costs are only partially 
iocluded. 
Spontaneous screening 
This type of screeniog iocurred no costs of coordination and iovitation. To 
estimate the costs of smear-takiog, we assumed that all smears were taken by 
general practitioners and calculated the labour costs of the general practitioner, 
the assistant and the material costs. Although this resulted io underestimatiog 
the costs sioce gynaecologists also took many smears which are more expensi-
ve, on the other hand, duriog a visit other medical activities may be performed 
as well, so only part of the costs should be atrributed to the smear. 
Costs of diagnosis and treatment 
There are two situations where diagnOSis and treatment take place: after an 
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abnormal preventative smear or in case of possible symptoms of cervical 
cancer. In tbe zero-option, witbout any early detection, costs of diagnosis and 
treatment are only important for women witb symptoms. In our study a detai-
led scheme was constructed to determine which diagnostic and tberapeutic 
procedures took place for woman having a suspicious smear. This scheme is 
subdivided by stage of disease and enabled us to calculate changes in number 
and types of procedures and costs when tbe stage-distribution of diagnosed 
(pre)-cancers alters due to screening. For more details see Ballegooijeu 
(1988). 
Table 2.1 Financial costs of screening per year for organized screening 
policies witb 250,000 and 1,000,000 smears per year and sponta-
neous screening, in millions Dfl. (including 4 % repeated smears, 
attendance rate: 65 %) 
Organized policies Spontaneous 
Smears per year (x 1,000) 250 (%) 1,000 (%) 910 (%) 
Coordination 3.4 (24) 4.3 (10) 
Invitations and results 1.1 (8) 4.4 (10) 1.2 (3) 
Smear taking 3.5 (24) 13.3 (31) 14.3 (40) 
Cytological evaluation 5.6 (39) 19.2 (45) 18.4 (52) 
Registration 0.8 (6) 1.5 (4) 1.7 (5) 
Total costs of screening 14.4 (100) 42.7 (100) 35.6 (100) 
Per smear (in guilders) 58.0 43.0 39.0 
Results 
Costs of screening 
In table 2.1 tbe annual financial costs of screening are summarized for two 
different sizes of policies. Table 2.2 shows tbe present value of tbe social 
costs of policies, operational during 1988-2015, taking into account tbe demo-
graphic scenario. The results in tables 2.1 and 2.2 include tbe costs of 4% 
repeat smears taken because of insufficient quality of tbe fIrst smear. The 
average attendance rate assumed is 65 %, as observed in tbe pilot regions. The 
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total financial costs per smear range from Dfl. 58 for 250,000 annual smears 
to Dfl. 43 for 1,000,000 smears per year. The economies of scale are conside-
rable, chiefly because the costs for coordination and registration are almost 
fixed. The costs of coordination, registration and sending of invitations and 
test results form a substantial part of the total screening costs (15-30%), 
whatever the size of the policy. The "medical activities" smear-taking and 
cytological evaluation make up 60-75 % of the total costs. Time and travel 
costs account for 10 % of the social costs of the screening (see table 2.2). 
The last column in tables 2.1 and 2.2 indicates the costs of spontaneous 
screening on a scale of approx. 910,000 smears per year resembling the 
situation in the Netherlands during 1985-1987. The costs per smear are 
relatively low, the total costs of the spontaneous screening are considerable, 
due to the large number of smears. 
Table 2.2 Present value for 1988 of social costs of screening for three effi-
cient policies and spontaneous screening during 1988-2015 in 
millions Dfl. Discount rate: 5% (Including 4% repeat smears, 
attendance rate: 65%). Invitation schedule: number of invitati-
ons/age-range/interval. 
Efficient policies Spontaneous 
screening 
Invitation schedule 7/37-73/6 10/27-72/5 16/26-74/3 
Average number of 390 610 975 910 
smears (x 1000) 
Coordination 63 67 75 
Invitation and results 23 35 56 18 
Smear taking 77 118 187 204 
Cytological evaluation 120 179 280 270 
Registration 13 16 20 23 
Time and travel costs 29 45 72 63 
Total costs of 325 461 691 578 
screening 
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Costs of diagnosis and treatment 
The costs of diagnosis and treatment were computed by combiniog the relevant 
number of women with the schemes for diagnosis and treatment and the tariffs 
charged. Fignre 2.2 depicts the extra costs and savings for diagnosis and treat-
ment induced by two different organized screening policies, compared with the 
zero-option. The data are not discounted (table 2.3 will show discounted 
costs). 
Positive smears induce costs for diagnosis (DS). The more screening, 
the more positive test results, the higher the costs of diagnosis. Due to 
screening the number of women with symptoms diminishes, causing a small 
saving (DC). Screening increases the number of women with diagnosed pre-
cancers, which incurs costs for primary treatment (PTS). These costs consist 
of two parts: costs for women detected by screening, who would develop 
invasive cancer without screening and costs for women with regressive lesions 
which never would become invasive. The prevention of invasive cancers 
permits substantial savings on primary treatment (PTC). With more intensive 
screening savings (PTC) rise, but the increase of the extra costs (PTS) is even 
sharper, since the proportion of regressive lesions increases. The reduction of 
invasive cancers causes a decrease in mortality. The savings on terminal treat-
ment (TT) increase gradually with more intensive screening. 
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Figure 2.2 
P" 
InVitatIons 
Extra social costs and savings for diagnosis and treatment compared with no early 
detection. for two efficient policies. in millions Dfl. No discounting. 
ds = extra costs of diagnosis induced by screening; dc = savings in costs of 
diagnosis; pts = extra costs of primary treatment induced by screening 
ptc = savings in costs of primary treatment; tt = savings in terminal treatment 
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The savings induced by screening lag behind the extra costs. Discount-
ing gives the results shown in table 2.3. The discounted costs of diagnosis 
increase, particularly with more intensive screening. Screening with 7 invita-
tions leaves the costs of primary treatment on balance unaltered. Intensifying 
screening means that the extra costs of primary treatment outweigh the savings 
at an increasing rate. Terrninal treatment still produces savings, although 
discounting diminishes the absolute level. Spontaneous screening generates a 
high level of costs for primary treatment but this does not produce large 
savings on terrninal treatment because the mortality reduction is relatively 
small. 
Table 2.3 
Costs 
Screening 
Diagnosis 
Present value for 1988 of social costs of screening, diagnosis, 
treatment and incremental costs for three efficient policies, 
spontaneous screening and no early detection in millions Dfl. 
Period 1988-2088. Discount rate: 5%. 
Efficient policies 
Invitations 7 10 16 Spontaneous No early 
screening detection 
325 461 691 578 a 
27 39 54 47 7 
Primary treatment 165 182 192 200 163 
Tenninal treatment 78 73 68 84 101 
Total costs 595 754 1,005 909 271 
Total incremental costs 324 483 735 638 
Total costs 
The costs of screening are by far the most important part of the total costs, 
especially for more intensive screening programmes. Costs of diagnosis and 
treatment are relatively small. Savings are to be expected on tertninal treat-
ment, but they are rather modest. The total incremental costs compared with 
the zero-option range from Dfl 324 million in case of 7 invitations per woman 
to Dfl 735 million if woman are invited 16 times. The incremental costs of 
spontaneous screening exceeds Dfl 600 million. 
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Cost-effectiveness 
The cost-effectiveness of the policies is expressed as the incremental social 
costs per life-year gained. Table 2.4 shows the results for three efficient or-
ganized screening policies and one level of spontaneous screening. The 
additional health effects of intensifying a screening policy are diminishing 
rapidly. An increase from 7 to 10 invitations per woman results in an additio-
nal number of 3.900 life-years gained, as an increase from 10 to 16 invitations 
ouly saves 2,900 life-years extra. 
Table 2.4 Present values for 1988 of incremental social costs, life years 
gained and cost-effectiveness of three efficient screening policies 
and spontaneous screening. All outcomes are compared with the 
zero-option. Discount rate 5 %. 
Efficient policies 
Invitations 7 10 16 Spontaneous 
screening 
Incremental social costs (millions Dfl) 324 483 735 638 
Life years gained (x 1000) 13.3 17.2 20.1 13.4 
Costs per life-year gained (x 1000 DIl) 24.3 28.0 36.5 47.6 
Marginal costs/life-year gained (x 1000 DIl) 24.3 40.8 86.9 
The incremental costs rise faster, more or less proportional to the 
number of invitations. Consequently the incremental costs per life-year gained 
increase if screening is intensified. The efficient policy with 7 invitations per 
woman costs about 24,000 guilders per life-year gained. For the policy with 
10 invitations the costs amount to 28,000 guilders. For policies with more than 
10 invitations the cost-effectiveness deteriorates rapidly. 
Spontaneous screening on a scale reflecting recent Dutch practice 
generates a number of life-years gained equal to the efficient policy with 7 
invitations, but the social costs are twice as high. When spontaneous screening 
takes place data indicate that pan of the women, especially younger women, is 
screened very frequently (yearly) whereas the rest of the women only rarely 
has a screen and hence the health effects are limited. If no spontaneous 
screening is perfonned and the efficient policy with 7 invitations were to 
implemented 20 millions guilders per year (finanCial costs) could be saved. 
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For a comparison of the efficient policies as well as for comparison 
with other health interventions, the marginal cost-effectiveness is important, 
Table 2.4 shows that extra costs per extra life-year gained rise rapidly when 
switching from 7 to 10 invitations. Further intensifying the policy yields a 
considerable increase in marginal cost-effectiveness. 
To ensure a rational health services budget, cost-effectiveness should be 
compared with other services. A recent Dutch study of breast cancer screening 
using the same methodological assumptions (Maas et al., 1989) reported that 
breast cancer screening with 10 invitations per woman cost Dfl. 9,700 per life-
year gained. Further extension to 15 invitations costs Dfl. 25,800 per extra 
life-year gained. For the same number of invitations cervical cancer screening 
appears to be less attractive. Comparison with other health care services is 
difficult because of methodological differences between analyses. However, in 
Torrance's widely cited table of cost-effectiveness ratio's (Torrance, 1986) the 
efficient policies of cervical cancer screening with 7 or 10 invitations have an 
intermediate cost-effectiveness ratio. 
Sensitivity anaJ.ysis 
Cytological evaluation 
On the basis of our recently collected data a workload of 7,200 smears per 
analyst per year has been estimated. Assuming that the cytology is regionally 
concentrated so that expertise can attain a sufficient level, our preliminary 
view is that 7,200 is a reasonable workload. 
However, Dutch pathologists recently agreed (Vooijs, 1987) that if 85% 
of the smears are preventive (15 % of the smears are from women with symp-
toms) the optimal workload to aim for is 5,000 smears. With 100% preventati-
ve smears the workload will then be about 5,500 smears. The costs of cytolo-
gical evaluation would increase 15 %, total costs of screening and the costs per 
life-year gained would rise 6%, compared with the results presented. This 
workload forms the subject of a future study. 
Discount rate 
Results were also calculated using discount rates of 0 and 7%. Table 2.5 
shows that discounting at a rate of 7 % implies that the number of discounted 
life-years gained is ouly 12 % of the amount without discounting, whereas the 
incremental costs are still 54% of the amount without discounting. This 
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confirms the importance of using a uniform discount rate in cost-effectiveness 
analyses. 
Table 2.5 Influence of the discount rate on social costs, health effects and 
cost-effectiveness for the efficient policy with 7 invitations. The 
percentages compared with no discounting are in parentheses. 
Incremental costs (millions Dfl) 
Life-years gained 
Costs per life-year gained 
Discussion 
Quality of life 
Discount rate 
0% 5% 
5!0 (100%) 324 (64%) 
68,300 (100%) 13,300 (28%) 
7.500 (100%) 24,300 (342%) 
7% 
277 (54%) 
7.900 (12%) 
35,000 (467%) 
Comparison of cervical cancer screening with other health care services should 
be based on costs per quality of life-year gained. Our study did not produce 
QAL Y-estimates, but two extreme variants were calculated to indicate the 
possible impact of quality adjustments. In the "weak variant" the quality of life 
reductions for Invasive cancer or being treated by hysterectomy or radiothe-
rapy are assumed to be modest. In the "strong variant" these reductions are 
greater and they are also applied to larger groups of women in less severe cir-
cumstances, like women with false-positive smears (Habbema et aI., 1988). 
For the efficient policy with 7 invitations the weak variant produces 
slightly more QAL Y's gained than without adjustment. The strong variant 
results in about 25 % less QALY's. We expect that empirical research will 
produce estimates between these two extremes. 
Other studies 
Comparison with other studies of cervical cancer screening is difficult for 
three reasons. First, the number of serious cost-effectiveness analyses on this 
subject is very limited. Second, some of them deal with the epidemiology in 
detail but use ouly superficial economic assumptions (parkin and Moss, 1986). 
Third, the ouly detailed study of economic aspects (Luce, 1981) focused on 
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screening in a clinical setting which is different from a mass screening program-
with respect to organization and costs. 
Organized and spontaneous screening 
In the Netherlands, as in many other countries a combination of organized and 
spontaneous screening existed in the past and will probably continue in the 
future. The results of some of these combinations were calculated. They incur 
high costs for an intermediate level of health effects, because some women are 
screened in both contexts. 
Screening in the future 
In the Netherlands the organized screening program terminated in 1984 was 
resumed in 1989. Women are invited from age 35 up to age 53 with a 3-year 
interval, this in spite of our fmdings that such a schedule is not efficient (in 
the efficient policies screening is performed up to 70 years). The costs per 
life-year gaIned amount to Dfl 36,400, assuming the organization described in 
this paper. However, in the new setting the general practitioners take the 
smears; the rest of the organization is not yet entirely established. Our 
preliminary research indicates that if the coordination of the activities of 6,000 
general practitioners and quality control is performed seriously the costs will 
not be much lower than reported here. The level of health effects is very 
uncertain, because the attendance rate and the quality of the smears in the new 
setting remain unknown. 
Our fmdings did not result immediately in any policy change. The 
govermnent department of health care has maintained its' old policy for 
organizational reasons. Further study of the effectiveness of screening in 
women older than age 55 will be carried out, which may influence the policy 
in the near future. 
Conclusions 
A large part of the costs of cervical cancer screening programs consist of the 
costs of screening itself. Screening enlarges the costs of diagnosis. Costs of 
primary treatment remaIn unaltered for efficient policies with 10 or less invita-
tions, but increase in case of more invitations. Costs of termInal treatment 
decline. 
The incremental costs per life-year gaIned are about 24,000 guilders for 
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the efficient policy with 7 invitations and increases to 36,000 in case of 16 
invitations per woman. The substantial influence of the discount rate on the 
cost-effectiveness confirms the need of uniform methodology. 
Cervical cancer screening is less cost-effective than breast cancer 
screening on the same scale. Compared with other health care services the 
efficient policies with 7 or 10 invitations are cost-effective. For the same 
amount of cost, organized screening programmes are always superior to 
spontaneous screening. Discouraging spontaneous screening in The Nether-
lands and replacing it by efficient policy with 7 invitations per woman can 
save over 20 million guilders (financial costs) per year, without any rise in 
cervical cancer mortality. The Dutch public health insurance funds are trying 
to restrict the spontaneous screening, except for situations in which women 
have possible cervical cancer-related symptoms, a small minority of the cases. 
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3 Cervical cancer screening: 
attendance and cost-effectiveness! 
Summary 
The influence of attendance on the health effects and cost-effectiveness of 
cervical-cancer screening is studied both for organized screening programmes 
and for spontaneous screening. The asymmetric distribution of smears among 
the female population and the higher risk incurred by women who never or 
only occasionally attend screening appear crucial in determining the health 
effects of screening. An increase in attendance rate induces a substantial rise 
in health effects and a less than proportionate rise in costs, thus improving 
cost-effectiveness. Wider screening coverage, in order to increase the number 
of life-years saved, is achieved more efficiently by encouraging a greater 
number of women to attend than by inviting the same number of women to 
attend more often, Le. with a shorter interval between successive screens. 
Spontaneous screening is cbaracterized by high coverage for younger women 
and low coverage for middle-aged and older women. This leads to a small 
amount of health effects and poor cost-effectiveness as compared with organi-
zed screening. 
Introduction 
Screening for cervical cancer has been performed in several countries with 
varying success (Hakama, 1986; Laara et al, 1987). This stresses the need for 
evaluation of screening policies with respect to health effects and costs. The 
level of attendance of women is the major determinant of the cost-effectiveness 
cervical-cancer screening policies (Habbema et al, 1988; Koopmanschap et aI, 
1989). Therefore, the following aspects are considered: 
- determining the level of attendance. The impact of elements of the screening 
organisation on the level of attendance will be analyzed. 
1 Chapter based on Koopmanschap e! al., In! J Cancer, 1990 
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- relating attendance, health effects and costs. Special attention will be paid to 
the distribution of smears among women and to the differences in risk between 
attenders and non-attenders. 
- implications for health policy. Two different ways to increase the screening 
coverage, namely, increasing the number of women attending and increasing 
the frequency of screening, will be evaluated in relation to additional health 
effects and extra costs. 
The argument will concentrate on organized screening programmes, 
under which women are invited for screening by specially trained personnel at 
certain ages and at predetermined intervals. The findings for such programmes 
will be compared with the coverage, health effects and costs for ' spontaneous' 
screening, which is performed only when requested by the woman concerned. 
Methods 
The term 'attendance rate' applies to organized screening. It is the percentage 
of women invited to undergo screening, who respond to the invitation. The 
term coverage is more generally applicable, denoting the percentage of women 
screened at least once during a certain period. In the case of organized 
screening~ the coverage rate reflects the reach of screening over one or several 
invitation rounds. Coverage can be calculated whether spontaneous screening 
is performed exclusively or in combination with organized screening. The 
latter situation is co=on practice in many countries. 
A study of health effects and costs 
Health effects and costs were predicted for 3 screening settings in the Nether-
lands, each in operation for the period 1988-2015: organized screening only, 
spontaneous screening only and the combination of organized and spontaneous 
screening (Habbema et al, 1988; Koopmanschap et al, 1990). The health 
effects and changes in treatment costs resulting from screening and becoming 
manifest in part after termination of the screening have also been taken into 
account. The computer simnlation program MISCAN was used for the 
calculations, which were based on a model for cervical cancer and the effects 
of screening (Habbema et al, 1984). The program gives the results of scree-
ning policies in terms of numbers of screen-detected pre-invasive and invasive 
cancers, interval cancers, incidence in non-attenders and reduction in mor-
tality. Influence of age-specific incidence, length of pre-invasive stages, 
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regression, sensitivity of the smear and the stage-specific survival are incorpo-
rated, 
The model was constructed on the basis of data from British Columbia, 
Canada (spontaneous screening) and from the Netherlands, where organized 
screening was performed in a pilot study in 3 regions (Nijmegen, Utrecht and 
Rotterdam) between 1976 and 1984 (EVAC, 1987; Boyes et al, 1982). In the 
Netherlands, women aged 35 to 53 were invited at 3-year intervals; the 
average rate of attendance was 65% (BVAC, 1987). 
Additional research was carried out to estimate the costs of screening 
and subsequent diagnosis and treattnent. This made it possible to simulate the 
total health effects and costs of about 100 screening policies. These policies 
differ in the number of invitations per woman in a lifetime (3-25), the length 
of the interval (2-15 years) and the age-group invited (always within the range 
20-75 years). 
The cost-effectiveness of the simulated policies is expressed as the 
incremental cost per life-year gained, compared with the (hypothetical) 
situation in which there is no early detection of cervical cancer. Policies 
producing the greatest number of life-years gained for a given level of costs 
(efficient policies) have been identified (Habbema et al, 1988). The results for 
different levels of attendance for 2 efficient policies will be presented. The 
conclusions are valid for all efficient policies. With respect to the health 
effects, ouly the number of life-years gained by screening will be shown. 
Taking the other health effects into consideration does not substantially alter 
the conclusions, which are presented elsewhere (Habbema et ai, 1988). 
Results 
The most important determinants of attendance are first discussed and, 
wherever possible, their influence is quantified. The link between attendance 
and both health effects and costs is then presented. 
DetermilUIJ7.ts of attendance 
Age-group screened 
In the Dutch pilot projects of cervical-cancer screening, the attendance rate of 
women aged 34 to 36 was 10% higher than for women aged 52 to 53 (BV AC, 
1987). All programmes of organized screening in other countries repon 
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highest attendance rates for women aged 30 to 49 and slightly lower rates for 
age 20 to 29 (Evans et ai, 1980; Berrino et ai, 1979: Magnus et ai, 1987; 
Johanuesson et ai, 1982; MacGregor et ai, 1986). With increasing age, 
attendance declines; at age 50 to 59 the rate is about 10-15% lower than at age 
30 to 49 and at age 60 to 69 the attendance is about 30% lower. For breast-
cancer screening, a similar relation between age and attendance has been 
reported (Verbeek, 1985). 
Socio-economic status 
In the Dutch pilot projects, a lower attendance rate was found for women with 
the lowest as well as the highest socio-economic status (Jansen and Kremers, 
1985). The latter group compensated by having spontaneous screens more 
often. Data from other countries also indicate lower coverage for women of 
lower socio-economic status (Evans et ai, 1980; Armstrong et ai, 1986; 
Ebeling and Nischan, 1986; Kleinman and Kopstein, 1981). For the UK Evans 
reported 30% difference in attendance between the highest and lowest status 
group. 
Marital status 
The Dutch projects reported a 15% lower than average attendance rate for 
unmarried and divorced women (EV AC, 1987). Data from other European 
countries show that the attendance of married women is about 10 % higher 
than that of unmarried women (Evans et ai, 1980; Berrino et ai, 1979; Ebeling 
and Nischan, 1986). 
Publicity 
In the Dutch pilot region Nijmegen the influence of publicity on attendance 
was investigated. In some municipalities, publicity in the form of descriptive 
brochures, newspaper articles and information meetings had a positive but 
statistically not significant influence. In other municipalities the influence was 
significant but the difference in publicity was confounded with other differen-
ces between municipalities (Emanuel-Viok and Tax, 1979). Women with lower 
socio-economic status respond more frequently to personal contact, whereas 
women with higher socio-economic status mostly acquire their information 
from letters and mass media (Wakefield, 1976). 
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Invitation system 
In the Dutch pilot projects, an up-to-date population registry in each municipa-
lity enabled selection and invitation of the eligible women, The invitation 
included an appointment for screening, This first invitation resulted in 60% 
attendance, A reminder yielded about 5 % extra attenders, total attendance thus 
being on average 65% (EVAC, 1987), In the UK, the lack of an accurate and 
complete population registry would help to explain the low coverage (Elkind et 
ai, 1987; Draper, 1982). 
Almost all examples of successful screening policies (successful with 
respect to participation and health effects) use invitation systems based on 
population registries (Magnus et ai, 1987; Johannesson et ai, 1982; Hakulinen 
and Hakama, 1985; Berget, 1979). The absence of a registry or invitations 
appears to be closely correlated with low coverage (parkin et ai, 1982; 
Olesen, 1986). One exception is the British Columbia project (Anderson et ai, 
1988). 
Few studies analyze systematically the influence of the invitation system 
on attendance. An invitation system with appointment induces an absolute 
increase of 15 % in the attendance rate as compared with invitations making 
women responsible for arranging time and place of screening (Wilson, 1987). 
Results from several countries and the Dutch breast cancer screening program 
indicate that a reminder can increase attendance by 5-10% (absolute increase) 
(Berrino et ai, 1979; Verbeek, 1985; Wilson, 1987; Sansom et ai, 1975). 
Travel distance and contribution in costs 
In the Dutch projects the average travel distance for the women was less than 
5 km, due to the use of stationary and mobile screening units. In the UK and 
Italy, attendance appears to be higher if (semi-) mobile screening units are 
used to shorten the travel distance (Berrino et ai, 1979; Brindle et ai, 1976). A 
study of breast cancer screening with mobile units in Scotland revealed a 
significant relation between travel distance and attendance rate (Henderson et 
ai, 1988). 
In the Dutch projects until 1984 women paid a small part of the scree-
ning costs. This did not appear to influence attendance. Between 1985 and 
1987 the contribution in costs increased substantially and attendance fell, 
indicating that charging substantial contributions may impede attendance. Data 
from abroad are scarce, but it is remarkable that screening in Sweden and 
Finland combines high attendance with the absence of cost contributions 
(Hakulinen and Hakama, 1985; Kjellgren, 1986). 
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Assumptions used for aJtendance 
The calculations are based on the observed attendance patterns in the Dutch 
pilot projects. Facilities such as an invitation system based on population 
registries including reminder. mobile screening units and publicity were 
considered indispensable to attain 65 % attendance. Therefore, the costs of 
these facilities were taken into account. 
For the relation between age and attendance we assumed a 65 % atten-
dance rate up to age 50, gradually decreasing to 60% at age 60, 55% at age 
70 and 40 % at age 75. The influence of socio-economic stams on attendance 
has not been explicitly modelled, but is taken into account by the relation 
between attendance and risk (see below). The influence of marital stams has 
not been used. 
Attendance and health effects 
The health effects of screening will be presented for three situations. First, 
attendance is assumed to depend on age and on the screening organisation 
ouly. Subsequently, the pattern of individual attendance is brought in. Finally 
the relation between attendance and risk will be added. 
Age 
In figure 3.1, the upper, dotted lines represent the health effects for two 
screening policies when ouly the relation between age and attendance is taken 
into account. Next to 65 % attendance, the health effects are depicted for 40 % 
and 75% average attendance. These results are too optimistic however, 
because taking into account the individual attendance and risk will result in 
lower health effects. 
Individual attendance pattern 
If all women invited had the same probability of attending at each screening 
round, the number of smears would be equally distributed over the women. 
However, in the Dutch projects, women who had attended the previous 
screening had a 50 % higher probability of attending the current screening than 
women who had not (Jausen and Kremers, 1985). Moreover, 10% of the 
women invited did not attend any screening. In Demnark, the same attendance 
pattern was observed: a difference in attendance of 61 %, and again 10% of 
the women never attending (Berget, 1979). The same attendance pattern was 
found for breast-cancer screening in the USA, and in the Nijmegen region of 
the Netherlands (Verbeek, 1985; Habbema et ai, 1983). 
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Figure 3.1 
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Number of smears and life-years gained by screening in the Netherlands during 
1988-2015, for three attendance rates (40%. 65%. 75%) discount rate: 5%. Results 
for two organized policies: I: 7 invitations between age 37 and 73. interval 6 years. 
II: 16 invitations between age 28 and 72, interval 3 years. 
Factors taken into account when estimating the health effects (see text): 
6 ..... 0 : age only 
0----0 : age and attendance pattern 
+-------+ : age, attendance pattern and risk differences 
The following assumption was used: irrespective of the average atten-
dance, women who attended the previous screening have a 50% higher atten-
dance probability than women who did not. Ten percent of the women never 
attend screening. Consequently, some of the women will be screened very 
regularly, some only occasionally, while others will never be screened. The 
more frequently a woman is screened, the lower the extra health effects of 
each additional screen. 
Therefore, the more unequal the distribution of a certain number of 
smears over the women invited, the lower the aggregate health effects of 
screening. The middle, dashed lines in figure 3.1 depict the health effects 
resulting from adding this assumption. Compared with the outcomes for 
uniformly distributed attendance, health effects are between 2 and 10% lower. 
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Attendance and risk 
Consensus exists that, controlling for age, risks of cervical cancer are unequal-
ly distributed. For example, on average, women with lower socio-economic 
status have a higher risk. 
Data from British Columbia indicate that the incidence of cervical 
cancer in women who never attend screening is higher than in the total 
population (Boyes et al, 1982). Analysis of the Dutch data appears to confirm 
this hypothesis (Habbema et al, 1988). 
In the three Dutch pilot regions, the cytological detection rate of CIN 
II + was about 50% higher for women attending the screening after a reminder 
compared with women attending after the first invitation (EVAC, 1987). The 
difference is highly significant (p<O.OOl). Data from Demnark and Norway 
support the assumption that non-attenders have higher incidence and mortality 
risks (Magnus et al, 1987; Berget, 1979). However, in a case-control study of 
about 150 women in the Nijmegen region, women having first sexual inter-
course at young age, a risk factor, were surprisingly found to be screened 
more often (Graaf, 1987). 
Other risk factors should be positively correlated with non-attendance, 
to maintain compatibility with the evidence on the overall risk mentioned 
earlier. This evidence was reinforced in our modelling efforts to explain the 
incidence rates in attenders and non-attenders both from British Columbia and 
the Netherlands. For obtaining a good fit, it had to be assumed that on the 
whole lower attendance is related with higher risk. We assumed that the 
relative risk of attenders compared with that of the entire population (in the 
same age-group) increases from 0.69 in case of 40 % attendance to 0.74 if 
attendance is 75 %. By incorporating the relation between risk and attendance 
in this direct way, the underlying mechanism is ignored. 
The resulting health effects are depicted by the lowest, solid lines in 
figure 3.1. The influence of risk rums out to be substantial, irrespective of the 
number of invitations. The health effects thus decrease another 13-17 %. These 
more realistic estimates result in a 15-28% lower level of health effects 
compared with the situation in which attendance is assumed to be influenced 
by age ouly. 
Cost-effectiveness 
Figure 3.1 also shows that higher attendance leads to a substantial increase in 
health effects, especially if the screening policy is not very intensive, as in 
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case of 7 invitations. On the other hand, the total costs increase less than 
proportionally with the level of attendance (Koopmanschap et aI, 1990). The 
total costs are dominated by the costs of screening itself. The changes in costs 
of subsequent diagnosis and treatment induced by screening are relatively 
small. The costs of screening itself increase less than proportionally because 
the major share of costs for coordination and registtation is fixed. This 
implicates that the incremental costs per life-year gained (as compared with the 
situation without any early detection) fall as attendance increases (table 3.1). 
Only in case of 16 invitations does a rise in attendance from 65 to 75% fail to 
improve cost-effectiveness further. This illustrates the decrease in extra health 
effects when an already intensive policy is extended. 
Table 3.1 
Policy 
7* 
7* 
7* 
16** 
16** 
16** 
Life-years gained (x 1,000) and incremental costs US $ (million) 
and cost-effectiveness (x 1,000 US $) for efficient screening 
policies with 7 and 16 invitations in the Netherlands during 1988-
2015 for several attendance rates. Discount rate: 5%. 
Attendance Costs Life-years gained Costllife-year 
gained 
($ million) ($ x 1.000) ($ x 1.000) 
40% 126 8.7 14.5 
65% 163 13.1 12.5 
75% 176 14.9 11.8 
40% 267 14.4 18.5 
65% 366 20.7 17.7 
75% 407 22.0 18.5 
* 7 invitations between age 37 and 73 with a 6-year interval. 
** 16 invitations between age 28 and 72 with a 3-year interval. 
Improving the health effects oj screening 
The health effects of cervical-cancer screening can be improved in two ways: 
A) by trying to increase attendance, without changing the invitation schednle; 
B) by intensifying the policy by sending more invitations per woman (in the 
same age-range, at shorter time intervals). 
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Two examples will illustrate the divergent results of these options. 
Suppose that an efficient policy with 7 invitations is in operation. Only a first 
invitation is sent, with no reminder, and the attendance is 60 %. A comparison 
is made between the results of sending a reminder (A) and those of increasing 
the number of invitations per woman in her lifetime from 7 to 8 (B). 
Both methods produce approximately the same amount of extra health 
effects (table 3.2 and figure 3.2). The costs of raising attendance to 65% by 
sending a reminder could be calculated on the basis of the Dutch data. This 
option gives rise to extra costs of 3 million US $ for producing the reminder 
and additional coordination, and another 9 million US $ because 700,000 
additional smears are taken, i.e. 12 million US $ in all. The alternative, exten-
ding the invitation schedule (B) leads to a greater number of additional smears 
(2.2 min), costing an extra 16 million US $, so sending a reminder is the 
more cost-effective option. 
Table 3.2 
Invitations 
7* 
7* A 
8** B 
Incremental costs (in US $ millions) and life-years gained (x 
1,000) by (A): increasing attendance from 60% to 65% by 
sending a reminder; versus (B): intensifying the policy from 7 to 
8 invitations. Screening in the Netherlands during 1988-2015. 
Discount rate: 5%. (rem = reminder). 
Attendance Smears Costs Life-years Cost/life-years 
gained 
(mln) ($ mln) ($ x 1,000) ($ x 1,000) 
Average Marginal 
60% (no rem) 9.9 152 12.0 12.7 
65% (rem) 10.6 163 13.1 12.4 10.0 
60% (no rem) 12.1 167 13.2 12.7 15.0 
* 7 invitations between age 37 and 73 with a 6-year interval. 
** 8 invitations between age 37 and 72 with a 5-year interval. 
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Example of incremental costS and life-years gained by (A): increasing attendance 
from 60% to 65% by sending a reminder; versus (B): intensifying the policy from 7 
to 8 invitations. Screening in the Netherlands during 1988-2015. 
Discount rate 5%. 
Intensifying the policy by sending more invitations implies that most of 
the extra smears will be taken from women who are already screened relative-
ly often; consequently the additional health effects of each extra smear are 
limited. Increasing the attendance rate means that the (smaller number of) 
extra screens will be allotted to the women least screened, i.e., with higher 
risk than average. The extra health effects for each additional smear are larger 
than in case of inviting more often. 
In the second example it will be assumed that attendance can be raised 
further, up to 78% ((A) in figure 3.3 and table 3.3). Seventeen million US $ 
extra costs are necessary for taking, evaluating and registering the additional 
smears. Attaining the same amount of extra health effects by extending the 
invitation schedule to 9 invitations (B) doubles the extra costs: 34 million US 
$. Raising attendance seems by far the most attractive option. 
However, stimulating attendance, for instance by additional publicity, 
will definitely require extra costs, over and above the 17 million US $ already 
mentioned. The exact amount of extra costs is difficult to estimate: they will 
probably rise for each percentage of higher attendance. Figure 3.3 shows that 
the maximum amount of extra costs, allowed by rational budget spending, is 
the difference in additional costs between method A en B: 34-17= 17 million 
US $. In general, the mor~ intensive the policy, the greater the amount of 
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costs can be devoted to stimulating attendance. For example, raising attendan-
ce from 65% to 75% for the efficient policy with 16 invitations may cost 70 
million US $. 
Table 3.3 
Invitations 
7' 
7* A 
9** B 
Incremental costs (US $ min) and life-years gained (x 1,000) by 
(A): increasing attendance from 65% to 78%; versus (B): chang-
ing the policy from 7 to 9 invitations. Screening during 1988-
2015. Discount rate: 5% 
Attendance Smears Costs Life-years Cost/life-years 
gained 
(min) ($ mln) ($ x 1,000) ($ x 1.000) 
Average Marginal 
65% 10.6 163 13.1 12.4 
78%*** 12.7 180 15.4 11.7 7.4 
65% 13.5 197 15.4 12.8 14.8 
* 7 invitations between age 37 and 73 with a 6-year interval. 
** 9 invitations between age 35 and 75 with a 5-year interval. 
*** 78 % was chosen, it yields the same health effects as the policy with 9 invitations. 
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Example of incremental costs and life-years gained by (A): increasing attendance 
from 65% to 78%; (B): intensifying the policy from 7 to 9 invitations. Screening in 
the Netherlands during 1988-2015. Discount rate 5%. 
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Elements of the screening organisation, such as the invitation system, 
pUblicity and travel distance, could be used as instruments to increase atten-
dance, This has also been suggested by several authors (Hakarna et al, 1985; 
Eardley et al, 1985; Haran et al, 1986), Further research on the costs of these 
instruments and the resulting extra attendance should be stimulated. Decisions 
concerning these features should preferably be based on considerations of cost-
effectiveness, along the lines presented in this chapter. 
Spontaneous screening 
Data for the Netherlands reveal that in the case of spontaneous screening, 
without a population-based invitation system, the distribution of smears among 
women is more uneven than in the case of organized screening. Some women 
are screened only occasionally and about 10% are never screened. There is no 
clear indication that women at higher risk will participate more frequently than 
in the case of organized screening (Habbema et al, 1988). 
In the Netherlands, as in many other countries, the coverage is the 
highest in the age range 20 to 35 (Hakulinen and Hakarna, 1985; Parkin et ai, 
1982; Anderson et al, 1988; Kjellgren, 1986; Choi and Nelson, 1986). In this 
age-group, screening is often performed every 2 years or more frequently. 
The coverage rate in older age groups is substantially lower. This implies that 
spontaneous screening does not reach those who would really benefit from 
screening: middle-aged and older women at high relative risk (Laara et al, 
1987). 
Table 3.4 compares the coverage rates for one efficiently organized 
screening policy and for spontaneous screening. The coverage rates differ 
substantially, for approximately the same number of smears and level of costs. 
Spontaneous screening shows a relatively high coverage below 40. However, 
organized screening (7 invitations between age 37 and 73) reveals a far better 
coverage of the middle-aged and older women. Since the incidence of invasive 
lesions is relatively low below age 35, better coverage in this age range yields 
only a small number of life-years gained. Furthermore, the high portion of 
regressive lesions in younger women results in a relatively large amount of 
unnecessary diagnosis and treatment. Organized screening, directed to the age 
groups with the highest incidence, is superior with respect to the number of 
life-years gained and consequently in terms of costs per life-year gained. 
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Table 3.4 Coverage rate of cervical cancer screening (% of women scree-
ned at least once in 6 years) by age, for organized screening only 
and spontaneous screening only in the Netherlands 1988-2015. 
Number of smears, life-years gained, incremental costs, 
incremental costs per life-year gained (discount rate 5%). 
Organized screening (7)* Spontaneous screening 
Coverage rate: 
Age 25 0% 28% 
30 0% 45% 
40 65% 49% 
50 65% 48% 
60 60% 30% 
70 55% 7% 
Number of smears (min) 10.6 12.7 
Incremental costs ($ mln) 163.0 178.0 
Life-years gained 68.0 43.0 
($ x 1.000) 
Costllife-year gained 12.4 26.9 
($ x 1.000) 
* 7 invitations between age 37 and 73 with a 6-year interval. 
Discussion 
The model used remains a simplified approximation of a complex reality. It is 
not always possible to detect the very true nature of the underlying relations. 
For example, it remains unclear if the negative relationship between attendan-
ce and risk can be explained by socio-economic status. If so, future social 
developments influence the link between attendance and risk. 
Other factors 
Efforts may be directed to influence other factors besides attendance which 
can alter costs and/or health effects. One of the most important determinants is 
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the sensitivity of the smear, which was varied in our study between 60% and 
80%. Such variation does not influence the cost-effectiveness to the same 
extent as attendance. The same conclusion holds for other factors. 
Organized and spontaneous screening 
A combination of organized and spontaneous screening, a co=on practice in 
many countries, is very inefficient, according to our calculations. Many 
women, especially young women, will be screened in both contexts, inducing 
ouly a marginal improvement in coverage. The additional health effects of the 
spontaneous screening are limited, whereas the large amount of smears results 
in high costs. Again, intensive screening of younger women leads to a 
relatively large amount of unnecessary diagnostic and treattnent procedures. 
Generalization 
The conclusions for the Dutch situation concerning the importance of attendan-
ce and the superiority of organized screening will to a large extent be valid for 
other countries, since we found many striking similarities between our data 
and other published findings. For countries with substantially higher incidence, 
all other parameters being equal, the cost-effectiveness will be more favoura-
ble than in our calculations. 
The future of screening in the Netherlands 
From 1989 onwards the Dutch organized-screening programme (7 invitations 
between age 35 and 53, with a 3-year interval) will be resumed, but modified 
as follows: 
- ouly a first invitation, no reminder, is to be sent to women in the target age 
range; 
- women should make an appointtnent to visit their general practitioner for a 
smear. 
The absence of a reminder, and rendering women responsible for 
making the appointtnents will probably lower the attendance substantially. It 
therefore seems unfavourable from the point of view of cost-effectiveness. 
Inviting women with higher risks 
The foregoing analysis may suggest that special efforts to invite women at 
high risk for cervical cancer will increase the health effects of screening at 
little extra costs. Three arguments may be advanced against this suggestion. 
First, it is impossible to identify high-risk women by means of a population 
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registry. Second. general measures. such as a reminder. directed towards 
increasing attendance, tend to raise the attendance of women at higher risk. 
Third, special campaigns might be justified if some of the women had a very 
high risk compared with the rest. This is not the case for cervical cancer 
(Hakama, 1986). 
Equity 
Women with low socio-economic status have a higher -than-average risk for 
cervical cancer and below-average attendance at screening. Increasing atten-
dance will attract these women more than proportionally, and therefore contri-
bute to a reduction in health inequalities. 
Breast cancer screening 
Our research group also carried out a cost-effectiveness analysis of breast-
cancer screening (Maas et al, 1988, 1989). For breast cancer, no clear 
relationship exists between attendance and risk. The much shorter duration of 
screen-detectable breast cancer makes frequent screening more cost-effective 
than in the case of cervical cancer. Taking this point into account, increasing 
attendance does not bear a clear advantage over intensifying the policy, as in 
the case of cervical-cancer screening. 
Conclusions 
Attendance rate is a major determinant of the health effects and cost-effective-
ness of cervical cancer screening. 
For a given number of smears, the amount of life-years gained is maxi-
mal if as many women as possible are reached. This holds true particularly 
because, on average, less frequent attenders or non-attenders are those at 
greater risk. Stimulating attendance preferentially attracts the least-screened 
women at greater risk. This is more effective, therefore, than inviting women 
more often during their lifetime, which merely means that women screened 
regularly will be screened even more often. Moreover, stimulating attendance 
helps to reduce health inequalities resulting from socio-economic differences. 
A reminder invitation (after the first invitation based on a population 
registry) is a cost-effective instrument for improving the attendance. Other 
aspects of the screening organization, such as specific publicity and mobile 
screening, appear to be useful tools for further increasing attendance. Sponta-
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neous screening results in low coverage for middle-aged and older women. 
Hence the health effects and cost-effectiveness are relatively poor. The same 
applies, a fonion, to combined organized and spontaneous screening, which is 
co=on practice in many countries. Spontaneous screening therefore should 
be discouraged and resources should be reallocated to well organized screen-
ing programs. 
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Supplementary comment 
The previous review of costs and health effects of cervical cancer screening 
was based on the analysis of centrally organized screening in the eighties in 
three Dutch regions as well as cervical cancer screening in other countries. 
Since 1992 the cervical cancer screening program in the Netherlands is 
less centrally organized, with nearly complete national coverage. Women are 
invited to visit their general practitioner to be screened. The analysis has been 
updated for both costs and health effects. However, the main conclusions as 
described above still hold (van Ballegooijen et al. 1993). The costs of the 
screening program itself remain dominant, the subset of efficient policies is 
still characterized by a broad age-range and a relatively long interval between 
successive screens. 
The relation between costs and effects has become somewhat less 
favourable, mainly because of the lower attendance rate, underlining the 
crucial role of attendance for cost-effectiveness. Recently, the Dutch govern-
ment decided to extend the interval between successive invitations from 3 to 5 
years and to broaden the age-range from age 35-53 to age 30-60. 
Part II Aggregate Analysis 

4 Cost of diseases in international 
perspective! 
Summary 
This smdy compares the health care costs of the Netherlands with the United 
States and Sweden and estimates the impact of demographic change on costs. 
Total health care costs were allocated to disease, age, sex and specific subsec-
tors. For the Netherlands 75% of the costs in 1988 were assigned to specific 
diseases. Costs of mental disorders and other chronic non-fatal diseases 
dominate, followed by cardiovascular diseases. The effect of age is strong 
from age 70 onwards. The effect of sex, adjusting for age, is small, except for 
elderly women, being more expensive. Both total and disease-specific costs are 
similar in the Netherlands and Sweden, but differ from those in the United 
States. The available data suggest that the differences in medical practice and 
health care system may explain a substantial part of the divergent results; 
demographic or epidemiologic aspects seem less important. Ageing induces, in 
the Dutch case, a modest 0.7%point annual increase in costs. The contribution 
of other forces in raising costs is probably more important. A structural 
upward pressure on costs also prevails in the Netherlands and Sweden, but it 
is more prominent in the U.S.A., due to a large amount of expensive surgery 
and high administration costs. 
Introduction 
The level of medical consumption is determined by epidemiology, medical 
practice, economic factors including the type of health insurance system and 
culinral circumstances. Having stated this, it is surprising that the recent 
debate on value for money in various health care systems focuses largely on 
aggregate expenditure levels, paying little attention to the important relation 
1 Chapter based on Koopmanschap et aI., EJPH, 1994 
48 Chapter 4 
between disease and medical consumption (Schieber and Poullier, 1991). In 
this study the costs of illness are estimated for the Netherlands, covering the 
entire range of diseases and providing data on disease specific costs, according 
to age, sex and health care sector. 
Next the level of medical care costs and the distribution according to 
disease will be compared with the United States and Sweden. For some 
diseases we will indicate whether the remarkable differences in costs appear to 
be due to divergence in demography and epidemiology or whether supply and 
fmancing of health care are most relevant in explaining these differences. We 
can not provide a complete analysis for all diseases, as this requires a reliable 
international overview of (longitudinal) morbidity data, which is currently 
lacking. Still this analysis may contribute to the debate on the quality and costs 
of health care. 
Another important policy item is estimating the consequences of ageing. 
It will be shown how rapidly medical costs may increase due to demography 
alone, compared with the impact of other expenditure increasing factors. 
Methods 
Cost of illness in the Netherlands 
Total health care costs in the Netherlands, excluding care in old peoples 
homes and social work, amounted to 39.8 billion Dutch guilders (ECU 15.9 
billion), according to the national Financial Overview of Health Care (WVC, 
1989). These costs were allocated to age, sex, health care sector and disease 
categories (Koopmanschap et al., 1991). To this end health care was divided 
into 18 sectors. All diseases of the International Classification of Diseases 9-
CM (WHO, 1975) were assigned to 48 disease categories, using as criteria 
comprehensive data on morbidity, mortality, costs and expected developments. 
They can be aggregated to the standard 17 lCD-chapters. The primary 
diagnosis of patients was used to assign costs to specific diseases. 
Most data were extracted from national registers with nearly complete 
coverage. The Dutch hospital registration system was described by Casparie 
(Casparie and Hoogendoorn, 1991). For some other sectors we use data from 
large surveys such as the Dutch National Health Interview Survey (CBS, 
1988), which is comparable to its US counterpart NHIS. For a few sectors 
insurance data were used (table 4.1). The available data on diagnosis were all 
registered by the responsible physician or nurse, conform the lCD 9-CM 
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rules. Costs incurred by dental or maternity services were allocated to dental 
diseases and pregnancy and delivery respectively. Information on diagnosis 
was not complete or absent regarding care for physically handicapped, home 
help, pharmaceuticals, general preventive care, patient transport and administ-
ration. They represent 25 % of the health care costs. 
Table 4.1 Overview of methods and data used for allocation of costs to 
disease categories per health care sector in the Netherlands 
(NL), Sweden and the United States. 
Health care % Data on Data type Allocati- Allocation Allocation 
service health diagnosis and on Sweden United 
care NL source Nether- States 
costs NL lands 
NL 
Hospital: 32% + National Hospital Hospital Hospital 
nursing and register days days & days & 
physician cost per expenses per 
services day; day; 
Hospital: 3% + National Surgical Outpatient Outpatient visits visits; 
surgery register proce- Surgical dures and 
tariffs 
procedures 
Nursing 10% + National Nursing Nursing Residents & 
homes register home home days monthly 
days expenses 
Psychiatric 6% + National Residents Expendi- Residents 
care register lUres 
in-patient 
Psychiattic 2% + National Clients Expendi- Psychiatric 
care register lUres visits 
out-patient 
Care for 6% + National Residents Expendi- Residents ** 
mentally register lUres 
retarded 
Care for 3% +- Registers Residents Not Residents ** 
physically and sam- allocated 
handicapped pIes 
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Health care % Data on Data type Allocati- Allocation Allocation 
service health diagnosis and on Sweden United 
care NL source Netber- States 
costs NL lands 
NL 
General 5% + Detailed Visits Visits Visits 
practitioner sample 
GPand 
patients 
District 2% + Regional Visits Visits Hospital 
nursing register days * 
Home help 4% Sample Visits Not Hospital 
allocatedff days * 
Maternity 1% + Insurers Expendi- Expendi- Visits 
services data tures tures 
Physical 3% + Sample Visits Visits Hospital 
therapy days * 
Dental care 4% + Dutch Visits Not Visits 
IDS allocated 
Drugs 9% Dutch Prescrip- Prescripti- Physician 
HIS (ions ons and visits 
prices 
Eyeglasses 2% + Insurers Expendi- Not Persons 
and data lUres allocated glasses! 
appliances hearing aids 
Governmen- 2% +- Govem- Equal Not Not 
tal public men! de- costs per allocated allocated 
health care partment person 
Patient 1% Insurers Expendi- Not Not 
transport data lUres allocated allocated 
Administra- 6% Govem- Equal Not Not 
tion men! and costs per allocated allocated 
(insurers & insurers person 
government) 
+ : information on diagnosis conform leD 9-CM 
+- : information on diagnosis partially conform ICD 9-CM 
: no information on diagnosis available 
* : costs were allocated to disease, using the distribution of hospital days 
** : not allocated separately, as they are included in the hospital sector 
# : in Sweden home help is not included in health care but in social services 
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For each health care sector total costs were assigned to age, sex and 
diagnosis by using utilization of services, the number of patients or the 
expenditures per group of patients (table 4.1). For example, the number of 
visits to physical therapists determines the distribution of costs for physical 
therapy, assuming each visit has the same costs. Regarding hospitals and 
nursing homes, we used the number of hospital days; for psychiatric care and 
care for mentally or physically handicapped the number of patients was used 
to allocate costs. For most ambulatory services we used the number of visits 
to attribute costs. In case of maternity services, appliances and patient trans-
port cost allocation was based on expenditures. 
Data on age and sex were available for all health services, except for 
general preventive care and administration; considered as indivisible goods, 
they have been assigned by assuming equal costs per citizen. 
International comparison 
The results for the Netherlands will be compared with Sweden (Lindgren, 
1990) and the United States (Rice et al., 1985). All three studies use the 
primary diagnosis to assign costs to disease categories. The data used are a 
mixture of natioual and regional registrations, samples and surveys on health 
care utilization and costs. In the US study non-personal health costs such as 
costs for government public health care and insurers and government administ-
ration were excluded. Costs of patient transport were not allocated to a 
specific disease (table 4.1). In Sweden, home help is a part of social services 
and was therefore excluded. The costs of dental care, appliances, patient 
transport, government public health care and administration were not assigned 
to disease. 
The proportion of costs which could be assigned to specific diseases is 
similar in the three countries. For Sweden 78% was assigned, for the Nether-
lands 75%, and the United States 82%. (table 4.2). As detailed cost analyses 
of the entire health care system would have been too complicated each study 
used aggregated data on utilization and costs to assign costs to diagnosis, age 
and sex. The procedures used in distributing costs to diagnosis are fairly 
similar, with a few exceptions. The US study used estimates of costs per 
hospital day by diagnosis category (table 4.1). In the Swedish study, costs per 
hospital day were made disease specific, by using cost estimates for several 
hospital departtuents. For the Netherlands, we assumed equal cost per day for 
all diseases, as reliable disease specific data on the costs per hospital day are 
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Table 4.2 Distribution of direct costs by disease categories (17 chapters of the 
lCD 9-CM) in the U.S.A. 1980, Sweden 1983 and the Netherlands 
1988 in percentages of total direct costs. 
Disease category (leD chaptets) U.S.A: Sweden Netherlands 
% % % 
Infective diseases 1.8 1.6 1.0 
Neoplasms 5.5 5.1 4.6 
Endocrine and metabolic dis. 3.1 2.3 1.7 
Diseases of the blood 0.4 0.5 0.3 
Mental disorders 8.3 21.1 19.9 
Dis. of the nervous system 7.1 4.2 3.8 
Cardiovascular diseases 13.6 12.3 8.7 
Respiratory diseases 7.0 5.0 3.1 
Dis. of the digestive system 12.9 3.8 7.6 
Genito-urinary diseases 5.1 3.0 2.7 
Pregnancy and delivery 2.7 3.5 
Diseases of the skin 2.5 1.7 0.9 
Locomotor diseases 5.5 3.9 7.0 
Congenital anomalies 0.5 0.5 0.4 
Perinatal diseases 0.5 0.9 
Symptoms 1.6 5.1 4.3 
Accidents, poisoning and violence 7.7 4.8 4.3 
Other diseases 3.6" 0.0 0.0 
Not allocated 14.2" 21.9 25.2 
Total 100.0 100.0 100.0 
* For comparability, the U.S.A. percentages derived by Rice were corrected for non 
personal health care costs (e.g. insurers- and government administration and government 
public health services). These costs now make up the lion's share of unallocated costs. 
** For the U.S.A. the costs of pregnancy and congenital anomalies could not be discerned 
separately and are mentioned as costs of other diseases. 
currently not available. The Dutch data on non-hospital care appear to be 
more complete and reliable. For example, in the US stndy the costs of several 
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home health care services had to be assigned to diseases, using the distribution 
of hospital days. 
Demography and costs 
Using the estimated average costs per person by disease, age and sex for 
1988, we calculated future health care costs, on the basis of expected demo-
graphic development (CBS, 1989). We used 2030 as the endpoint of our 
predictions, when ageing of the Dutch population is expected to reach its 
maximum. In order to relate the increase in costs to expected economic 
growth we used the "Europe-scenario" drawn up by the Netherlands Central 
Planning Bureau, predicting a 2.8% yearly increase in real GNP (van der 
Berg, 1991). 
Results 
Costs by disease and sex 
In figure 4.1 we show the costs by 17 disease categories and sex. Mental 
disorders (including mental retardation) generate by far the highest costs, 
accounting for 20% of total costs, followed by cardiovascular diseases (9%), 
disease of the digestive system (8 %, including dental diseases) and locomotor 
diseases (7 %). The most expensive disease categories are chronic, non-fatal 
illnesses. Cardiovascular diseases and cancer, accounting for 71 % of Dutch 
mortality, make up ouly 14% of the health care costs. Women account for 
57% of total costs, including the costs of pregnancy. The distributiou of costs 
among lCD-chapters is quite similar for both sexes. Costs of cardiovascular 
disease are relatively more important for men (10% vs 8%), locomotor 
diseases for women (8 % vs 6 %). Due to standard registration procedure, the 
small amount of pregnancy-related costs for men are attributable to healthy 
babies who stay a short period in hospital, after birth. 
The results for the U.S.A. (Rice et al., 1985) are similar. Rice conclu-
des that women account for 59 % of health care costs and that the distribution 
of costs by disease is not very sex-specific. 
Costs by disease and age 
The pattern of costs of illness related to age is quite diverse. For the age-
group 0-19 year, costs of mental disorders, gastro-intestinal diseases (in 
particular dental care) and perinatal diseases are the most expensive. In the 
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Figure 4.1 Costs of health care by disease category and sex for the Netherlands 1988, in million Dutch guilders. 
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age group 20-44, costs of mental disorders still dominate, followed by costs of 
pregnancy, dental diseases and locomotor diseases. From age 45 to 64 
cardiovascular, locomotor disease and cancer represent the greatest costs, 
followed by mental disorders. Costs of cardiovascular disease are the most 
important in people aged 65-79. From age 80 onwards, the typical impair-
ments of the most elderly are reflected in high costs for dementia, stroke, 
locomotor disease and non-traffic accidents. 
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Figure 4.2 Average health care costs per year per person by age and sex for the Netherlands 1988. 
in thousand Dutch guilders. 
Costs by age and sex 
Figure 4.2 presents the average annual costs per person by age and sex. These 
costs rise gradually from dfl 1,000 for age 5-9 to 3,000 for age 55-59. From 
age 60 on costs accelerate, reaching a maximum of dfl 18,000 for age 85 and 
older. Given their age, differences in costs between men and women are 
small, except for the higber costs for women of age 80 and older. The causes 
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of this exception are at least twofold: these women are on average older than 
men in the same age-group and more often single, which increases their 
probability of hospitalization (Huijsman, 1990). 
The higher costs for women aged 20-44 are due to pregnancy and child-
birth. Our Dutch cost estimates correspond quite closely to results for the 
U.S.A. In 1980 the average costs per U.S.A.-citizen older than 65 were 2.75 
times the average for all citizens (Hodgson and Kopstein, 1984); the corres-
ponding Dutch ratio is 2.86 in 1988. Waldo's estimates for health care costs 
by age for the U.S.A. in 1987 confirm this conclusion (Waldo et al., 1989). 
InrernaIional comparison 
Table 4.2 presents the distribution of health care costs by lCD-chapters for the 
United States (1980), Sweden (1983) and the Netherlands (1988). A satisfacto-
ry explanation of all differences requires a systematic analysis of health care 
systems, demography and epidemiology, which is beyond the scope of this 
study. The main obstacle for a complete analysis is the lack of reliable, 
comparable data regarding disease specific morbidity. Nevertheless, our partial 
comparison reveals interesting outcomes. 
The results for Sweden and the Netherlands are very similar; the low 
costs for diseases of the digestive tract in Sweden are due to the omission of 
dental care in Lindgren's study. The U.S.A. pattern of costs deviates on 
several points from the two European countries. The low costs for mental 
disorders in the U.S.A. probably do not reflect a lower prevalence. Two meta-
analyses show no different prevalence rates of dementia. for Europe (Jorm, 
1987) and the U.S.A. (Ritchie, 1992). For mental retardation evidence is less 
firm, but prevalence estimates for children in the U. S and Scandinavia are in 
the same range (Yeargin-Allsopp et al., 1992; Dupont, 1989). Therefore, it 
appears that the low costs for mental illness in the U.S.A. are due to the small 
extent of inpatient psychiatric care: the number of beds per 1,000 citizens in 
psychiatric hospitals in the Netherlands and Sweden is much higher than in the 
U.S.A., both for 1980 and 1989 (table 4.3). 
For cardiovascular disease comparative morbidity data are not available, 
but the high U.S.A. costs may be at least in part related to more surgery, as 
the relative frequency of coronary artery bypass grafting in the U.S.A. in 
1988 is more than twice the Dutch and Swedish rate (table 4.3). In addition, 
the rate of increase in perfomting bypasses between 1985 and 1988 for the 
U.S.A. was much larger than for the Netherlands. The automatic reimburse-
ment of costs in the U.S.A. clearly provides an economic incentive for increa-
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sing the number of CABG's, whereas in the Netherlands and Sweden the 
number of bypasses is highly regulated (Banta and Bos, 1991). 
Regarding digestive diseases the story is analogous: the surgery rate in 
the U.S.A. is 16.6 per 1000 citizens as compared to 9.2 for the Netherlands 
(OECD, 1991; SIG, 1990), whereas in both countries surgery for digestive 
diseases makes up 16 % of total surgery. 
The substantial costs of accidents, poisoning and violence in the U.S.A. 
are undoubtedly due to their high incidence. The U.S.A. mortality rate for 
traffic accidents involving passenger cars is twice as high as for the Nether-
lands and Sweden. As this cannot be explained by differences in lethality, it 
points to higher incidence, caused by the larger mobility in the United States 
(United Nations, 1987 and Beeck et aI., 1989 and WHO, 1991). With respect 
to homicide an average U.S.A. citizen has a 10 times higher risk of being 
killed than the average Dutchman, indicating a much larger incidence of 
accidents related to violence (WHO, 1991). 
Turning to total costs, table 4.3 shows that both the share of costs in 
GDP and the average costs per capita are substantially higher in the U.S.A. 
Furthermore, the costs are still rising in the U.S.A. while they are stabilizing 
in the Netherlands and Sweden (OECD, 1991). Hence, one may ask: what 
makes U.S.A.-health care so expensive? 
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Table 4.3 Public health and health care in the Netherlands, Sweden and the 
U.S.A. 
Item Year/Gender Netherlands Sweden U.S.A. 
Epidemiology 
Life-expectancy at birth in male 73.7 74.2 71.6 
years2 female 80.5 80.4 78.6 
Infant mortality rate per male 798 668 1,099 
100,000 live births' female 563 553 866 
Monality rate for traffic acci- 1987 5.2 5.7 10.6 
dents with passenger cars per 
100.000 persons' 
Mortality rate for homicide male 1.1 1.5 12.8 
per 100,000 persons' female 0.7 0.9 4.0 
Costs 
Health care costs as share of 1988 8.2% 8.5% 11.4% 
GDP in % 1990 8.1% 8.7% 12.4% 
Costs p person US $ PPP 1990 1,182 1,421 2,566 
Input 
Physicians per 1000 inhab. 1988 2.4 2.9 2.3 
Psychiatric care beds per 1980 1.7 3.2 0.9 
1000 inhabitants 1989 1.6 1.8 0.6 
Hospital beds per 1000 inhab. 1988 4.5 4.1 3.7 
Output 
A v. length hospital stay 1988 11.3 7.5 6.5 
In hospital surgery per 1988 56.8' NA 105 
1000 habitants 
CABG surgery per mIn 1985 480 250 780 
inhab.4 1988 583 464' 1,265 
Incomes 
A v. earnings per 1988 70.000' 48,000 144,700 
physician US $ PPP 
* PPP= Purchasing Power Parities: Sources: if not indicated by superscript: OECD, 1991: 1 
United Nations. 1987; , WHO. 1990 and 1991; , SIG, 1990; , Banta and Bos, 1991; , 
Jendteg. 1991; 6 Personal Communication. 1991. 
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If a less favourable age-composition of the U.S.A.-population were the 
cause. standardizing the population of the Netherlands to that of the U.S.A. 
regarding age and sex (US Bureau of the Census, 1989), combined with actual 
pro capita costs for the Netherlands, should result in higher projected costs 
compared to the actual Dutch costs. However, this calculation gives almost 
identical costs, so differences in demography can be ruled out as an explanati-
on. Moreover, although the Swedish popUlation is considerably older, Swedish 
health care costs are still quite moderate. 
Undoubtedly, the high administration costs in the U.S.A., especially 
within hospitals, play an important role in expansion of costs. For the U.S.A., 
these were estimated as between 19 and 24 % of the total health care costs in 
1987 (Woolhandler and Himmelstein, 1991). Using the same definition with 
respect to administration costs for the Netherlands we estimate them to be 11-
14% in 1988 (table 4.4). 
Table 4.4 Administration costs (Woolhandler's definition) as % of total health 
care costs for the U.S.A. 1987 and the Netherlands 1988. 
Expenditure category Netherlands 1988 U.S.A. 1987 
Program administration and 4.4% 5.1 % 
insurance overheadl 
Hospital administration2 3.5% 7.8% 
Nursing home 0.8% 1.3% 
adrninistration2 
Physicians' overhead) 3.5% 5.1-9.8% 
Total 11.7-13.7% 19.3-24.1 % 
Sources: ' For the U.S.A. (all items): Woolhandler and Himmelstein, 1991: ' For the 
Netherlands the calculation was based on WVC, 1989: 2 For the Netherlands: National 
Hospital Institute, 1988; 3 For the Netherlands: Personal Communication. 1991. 
Regarding input, the number of physicians and beds in acute care hospi-
tals per citizen in the U.S.A. is slightly smaller than for the Netherlands and 
Sweden (table 4.3), which cannot explain higher costs. Turning to output, the 
length of stay in acute care hospitals in the U.S.A. is lower than in the 
Netherlands and comparable to Sweden, which would rather point to lower 
costs. A really striking difference is the "high intensity" of U.S.A. medicine, 
illustrated by the rate of inpatient surgical procedures which is for the U.S.A. 
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about twice as high as for the Netherlands (table 4.3). Studies of pacemaker 
implantation (Greenspan et al.. 1988), endoscopy (Kahn et al., 1988) and 
carotid endarectomy (Winslow et al., 1988) indicate that overtreatment of 
insured patients is not exceptional in the United States. The costs of 'defensive 
medicine' in the U.S.A. were estimated to be $ 15 billion US $ in 1989 
(Center for Health Policy Research, 1990). 
This style of practising medicine may also be related to the competition 
between U.S.A.-hospitals concentrating on "quality" rather than on price, 
resulting in the duplication of expensive eqnipment and services. Robinson has 
shown convincingly that in the U.S.A. the amount of medical equipment 
within each hospital increases with the number of other hospitals in the 
neighbourhood (Robinson and Luft, 1985). In the Netherlands regional 
dispersion of expensive services is regulated by licensing, which reduces the 
inefficient use of medical equipment. 
Comparing prices of health care services between countries is not 
without problems, but an OECD study indicates that for the equivalent of one 
US $ significantly more medical services can be bought in other OECD 
countries than in the U.S.A. (OECD, 1987). Viewing the mentioned data on 
volumes and prices, it is not surprising that average earnings of physicians in 
the U.S.A. are three times as high as in Sweden and twice the Dutch level 
(OECD, 1991; Jendteg, 1991) (table 4.3). The formidable liability insurance 
premiums for US-physicians, which have grown by about 15 % per year in 
recent years (Centre for Health Policy Research, 1990), contribute to the rise 
in health care costs, although the physician's net disposable income is not 
affected. 
Derrwgraplry and costs 
For the years 2010 and 2030, we calculated the consequences for health care 
costs of expected demographic developments in the Netherlands, using the 
estimated average costs per person by age and sex for 1988. As presented in 
table 4.5, total costs will rise by 1 %point per year during 1988-2030. Seventy 
percent of this increase (0.7%point), is due to ageing, the remaining 0.3% 
being a result of population growth. During 2010-2030 ageing is responsible 
for 90 percent of the increase in costs: 0.9% per year. For the period 1980-
2040, Rice estimated U.S.A. health care costs to grow 1.1 % per year, of 
which ouly 0.3% caused by ageing (Rice, 1989). 
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Table 4.5 Indices for predicted of health care costs by disease, due to demo-
graphy in the Netherlands, for 2010 and 2030, 1988=100. 
Disease category Year 
2010 2030 
All diseases 121 139 
Prostate cancer 141 206 
Dementia 148 203 
Heart failure 143 196 
Stroke 140 193 
Lung cancer 142 185 
Male genital diseases 136 181 
Diabetes 134 174 
Ischaemic heart diseases 141 174 
Diseases for which costs are expected to rise faster than average are 
shown in table 4.5. The forecasts for these diseases are quite reliable, as they 
depend largely on the life expectancy of the living population and for most of 
these diseases the pattern of care and costs is not expected to change radically. 
Costs of dementia, lung and prostate cancer, stroke and heart failure will rise 
substantially up to 2010, but will increase more rapidly still in the decades 
thereafter, as the Dutch postwar baby boom reaches the age of 70 at which 
age medical consumption will accelerate (figure 4.2). 
The 0.7%point annual growth of costs due to ageing is quite modest 
when compared with expected long term economic growth: 2.8%. Other 
forces than ageing seem to be more important in raising health care costs. For 
example, in the majority of OBCD-countries, including the U.S.A., health 
care prices structurally tend to rise faster than in the rest of the economy 
(OBCD, 1991; Baumol, 1985; CPB, 1987). In part this is due to lower 
productivity growth in health care than in manufacturing industries, but it also 
may reflect improved quality of medical services. This relative price increase 
of health care services acts as a continuous upward pressure on health care 
costs. During 1980-1990 health care prices in the U.S.A. rose 2.75% more 
than general inflation, in Sweden 1.0%, whereas in the Netherlands no 
difference occurred (OBCD, 1991). 
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Discussion 
The international comparability of disease specific data has been questioned 
recently. Stehbens demonstrated that diagnostic errors in certified causes of 
death may result in unreliable mortality statistics, invoking wrong conclusions 
on epidemiologic trends (Stehbens, 1987). It is not known whether the 
misclassification bias as reported for causes of death is equally important for 
diagnosis related to medical consumption. However, the international compari-
son presented is limited to very broad disease categories: the 17 lCD-chapters. 
Although differences in case-mix between countries within lCD-Chapters may 
be substantial, misclassification between lCD-chapters appears to be less 
likely. 
We used only the primary diagnosis of patients to assign costs to 
disease. This facilitates the comparison of results between diseases, a frequent 
problem in cost of illness studies, but it may underestimate costs of diseases 
which often prevail as comorbidity, such as diabetes. Reliable data on comor-
bidity and its influence on medical consumption may improve the cost estima-
tes, especially for elderly people, but at the moment these are not available. 
If disease specific data on pharmaceuticals become available for the 
Netherlands, it is unlikely that the ranking of diseases by costs will change 
substantially, because drugs only represent 9% of total health care costs in the 
Netherlands. Lindgren's data for Sweden indicate that, except for mental 
diseases, the ranking of total costs and costs of drugs by disease is quite 
similar (Lindgren, 1990). 
The most recent cost estimates for the U.S.A. date from 1980, but may 
still be valid, as comparison of the distribution of U.S.A. costs by disease for 
1980 and 1972 also showed only minor differences (Rice et aI., 1985; Cooper 
and Rice, 1976). This also holds for the Swedish results regarding 1975 and 
1983 (Lindgren, 1990 and 1981). 
Although we do not provide a complete analysis of international 
differences in health care costs, numerous findings point to more aggressive 
medical practice, higher administration costs and higher prices as the main 
causes of unparalleled costs in the U.S.A. Further research is urgently needed 
to shed more light on the contribution of epidemiological causes. However, 
the high costs in the U.S.A. do not seem to produce better health care and 
public health for the average American citizen. In the U.S.A. the amount of 
care in psychiatric hospitals and nursing homes is substantially smaller than in 
the Netherlands and Sweden (United Nations, 1987) (table 4.3). Life expectan-
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cy at birth is lower in tbe U.S.A. than in tbe Netberlands and Sweden, while 
infant mortality is higher (WHO, 1991). This may be closely related to tbe 
fact tbat about 14% of Americans are uninsured (Congressional Budget Office, 
1991). 
In tbe Netberlands tbe number of uninsured is negligible (0,3-0,5%) 
and Sweden has a national healtb care system ensuring universal access to 
healtb care. Preventive care in tbe U.S.A. is underdeveloped, resulting in, for 
example, low immunization rates for infants (Starfield, 1991; Children's 
Defend Fund, 1987). 
Witb respect to tbe impact of demographic change on costs we assumed 
tbat tbe relation between age, sex and healtb care costs for 1988 is a valid 
estimate for tbe future. In tbe absence of reliable evidence of tbe influence of 
epidemiology and technology on future medical consumption this estimate 
provides a reasonable baseline scenario, to be modified after more detailed 
research. If, for example, tbe healtb care costs for elderly will increase 
relatively more tban for tbe younger, our calculations may underestimate tbe 
true costs of ageing. Furtber research on tbe development of tbe relation 
between age, morbidity and healtb care costs is needed to improve tbese 
estimates. 
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5 Current and future costs of cancer! 
Summary 
Cancer costs in the Netherlands amounted to 4.8 % of health care costs in 
1988. For five cancer types, and a sixth group, covering all other 
malignancies, costs were broken down by age, sex and disease phase, showing 
a remarkably similar pattern of medical consumption. Costs were linked to 
observed incidence and mortality and estimated prevalence, together allowing 
for prediction of future costs of cancer. In 2020, as a result of ageing, cancer 
costs will have increased much more rapidly than total health care costs, in 
particular for cancer of the lung and prostate. Colorectal cancer costs were 
predicted for epidemiological scenarios. Our model shows that an increase in 
future prevalence may bear qwte different cost implications. If it is due to 
higher incidence, the costs will increase substantially. If due to survival 
improvement, the increase will be less prominent. Simply extrapolating costs 
based on future prevalence or mortality may produce serious errors. 
Introduction 
An optimal allocation of health care resources requires insight in the 
epidemiology and costs of diseases. Regarding cancer, we need to know both 
the absolute costs and the relative costs as compared to other diseases and total 
health care. Furthermore, the impact of demography, changes in medical 
practice and epidemiology on future health care costs should be analyzed. In 
this chapter we estimate the costs for five cancer categories: cancer of the 
lung, breast, colorectum, prostate, stomach; and all other malignancies in a 
sixth category. These cancer categories were selected, based on their 
importance for mortality, morbidity and medical consumption. 
First, we calculated the total costs per type of cancer, age-group and 
sex for 1988. Next, these costs will be assigned to three disease phases: the 
1 Chapter based on Koopmanschap et aI., Eur J Cancer, 1994 
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year following incidence, the year preceding death and the period in between. 
The estimated costs per patient by disease phase will be combined with 
incidence, mortality and prevalence, as calculated by our cancer disease 
model. This allows for prediction of furore cancer costs for several possible 
scenarios: a demographic scenario and scenarios concerning expected trends in 
incidence and survival. The costs predicted by the 'three phase model' will be 
compared with outcomes using simple extrapolations of average costs per 
patient. 
Material and methods 
Total costs of cancer 
In a recent study we estimated total health care costs for the Netherlands in 
1988, for the 6 cancer types mentioned, together with 42 other disease 
categories, covering the entire lCD 9-CM classification (see chapter 4). Total 
health care costs were allocated to diseases, age-groups and sex, using 
utilization of services or the number of patients. Data on in-hospital and 
nursing home care were extracted from national registers with (nearly) 
complete coverage. For general practitioner's care, physical therapy and 
district nursing we used data from recent, large surveys. These results were 
used to calculate the costs of inpatient hospital care and non-hospital care for 
cancer. 
Costs of outpatient hospital care consist of radiotherapy, chemotherapy 
and fOllow-up. Costs of Dutch radiotherapy-centres were assigned to the six 
cancer types, using the number of new patients receiving radiotherapy by type 
of cancer (Health Council, 1984). The costs of cytostatics administered in 
hospitals (Nepharma, 1989) were assigned to the six cancer types, in 
proportion to the distribution of in-hospital costs. The costs for monitoring 
patients without symptoms after diagnosis and primary treatment, were 
calculated in detail for breast cancer (de Koning et al., 1991) and were 
extrapolated to other cancers (see below). 
Costs by disease phase 
Several studies (Baker et al., 1989 and Bried et al., 1989) indicated that over 
the course of cancer, the costs show two peaks. The first peak, due to 
diagnosis and primary therapy; the second peak, due to palliation of often 
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severe symptoms in advanced disease. In between, medical consumption is 
modest. Hence, we discerned three disease phases, inspired by Baker: 
- the first year following incidence, as a result of diagnosis and primary 
treannent; 
- the last year of life for people dying of cancer (only for people who survived 
the first year, who get recurrent or metastatic disease and do not die from 
other causes); 
- the period in between: 'the intermediate phase', during which people are 
disease-free or having already diagnosed metastases (in these terms disease-
free is a mixture of cured patients and patients who currently have no disease 
symptoms, but who will later get recurrent or metastatic disease); 
Costs for patients dying within one year after incidence were assigned to the 
incidence phase. 
The average costs per patient by type of cancer, age, sex and phase 
were estimated as follows. For the intermediate phase we used detailed 
estimates for the Netherlands of annual follow-up costs per patient for breast 
cancer (De Koning et aL, 1991). For the other types of cancer the relative 
follow-up costs compared to breast cancer, caIculated for 87,000 patients in 
the United States (Baker et aI., 1989), were combined with the costs for breast 
cancer, yielding the annual follow-up costs per patient. 
The hospital costs in the incidence phase were primarily based on the 
length of stay in 1988, by type of cancer, age and sex, according to nation 
wide Dutch hospital register (SIG, 1990a). The length of stay for patients with 
metastases as primary cause for hospital admission determined the in-hospital 
cost during the last year of life. Although the last year of life and the period of 
metastases are not equivaIent, hospital stays concerning metastases are often 
concentrated in the last year of life (Baker et aI., 1989, Riley et aI., 1987 and 
Van BaIlegooijen et aL, 1992). This leIlooth of stay is assumed to be age- and 
sex specific, but not cancer specific, because if metastases are coded as 
primary cause of admission, the site of the primary tumour is seldomly 
known. 
The average hospital admission rate was derived by comparing the 
number of model based incident cases and deaths for 1988 (correcting for 
patients dying within the first year after diagnosis) to the number of hospital 
stays registered in 1988, for each combination of cancer, age and sex. The 
ratio of hospital stays versus incidence plus deceased served as the average 
admission rate. The admission rate was assumed to be equaI for the incidence 
phase and the last year of life, because the data did not allow for separate 
68 Chapter 5 
estimates (see discussion). Combination of the model-based incidence and 
mortality with length of stay and admission rate yielded the number of 'model-
based hospital days', which corresponds closely to the number of registered 
hospital days per cancer type, age and sex. Combining the number of hospital 
days with costs per day and adding other hospital costs (for surgery, 
radiotherapy, chemotherapy etc.) and non-hospital costs generated the average 
costs per patient. 
Disease model 
Our cancer model calculated the number of patients in each disease phase, per 
cancer type, age and sex (Bonneux et al., 1994). The model is a deterministic 
state transition model: it divides the population in subpopulations, defmed by 
states. Each model year, the population 'ages' one year and the states are 
updated. Transitions from one state to another are governed by probabilities, 
extracted from registries and literature. Transition probabilities depend ouly on 
the current state defined by age, sex, cancer type, and disease phase. 
A demographic module reproduces the population forecasts for the 
Netherlands (CBS, 1989) and generates first incidents of cancer by age and 
sex similar to the 1989 national cancer incidence rates for the Netherlands 
(Netherlands Cancer Registry, 1993). 
After incidence patients first run a risk of innnediate death as a 
consequence of primary trearment. The survivors are divided into two groups: 
a fraction which is cured and a fraction which is not. The not cured will enter 
the intermediate ('disease-free') phase of the disease, and subsequently will die 
of the disease, provided they do not die from other causes first. In practice of 
course cured and disease-free patients cannot be distinguished, and both will 
incur follow up costs. 
The cancer-specific mortality of the not-cured is modelled by applying a 
lognormal survival to the relative survival rates. Relative survival rates correct 
the observed mortality in the diseased population for the expected mortality in 
the reference population with the same age and sex (Rutqvist et al., 1984 and 
1985). Together this implies that survival after diagnosis can be characterised 
by 4 parameters: a fraction dead after trearment, a fraction cured, and the 
geometrical mean (equalling the median survival time) and variance of the 
lognormal distribution. A mathematical description of the survival is in 
appendix 5. 
The demographic module takes care of all other causes of death, 
corrected for the studied diseases by using cause elimination life table 
Costs of cancer 69 
methodology. This other causes mortality probability is applied to all states in 
the model, under the assumption that it is independent. Prevalences are 
calculated is the result from incidence, disease specific mortality and all other 
causes mortality. 
Surviving patients run a higher risk of a second cancer episode. 
Therefore they are again subjected to the cancer incidence of the reference 
population, multiplied by the relative risks observed in the Connecticut cancer 
register (Boice et aL, 1986). 
The model was calibrated on aggregate data of cancer survival from 
Dutch and Scandinavian cancer registries, corrected for other causes of death. 
The fraction dead after treatment is from the Dutch hospital register (SIG, 
1992), the other three survival parameters were estimated by an iterative 
noulinear least squares regression, weighted for the numbers of deaths. 
Residual errors were smaiL 
Scenarios 
We have illustrated the relevance of epidemiology for future cost estimates 
with four scenarios for colorectal cancer. Scenario 1 ouly incorporates the 
expected demographic development. In scenario 2 we have added an 
improving prognosis after diagnosis. In the Norwegian and Finnish registries a 
very significant improvement over time of 5 year relative survival rates has 
occurred between 1954 and 1985 of 2% per year (Cancer Registry Norway, 
1980; Langmark and Hagen, 1990; Hakulinen et aI., 1981; Finish Foundation 
on Cancer Research, 1989). We have extrapolated an average relative decrease 
of cancer specific mortality of 2 % per year to 2005. Five year survival rates 
thus increased from 44% (1985) to 55% (1995) to 66 % (2005). 
Scenario 3 involves, in addition to demography, a 2% annual relative 
increase in the incidence of all stages for men, and 1 % for women. The trend 
in incidence is assumed to be 2 % higher than the observed mortality trend in 
most western countries and is primarily caused by earlier diagnosis and 
increased detection of slower growing tumours (Doll and Peto, 1981). 
Scenario 4, in our opinion the most realistic one, incorporates 
demography, increasing incidence (2.5 % per year for men, 1.4 % for women) 
and improved survival. As a consequence, mortality rates for men decrease by 
0.4% annually and by 1.1 % for women, as has been observed in the 
Netherlands over the period 1978-1989 (SIG, 1992). 
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All costs are given in millions of Dutch guilders. In 1988, the exchange 
rate of one Dutch Guilder (dfl) was approximately 0.3 British Pound and 0.5 
U.S. Dollar. 
Results 
Total costs 
Total costs of malignant cancer in the Netherlands amounted to 1894 million 
Dutch guilders in 1988 (table 5.1), representing 4.8% of total health care 
costs. West-Germany and Sweden have a comparable share: 4 % and 5.1 % 
respectively (Henke and Behrens, 1986; Lindgren, 1990). For the United 
States it is somewhat higher: 6.2% (Rice et al., 1985). In-hospital care takes 
about 60 % of total costs. Outpatient hospital costs consist of radiotherapy (200 
min), chemotherapy (200 min) and follow-up costs (143 min). 
Table 5.1 Health care costs for cancer, by sector in millions of Dutch 
guilders (in parentheses as % of total cancer costs). The 
Netherlands 1988. 
Health care sector 
In-patient hospital care 
Out-patient hospital care 
Non-hospital care 
Total health care 
Costs for 1988 in min dfl 
1,148 
543 
203 
1,894 
(61 %) 
(29%) 
(11%) 
(100%) 
About Dfl 1,000 min was assigned to the five specific cancers, leaving 
almost 900 min for the other cancers (table 5.2). Lung cancer is in first place: 
it is responsible for 16% of the costs of cancer (300 min), and is mainly 
caused by men. Colorectal and breast cancer each represent about 14% of the 
total cancer costs, whereas stomach cancer and prostate cancer cause about 5-
6% of the total costs. This ranking corresponds to recent estimates for Texas 
(Williams and Begley, 1992). Hospital costs predominate and costs are fairly 
equal for both sexes. 
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Table 5.2 Health care costs per type of cancer, sex and health care sector, 
for six types of cancer in millions of Dutch guilders. The 
Netherlands 1988. 
Type of cancer Total costs % for men % in hospital 
Lung cancer 300 83 % 92 % 
Breast cancer 253 0% 82 % 
ColorectaI cancer 250 45 % 88 % 
Prostate cancer 110 100 % 87 % 
Stomach cancer 99 59 % 84 % 
Other cancers 882 46 % 92% 
All malignant cancers 1,894 49 % 89 % 
* 83 %: 83 % of total costs are incurred for men, leaving 17 % for women. 
Length of stay and admission rl11e 
Figure 5.1 shows the average length of hospital stay by age and sex for 
colorectal cancer for the incidence phase and the last year of life. Only the 
results for colorectal cancer are shown, but the general pattern applies to all 
types of cancer. 
Until age 55, the length of stay (per stay) is stable and fairly equal for 
both sexes. With increasing age, hospital stays become longer for both sexes, 
but at a quicker pace for women. For each type of cancer, older women in the 
Netherlands stay significantly longer in hospital than men of the same age, 
irrespective of the disease phase. Subsequent analyses have shown that this 
holds for the majority of diseases in the Netherlands (SIG, 1990a). Older 
women are more often single than older men (41 % verSus 15% in 1987 (CBS, 
1990), limiting the oppommities for home care, which may cause longer 
hospital stays. 
The average admission rate for colorectal cancer patients is 1. 8 until 
age 45, but diminishes considerably with increasing age (figure 5.2). For 
people of age 80 and older it becomes smaller than 1, implying that a 
substantial number of these patients are not hospitalized. Consequently, they 
consume relatively more nursing home care, district nursing care and general 
practitioner's services, which we took into account. The admission rate is 
hardly sex-specific. 
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Figure 5.1 Average length of hospital stay in days for colorectal cancer, by age-group, sex and 
disease phase. The Netherlands 1988. 
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and sex (model based outcomes). The Netherlands 1988. 
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Costs per disease phase 
Figure 5.3 shows the average costs per patient having colorectal cancer, 
during the incidence phase and the last year of life respectively. Until age 55 
the costs are stable, amounting to dfl 20-30,000 per patient. For women 
between age 60 and 75 they rise, due to the increase in length of stay which 
more than compensates for the falling admission rate. For people older than 
80 the costs fall to 12-20,000, as the low admission rate then becomes the 
dominant factor. Relatively low costs for patients older than 80 years were 
also found by Riley and Lubitz (1989). During the incidence phase, costs (dfl 
25-30,000) are higher than during the last year of life (20,000), Irrespective of 
age and sex. For women over 60 the costs are about dfl 5,000 higher than for 
men of the same age. 
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A considerable part of the results for colorectal cancer holds for all 6 
cancer types, such as the lower costs for patients older than 75. The higher 
costs for women older than 60 apply to all 4 cancer types that are relevant for 
both sexes. Fairly stable costs until age 60 prevail for all cancers, except for 
'other cancers', in which patients younger than 15 years incur considerably 
higher costs. This category is a mixture of very different types of cancer, both 
for young and for old patients. The high costs for people under 15 are mainly 
caused by leukaemia, brain cancer and non-Hodgkin's disease (Coebergh and 
van der Heijden 1991) for which therapy (immuno- and chemotherapy and 
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bone marrow transplantation) is very expensive (OTA, 1981; Black, 1982; 
Office of Health Economics, 1980). The notable increase in costs between age 
60 and 75 also applies to prostate cancer and lung cancer (women), but not to 
stomach cancer and other cancers. The incidence phase is not always more 
expensive than the last year of life. For breast-, prostate- and other cancers the 
last year of life appears to be more expensive. De Koning's smdy (de Koning 
et al., 1992) confirms this result for breast cancer. 
During the incidence phase, the average costs per person are the highest 
for stomach cancer (dfl 30,000) and other cancers in younger people (30-
50,000). Breast- and prostate cancer are relatively 'cheap' (21,000), leaving 
colorectal- and lung cancer in the middle-range (dfl 25-30,000). The variation 
in costs for the last year of life is much smaller, resembling Baker's fmdings 
for U.S.A. Medicare cancer patients (Baker et al., 1989), as well as Dutch 
results for breast and cervical cancer (van Ballegooijen et al., 1992; de Koning 
et al., 1992). We estimated these costs at about dfl 25,000. The only 
exception is 'other cancers', causing higher costs during the last year of life. 
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Costs over the course of cancer 
Assembling the three disease phases illustrates the costs over 1;he course of 
cancer (figure 5.4). The costs show two peaks, the first just after clinical 
detection, the second in the last year of life. In the intermediate phase, annual 
costs are very modest. The total costs of the intermediate phase depend chiefly 
on the length of disease-free survival. The total costs related to prevalence of 
cancer only become important if the intermediate phase is very long, say 15 
years. 
Table 5.3 Predicted costs per type of cancer for the Netherlands in 2005 
and 2020, demographic scenario, in millions of guilders in 1988 
prices, and as index compared to 1988 (1988= 100). 
Type of cancer Costs in 2005 Costs in 2020 
Lung cancer 377 (126) 474 (158) 
Breast cancer 311 (123) 352 (139) 
Colorectal cancer 308 (123) 375 (150) 
Prostate cancer 134 (123) 173 (157) 
Stomach cancer 122 (123) 151 (150) 
Other cancers 1.060 (120) 1.253 (142) 
All cancers 2.312 (122) 2.778 (147) 
All diseases 45,110 (116) 51.675 (130) 
DerrwgraphY and costs 
Table 5.3 shows the predicted costs regarding all 6 cancer types, for the years 
2005 and 2020, applying the demographic scenario. In 2005, the index for 
total cancer costs (in 1988 it was 100) is 122: a 1.2 %point annual increase, 
comparable to total health care (index 116). Costs increase at about the same 
rate for each type of cancer. In 2020, the burden of ageing becomes heavier, 
as the Dutch postwar baby boom reaches ages 60-75. By then cancer costs 
(index 147) will have increased considerably more rapidly than total health 
care costs (index 130). The costs of lung- and prostate cancer will be most 
seriously affected by ageing (index 158 and 157 respectively). The 
consequences for breast cancer and other cancers are less severe as they 
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prevail at relatively young age. Still, their rate of cost increase is higher than 
for total health care. 
Scenarios for colorectal cancer 
The two-peaked cost pattern has important implications for furore cancer costs. 
The results of four scenarios for colorectal cancer are presented for the year 
2005 (table 5.4). According to our model, costs of colorectal cancer in 2005 
amount to 308 million guilders, if only demography is taken into account. 
Improving disease-free survival (scenario 2), and consequently increasing the 
prevalence of cancer, will result in dfl 299 min, since it only raises the 
number of patients consuming the relatively inexpensive follow-up (incidence 
remains the same) and cancer specific mortality declines, because of other 
causes mortality. On the other hand, if the same increase in prevalence of 
disease-free persons occurs, but due to a rise in incidence (scenario 3), the 
costs will rise substantially to dfl 395 min. All extra patients will undergo 
expensive diagnosis and primary therapy. Furthermore, cancer mortality 
increases, causing extra costs as well. In case of the most realistic course of 
events (scenario 4), the costs will amount to dfl417 min. 
Table 5.4 Predicted costs for colorectal cancer for the year 2005 applying 4 
models to 4 scenarios, in millions of guilders. In parentheses: 
differences in % compared to outcomes of the 3-phase model. 
1988 2005 2005 2005 2005 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 
Three phase 250 308 299 395 417 
model 
No phase model 250 309 358 358 413 
prevalence (+20%) (-9%) (-1%) 
based 
No phase model 250 310 218 401 279 
mortality-based (-27%) (+2%) (-33%) 
No phase model 250 290 290 380 460 
incidence-based (-6%) (-3%) (-4%) (+10%) 
Scenario 1: only demography; Scenario 2: demography and survival improvement; Scenario 
3: demography and incidence increase; Scenario 4: demography. incidence increase and 
survival improvement: For exact details on the scenarios. see the material and methods. 
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Table 5.4 also presents the predicted costs using simple extrapolations 
without discerning disease phases. Three variants are shown, based on 
constant costs per prevalent case, per death and per incident case, 
respectively. In case of scenario 1, incorporating only demography, the 
predictions are quite accurate, although the incidence method understates the 
costs by 6%. 
The prevalence-based method predicts the same costs for scenario 2 and 
3 since either produces the same prevalence in 2005. In case of improved 
survival (scenario 2), this leads to overestimating the costs by 20%. If the 
incidence increases (scenario 3), the costs are underestimated by 9%. The 
mortality-based approach is quite accurate if the incidence rises (and 
consequently mortality) but fails completely in predicting the costs of survival 
improvement. For scenario 2 and 4 the costs are understated by 27-33 %. The 
incidence-based method performs reasonably in case of scenario 1 to 3, but for 
scenario 4 costs are overestimated by 10 %. 
Discussion 
Epidemiology and medical consumption vary considerably between types of 
cancer as well as between individual patients. Recoguising this variability, our 
analysis shows that the general pattern of medical consumption coincides 
remarkably well for the six cancer types described. The length of hospital stay 
increases uniformly with age, especially for women. On the other hand, the 
admission rate falls with age. For patients older than 75, the second factor 
dominates, resulting in lower costs. Over the course of cancer, medical 
consumption shows two peaks: during the first year after incidence and in the 
last year of life. In between the costs are modest. 
We assumed the same admission rate for patients in the incidence phase 
and the last year of life. The length of hospital stay for patients with 
metastases was assumed to be age- and sex specific, but equal for all cancer 
types, which is supported by research in the U.S.A. and the Netherlands. Both 
assumptions are obviously rather crude, but sufficient to demonstrate the 
divergent consequences of several scenarios. Sensitivity analysis by 
substantially varying the most uncertain parameter -the admission rate during 
the incidence phase versus the last year of life- proved not to affect the basic 
two-peaked pattern of costs seriously. Consequently, the predictions of future 
costs for the scenarios described are robust. 
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The costs during the prevalence phase were based on Dutch calculations 
for breast cancer, combined with Baker's relative estimates for other types of 
cancer. As the costs are relatively low, errors in these estimates will not 
influence the results seriously. 
The assumed survival improvement for colorectal cancer (scenario 2 
and 4) Seems high, but is the results of two processes: a true decrease of 
mortality due to more effective treatment and a spurious increase of survival 
due to earlier diagnosis (lead time) and increased detection of slow growing 
tumours which had passed unnoticed before (length time and pseudo-diagnosis) 
(Doll and Peto, 1981; Cole and Morrison, 1980). 
If one is ouly interested in the costs of demographic scenarios, simple 
extrapolations of current costs are satisfactory, provided that reliable 
information on costs by type of cancer, age and sex is available. However, it 
is highly plausible that in the future, trends in incidence and survival will 
prevail, as they have over the past 20 years. Although our three-phase model 
is still somewhat crude, it takes these dynamics into account and thus provides 
useful predictions of the costs of epidemiological scenarios. 
The demographic scenario, as described, is quite restrictive, since it 
does not account for future trends in risk factor exposure, like smoking for 
lung cancer and the influence of screening on breast cancer. Further 
refmement of the disease model and cost estimates is underway, in order to 
predict the influence of these trends on future morbidity, mortality and costs. 
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6 Indirect costs in economic 
confronting the confusion! 
Summary 
studies: 
Indirect costs of disease often constitnte a substantial part of estimated costs or 
savings in econontic evaluations of healtb care programs. The human capital 
approach is ahnost unanimOUSly used for estimating indirect costs, defmed as 
production loss due to disease, altbough a growing number of autbors 
questions its validity. Tbis chapter discusses tbe relevance of indirect cost 
estimates for healtb policy and reviews tbe current empirical and metbodologi-
cal literatnre on tbis issue. It describes several important issues and controver-
sies regarding indirect costs, such as tbe consequences of short term absence 
from work for productivity, reduced productivity witbout absence form work, 
tbe influence of unemployment on production loss, tbe relation between healtb 
effects and indirect costs and tbe possible medium term macro-econontic 
consequences of absence from work and disability. 
It concludes that indirect costs are relevant for healtb policy, provided 
that tbe estimates of indirect costs reflect tbe real changes in production due to 
disease, including tbe production of unpaid labour. Futnre research should 
focus on attaining tbese estimates. Indirect costs in econontic evaluations 
should preferably be presented separately from direct costs, healtb effects and 
otber study outcomes. 
Introduction 
In econontic studies often a distinction is often made between direct and 
indirect costs (or indirect benefits in tbe case of savings), and sometimes tbe 
latter category is further divided into indirect costs witbin and outside tbe 
healtb care sector. An example of indirect costs witbin healtb care is medical 
consumption during prolonged period of life due to life-saving interventions. 
I Chapter based on Koopmanschap and Rutten, PharmacoEconomics. 1993 
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We consider here only indirect costs outside the health care sector, also 
referred to as societal production losses as a consequence of illness (including 
its treatment), disability or death, This definition explicitly excludes the 
valuation of life per se, as applied in cost-benefit analysis; we consider only 
the changes in the individual's contribution to societal production, Some 
authors incorrectly describe direct non-medical costs, such as costs to the 
family and patient transportation, as 'indirect costs', Sometimes the nomnone-
tary costs of pain, suffering, discomfort etc. are also included in the concept 
of indirect costs. It is more appropriate to consider these items as health 
effects and to quantify them in terms of reduced quality of life. The latter 
procedure reduces the risk of double counting (both as costs and health 
effects). 
In sum we take an extra-welfarist position (Culyer, 1991), suggesting 
that an economic appraisal assesses the contribution of the intervention in 
terms of health gains, however measured, and in terms of the opportunity 
costs to society of performing a health care intervention or implementing a 
health care program. Clearly, these opportunity costs include changes in the 
production of those individuals who undergo such intervention or participate in 
such program. 
Indirect costs appear in cost-of-illness srudies as well as in economic 
appraisals of interventions, and the appropriateness of their appearance in the 
latter type of srudies is often debated. This is illustrated by the fact, that the 
Ontario guidelines for economic appraisal in support of reimbursement 
decisions regarding pharmaceuticals do not object to including indirect costs in 
economic evaluation studies (Detsky, 1993; Ontario Ministry of Health, 1991), 
whereas the earlier version of the Australian guidelines stated that indirect 
costs should not be included in srudies submitted to the Australian pharmaceu-
tical benefits advisory committee (Commonwealth of Australia, 1990). The 
most recent version of the Australian guidelines suggests that economic 
appraisals of pharmaceuticals should present results both with and without 
indirect benefits and costs included, but stresses that valuation of work time 
gained or lost should be made explicit (Henry, 1992). 
Part of the confusion on the proper place of indirect costs in economic 
srudies is related to uncertainty about the appropriate methodology to estimate 
their magnirude accurately and to the fact that, in many studies to date their 
magnitude has been grossly overestimated. This chapter reviews the current 
starus of estimating indirect costs in economic studies, to clarify some metho-
dological and policy-related issues and to suggest how the issue of indirect 
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costs should be properly addressed. 
A literature review 
Before discussing methodological issues, it seems useful to see how economic 
evaluations practically deal with production losses. The MEDLINE literamre 
retrieval system was scanned for studies considering indirect costs of disease, 
published between 1987 and 1992. We identified 49 articles related to indirect 
costs, of which 23 papers have appeared since 1991, mirroring the growing 
popularity of economic evaluations (table 6.1 and appendix 6). The majority 
has been written by U.S.A.-authors, whereas in Europe the Swedish have 
published many articles. 
Cost-of-illness studies, followed by cost-effectiveness analyses, are most 
likely to include indirect cost estimates. Almost all disease categories are 
being addressed. Ten smdies concern health care interventions related to 
drugs, 7 of these being complete economic evaluations (cost-effectiveness/cost-
utility analysis or cost-benefit analysis). 
Virtually all studies used the human capital approach, which estimates 
the value of potentially lost production (or potential lost income) as a conse-
quence of disease. We use the world potentially because in case of permanent 
or premature death at a specific age, the total productive value (or income) 
from that age until the age of retirement is counted as indirect costs (McGuire 
et al., 1988). In several articles the methods used were not stated clearly. As a 
rule, costs of absence from work are taken into account, just like mortality 
costs, if relevant. It is often not clear whether long term disability was 
considered. Production losses due to unpaid labour are valued in ouly 14 of 
the articles, mostly at market prices. 
Ouly 6 articles, mostly European, point at the problems associated with 
calculating indirect costs or criticize the use of the human capital method. Two 
authors stress that estimating production losses should not be confused with 
valuing lives (Fitzgerald and Gafni, 1990; Levin and Jonsson, 1992). Three 
authors point to the fact that the human capital method will overestimate 
indirect costs for patient groups in an economy with less than full unemploy-
ment (Levin and Jonsson, 1992 ; Gerard et al., 1989; Olsson et al., 1987). 
The influence of indirect costs on results was substantial. On average, indirect 
costs represented 52 % of total disease costs or total costs saved by health care 
interventions. 
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Table 6.1 Overview of empirical studies concerning indirect costs, extrac-
ted from the Medline literature retrieval system and published 
during 1987-1992. 
Year 1987 1988 1989 1990 1991 1992 
Number of 5 7 5 8 12 11 
studies 
Country United Sweden United Canada Other 
States Kingdom countries 
Number of 27 6 2 2 12 
studies 
Health care Total Drugs Prevention Orthopae- Other Total 
sector health dies 
care 
Study category 
Cost of illness 23 0 1 0 3 27 
CENCUA 0 6 2 2 2 12 
CBA 0 0 3 
Cost analysis 0 3 1 0 0 4 
Other 1 0 0 0 2 3 
Total 24 10 5 2 8 49 
Some controversies 
Despite the widespread use of indirect costs in economic evaluations and the 
predominance of the human capital approach, many authors of methodological 
papers feel uncomfortable with the concept. Some have philosophical objecti-
ons against using indirect costs. Including of production losses may favour 
health care interventions directed to (well paid) working people, which may 
conflict with equity considerations. This is because, on average, nonworking 
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people already have a lower health status. This is true especially if the results 
of economic studies are used to suppon decisions at the level of individual 
patient treatment. 
Others criticize the way in which indirect costs are estimated. They 
state that the human capital method estimates the value of potemiaJ production 
lost, whereas the actual loss for society may be much smaller. Drummond 
commented in this respect: " for shon term absences, a given person's work 
may be covered by others or made up by the sick person on his return to 
work. For long term absences, an individual's work can be covered by 
someone drawn from the ranks of the unemployed. Therefore, while absence 
from work may cost the individual, or that person's employer, it may not cost 
society very much" (Drummond, 1992). 
Production losses are not restricted to absenteeism. For several disea-
ses, sick people may continue working at a slower pace. Thus far, only a few 
studies tried to estimate the extent of the production losses involved in such 
case. These studies concern the cost of migraine (Osterhaus et aI., 1992) and 
the costs and effects of using cimetidine for peptic ulcer (BIPE, 1978). 
If the societal perspective is used, estimates of indirect costs should 
incorporate production losses of unpaid labour. Nevenheless, such costs are 
often not taken into account, which may lead to an undesirable bias in health 
policy in favour of preventing and fighting diseases which occur predominant-
ly in men. 
Finally, it is sometimes suggested that including quality of life and 
indirect costs in economic evaluations may lead to double counting. Russell 
stated: 'Estimates of earnings help to describe the consequences of better 
health in greater detail, but they are not an addition to the health effects. To 
include them as a separate item is to count some of the effects twice, once as a 
gain in health and again as a saving to be subtracted from program costs' 
(Russell, 1986). 
Why and how to include indirect costs 
The philosophical objections could easily be met by excluding indirect costs 
from economic evaluations. However, this would deny a significant part of 
economic reality, since production losses do contribute to the scarcity of 
resources and hence decrease the wealth of society. It seems preferable to 
insist that economists estimate indirect costs as realistically and trustwonhily 
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as possible, incorporating production losses in relation to unpaid labour, 
Indirect costs may be presented together with, but separate from, health 
care costs, health effects, consequences for equity and ethical and legal 
considerations. It is the responsibility of health care decision makers to decide 
on the relative weight that they want to attach to indirect costs, compared with 
other costs. 
Shan term absence 
Regarding short term absence from employment, Drummond's opinion has not 
provoked much discussion among health economists yet, but it seems to have 
inspired health authorities. Australian guidelines for economic evaluations in 
health care that were issued in 1990 in the context of decisions on reimburse-
ment of pharmaceutical products deuied any production loss due to short term 
absence: flISt, because production will be made up on the return to work, and 
secondly because employers usually have excess capacity in the labour force to 
cover absenteeism (Co=onwealth of Australia, 1990). This line of reasoning 
was obviously an oversimplification. We agree with Drummond that 'the real 
position is likely to vary from case to case. An approach that ascribes either 
full production losses or zero losses in every case is likely to be incorrect' 
(Drummond, 1991). In addition, if the excess labour force within a company 
is structural, part of these excess labour costs may be the result of absentee-
ism. 
The exact relation between short term absence and production loss 
depends on the employee's profession, the type of organisation and the 
production process. For example, a bus driver must be replaced in order to 
deliver the transportation services, whereas a sick health economist may make 
up his or her work later. 
Complete insight into the consequences of short term absence for 
indirect costs requires detailed study at company leveL A more recent version 
of the Australian guidelines takes these objections into account and suggests 
that study results should be presented with and without indirect benefits and 
costs included. In addition, evidence is required that indirect benefits are 
really achieved through introduction of the dmg (Henry, 1992). This requires 
detailed analysis of the relationship between illness and productivity, prefera-
bly at the level of the employer. 
Generally, absence from work affects the effective labour time of 
workers. Numerous studies demonstrated that a reduction of annual labour 
time causes a less than proportional decrease in labour productivity per year. 
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The elasticity found for some large companies in the Netherlands ranges from 
0.6 to 0.9. (de Koning and Tuyl, 1984). In the absence of specific data, these 
estimates of the relationship between labour time and productivity may be 
usefully employed to deal with production losses due to short term absence 
(see chapter 8). 
Long term absence 
With respect to long term absence, many health economists agree on the 
mitigating effect of unemployment on production losses due to long term 
absence (Drummond et aI., 1987; Gerard, 1989; Lindgren, 1981; Williams, 
1985). They restrict the argument to substantial, persistent unemployment. If 
unemployment is less than frictional, workers may not be replaced easily and 
production losses would approach the human capital estimates. Frictional 
unemployment is an inevitable part of unemployment, since filling vacancies 
takes time and some qnalitative discrepancies between labour demand and 
supply always prevail. Generally, frictional unemployment is assumed to be 1-
2 % of the labour supply. 
When authors recognize the influence of unemployment on production 
losses, they tend to incorporate this relationship rather crudely in their 
analysis. Thus, if unemployment is assumed to be less than frictional unem-
ployment, all absence is counted as production loss, whereas if unemployment 
is substantial, the loss is assumed to be nihil. It seems more realistic to assume 
that production loss always occurs to some extent, but that the amount depends 
on the time span needed to replace a sick worker, or to reorganise the produc-
tion process otherwise. The length of this time span depends on the availability 
of qualified personnel within firms and on the labour market. During this 
adaptation period the production falls, or the production remains equal at extra 
costs. Consequently, the indirect costs are proportional to the length of the 
adaptation period. 
In our view, a suitable proxy for the length' of this period is the 
duration of vacancies, since it is sensitive both to the unemployment rate and 
to the efficiency of the labour market (van Ours and Ridder, 1991). The use 
of this concept in estimating indirect costs of disease, the so-called "friction 
cost method", was introduced recently (Koopmanschap and van Ineveld, 
1992). In cases of very low unemployment, the friction cost method is less 
obvious applicable, since it may underestimate the true production losses. On 
the other hand, even then production losses will not last forever, so the human 
capital approach will still overestimate indirect costs. 
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Production loss without absence 
Production losses that may occur when an individual is not absent from work 
are even more difficult to measure. Data have to be collected by questioning 
individuals on their remaining productivity during sickness, and the opportuni-
ties to make up later for the productivity lost or to reorganise parts of the 
work. With respect to Osterhaus and colleagues' study (Osterhaus et al., 
1992), Drummond (1992) questioned the reliability of asking a person to recall 
reduced productivity over the last year, and the associated heavy reliance on 
subjective assessments. These objections may be met partially by using diary 
methods or recalling over a short period, for example the past two weeks. 
Unpaid work 
With respect to unpaid work, data on work absence and disability are very 
scarce. At the moment, the best solution appears to use data from time 
surveys, combined with specific patient questionnaires. In addition, it is 
important to know what happens if an unpaid worker gets ill. As for paid 
labour, short term illness may also lead to postponement of work, which can 
be made up later. If the illness takes longer, the work may be taken over by 
professional workers, for example home helps, and/or by the patient's co=u-
nity (family, friends, neighbours etc.). 
Professional replacement can be valued at market prices. Informal care 
supplied at the expense of paid labour may be valued by the workers labour 
costs. If supplying informal care reduces leisure time, the valuation should 
reflect the opportunity costs of leisure time. The latter costs are difficult to 
measure properly, and the possible positive utility (i.e. the satisfaction of the 
person who supplies informal care) of taking care of a partner, relative or 
friend should be taken into account too (Wright, 1987). 
Double counting 
Russell's fear of double counting of indirect cost and health effects (Russell, 
1986) raises the question of the impact of disease on health and on the 
economy, respectively. The impact on health and that on production are to a 
high degree distinct consequences of health care programs requiring separate 
measurement. However, if income from labour is (among other things) 
determining health status, the influence on health and on the economy become 
mutually dependent and the danger of some double counting arises. It may be 
possible to disentangle these effects. In quality-of-life studies, respondents may 
be asked to value the effect on their quality of life of being able to work, apart 
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from the value of extra earnings. According to Jonsson and colleagues: 'the 
existence of health insurance and cash benefits, ... make(s) it reasonable to 
assume that respondents take only limited account of the effect of health statns 
on their income when asked to state their preferences for differem health 
states' (Jonsson et aI., 1991). This argument seems rather convincing for 
developed countries. However, in less developed countries where people are 
lacking adequate health insurance, labour income may be indispensable to the 
enjoyment of any quality of life, bringing about Russell's problem of double 
counting again. 
Macro-economic consequences 
Absence from work and disability may influence the national economy in 
several ways ('the macro-economic conseqnences of disease'), in addition to 
the direct consequences for production, as described above. Absence from 
work, by influencing labour productivity, directly affects the labour costs per 
unit of output, an important determinant of competitiveness on the world 
market. This may affect the level of production of the sector exposed to 
international competition and consequently the national income of a country, 
which is an important indicator of a nation's wealth. 
Reducing the incidence of disability will raise labour supply and 
unemployment, lowering labour costs, which again improves the production of 
the sector exposed to international competition and increases national income. 
Although disability benefits do not represent indirect costs, because they are 
income transfers, they may have an economic impact. The level of insurance 
premiums paid influences the labour costs per unit of output, affecting the 
performance of the exposed sector of the economy, as described above. 
Insurance premiums may also affect the net disposable income of workers, 
influencing private consumption and domestic production. 
These macro-economic consequences are not simple to quantify, 
because several processes mutnally interact, each having a different time lag. 
For example, a change in disposable income almost instantaneously influences 
private consumption, whereas the effect of labour costs on exports takes much 
longer. For a correct estimation of these macro-economic consequences a 
macro-economic model is indispensable (see chapter 8). 
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Indirect costs and health policy 
Depending On the level and context of decision making and on the associated 
perspective on costs, policy makers are more or less inclined to take indirect 
costs in consideration when choosing between alternative strategies. But even 
when the societal perspective is regarded as the relevant one, there is still 
reluctance to accept indirect costs as a relevant factor in the decision-making 
process. Hence, there is still the challenge for health econontists to clarify the 
concept of indirect costs and to present accurate and reliable estimates of their 
magnitude in econontic studies. 
Important in this respect is the fact that estimates of indirect costs of 
disease in cost of illness studies mostly refer to the total costs of absence from 
work, disability and mortality. These total costs of disease represent the 
possible savings of eradicating disease, which comes down to estimating 'the 
benefits of the unattainable' (Shiell et aI., 1987). For health policy purposes, 
the consequences of attainable changes in absence from work and disability 
are highly relevant. In this respect, we need reliable estimates of the possible 
change in absence, disability and mortality, as a result of health care interven-
tions. This again illustrates the greater relevance of cost-effectiveness analysis 
compared to cost of illness studies (Drummond, 1992). 
The estimates of indirect costs should preferably take into account the 
possible competition between diseases. If for example, absence due to ntigrai-
ne can be curbed, without simultaneously reduction of workplace stress (one 
of the possible underlying causes), absence due to other diseases related to 
stress may increase, offsetting part of the estimated cost savings: 
The agenda for future research 
In setting an agenda for future research concerning indirect costs of disease, 
the following issues may be considered. First, we observed that production 
losses may occur as a consequence of lost opportunities for both paid and 
unpaid labour. As the literature review revealed very little research on the 
value of unpaid labour, a first point on the research agenda may be the 
estimation of the amount and value of production losses due to unpaid labour. 
A number of issues discussed led us to suggest the use of another 
concept in estimating indirect costs of disease, the so-called 'friction cost 
method', which seeks to estimate the real amount of indirect costs attributable 
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to disease, taking into account the situation within firms and on the labour 
market. If this approach is to be followed, a number of questions need to be 
addressed: (a) what is the frequency of friction periods (dependent on instituti-
onal arrangements)? (b) what is the average length of the friction period 
(dependent on age, sex, and education level); and (c) what is the relationship 
between the valuation of lost production and the length of the friction period? 
Such an approach would take explicit account of the situation on the labour 
market, which will influence the length of the friction period (see chapter 7 
and 8). 
Further analysis of the consequences of short term absence from work 
for output, productivity and costs is needed, as well as a study of the extent of 
production losses that may occur during illness without absence from work. 
And frnally, the macro economic consequences of absence from work should 
be quantified, taking into account the various interactions described. 
Each of these topics would require significant research effort. We 
believe that such research effort is required because indirect costs will become 
accepted as an integral part of economic appraisal, both by the scientific 
co=unity and by health policy makers, only when they can be estimated in a 
valid and reliable manner. 
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7 Towards a new approach for estimating 
indirect costs of disease! 
Summary 
Many researchers in the field of evaluation of health care doubt the usefulness 
of estimates of indirect costs of disease in setting priorities in health care. This 
paper attempts to meet part of the criticism on the concept of indirect costs, 
which are defmed as the value of production lost to society due to disease. 
Thus far in cost of illness studies and cost-effectiveness analyses the potential 
indirect costs of disease were calculated. In the following a first step will be 
taken towards a new method for estimating indirect costs which are expected 
to be effectuated in reality: the friction cost method. This method explicitly 
takes into account short and long run processes in the economy which reduce 
the production losses substantially as compared with the potential losses. 
According to this method production losses will be confined to the 
period needed to replace a sick worker: the so called friction period. The 
length of this period and the resulting indirect costs depend on the situation on 
the labour market. Some preliminary results are presented for the indirect 
costs of the incidence of cardiovascular disease in the Netherlands for 1988, 
both for the friction costs and the potential costs. 
The proposed methodology for estimating indirect costs is promising, 
but needs further development. The consequences of illness in people without 
a paid job need to be incorporated in the analysis and also the relation betWeen 
internal labour reserves and costs of disease should be further investigated. In 
addition, more refined labour market assumptions, allowing for diverging 
situations on different segments of the labour market are necessary. 
1 Chapter based on Koopmanschap and van Ineveld, Soc Sci Med, 1992 
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Introduction 
In most cost of illness-studies and in some cost-effectiveness analyses the 
indirect costs of disease are considered and estimated. Not all researchers are 
convinced that indirect cost estimates contribute to the economic evaluation of 
health care programs. In this paper a first step will be taken in developing an 
alternative method of estimating indirect costs, which meets an important part 
of the criticism. The conceptual elements of this method will be described in 
detail. Some preliminary results will be presented for the indirect costs of the 
incidence of cardiovascular disease in the Netherlands for 1988. A comparison 
will be made with the traditional method of estimating indirect costs based on 
the human capital approach. 
The concept of indirect costs 
Indirect costs of disease can be defmed in several ways, depending on the 
perspective and objective of analysis. In this paper the indirect costs of disease 
will be defined as the value of production lost to society due to illness, with 
respect to paid labour as well as unpaid labour. While defmed this way, this 
paper deals ouly with paid labour. 
Production losses can be the consequence of: 
- temporary absence from work; 
- disability; 
- premature mortality. 
Basically, production losses can even be relevant without absence from 
work if sick people continue working at a suboptimal level. Information on 
this topic is nnfortunately not available, so it won't be analyzed in this paper. 
The specification excludes the "costs" of pain, suffering, discomfort etc. Next 
to the formidable problem of valuing these items in monetary terms, it seems 
more appropriate to consider these psychological factors as effect variables 
and to quantify the consequences in terms of reduced qnality of life. This 
procedure will also avoid possible double counting. 
As a consequence we will focus on the "pure" economic consequences 
of disease. Furthermore it should be stressed that we don't seek to assign a 
value to human life per se, as in some cost-benefit analyses (Schoenbaum et 
a1., 1976). This definition of indirect costs is therefore compatible with social 
cost-effectiveness analyses and cost-utility analyses. 
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Almost all studies estimating indirect costs use the human capital 
approach. The way in which the human capital approach is usually being 
applied leads to an estimate of the value of potentially lost production (or the 
potentially lost earnings) as a consequence of disease. We use the word 
potentially because in case of permanent disability or premature mortality at a 
specific age the total productive value ( or earnings) from that age until the age 
of retirement is counted as indirect costs. 
This concept of indirect costs in the economic appraisal in health care is 
not uncontroversial (Drummond et a!., 1986 and 1987; McGuire et al., 1988; 
Harnmian et a!., 1981). The critical comments focus on four topics: 
1) earnings may be a poor estimate for the amount of production forgone to 
society. Abetter, though not perfect, estimate used in the rest of this paper is 
labour costs. 
2) health cate programs directed to working people will always generate more 
gains in production than programs for mentally handicapped or elderly. This 
could lead to priority setting enlarging existing inequalities in health, which 
may conflict with policy objectives. 
3) sometimes it is not clear if costs are direct or indirect and this may cause 
double counting of costs. 
4) the real production losses can be much smaller thau the potential losses 
because sick people can often be replaced at little cost. 
Notwithstanding this critique the fact that production losses due to 
illness (and production gains due to health cate) influence the scarcity of 
resources and therefore the wealth of society is not disputed. In this respect 
there exists no difference in assessing direct and indirect costs; both should be 
incorporated in economic evaluations of health care programs. 
The first and fourth criticism don't overthrow the concept of indirect 
costs but merely stress the importance of using estimates of the production 
losses which are expected to be effectuated in reality. 
Addressing the first point of critique, an example in which labour costs 
are a poor estimate for the value of production is unpaid labour in the 
household. Reliable estimates of production losses shonld therefore include the 
production involved in this type of labour. 
With respect to the second critical comment, the gain in society's 
wealth will indeed be larger for programs directed to economically active 
people. Explicit estimates of these gains will be more helpful in decision 
makjng thau using implicit notions. Next to this, estimates of indirect costs 
should never be weighed in isolation, but always as a part of the political 
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decision making process, in conjunction with other criteria like direct costs 
and equity, In addition, including indirect costs has implications for equity. 
If a health care service is actually implemented estimates of production 
gains can be useful in the discussion about how the program needs to be 
financed. 
An example of the third comment: if a sick person is a day absent of 
work and needs to visit a physician one could approximate the value of the 
time spent on the visit by the value of production lost in this time-span. If one 
also calculates the production lost due to a day of absence from work, the sum 
of direct and indirect costs is clearly an overstatement. We think this problem 
can be avoided by continuous awareness of the possibility of simultaneous 
sickness absence and medical consumption. 
The last item can be met when taking into account the economic 
processes which make that sick people can be replaced, mitigating the amount 
of production losses. Several examples can be given in which the expected 
production loss due to illness may be much smaller than the potential loss. 
- If unemployment, registered as well as hidden unemployment, is well beyond 
the level of inevitable frictional unemployment, sick persons can be replaced 
by unemployed. 
- If labour reserves exist within firms with sick employees the loss in 
production may be negligible. 
- Non-urgent work may be cancelled or postponed without consequences for 
the level of production. 
- If replacement is ouly feasible by persons already working, a reallocation of 
employees over jobs can induce a smaller production loss, resulting from a 
vacant job at a lower productivity. 
The underlying notion is that processes within firms and on the labour 
market will lead to replacement of sick persons, after a period of adaptation, 
reducing the production loss substantially. Unemployment is important in this 
respect, but it is not the ouly factor causing the difference between potential 
and real production losses. The above mentioned processes are effective in the 
short run when the organisation of the production and the labour market 
conditions are merely fixed constraints. 
In the longer run unemployment may fall substantially or enhanced 
efficiency within firms may reduce internal labour reserves, both inducing 
higher production losses. However, in the longer run labour shortages and 
production losses will be mitigated by increasing possibilities for restructuring 
the organization of the production, by reallocation of employees and as a 
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result of laboursaving investments. To illustrate this process the analysis 
should preferably be linked to a macro-economic model incorporating vintages 
of capital goods in relation to the relative costs of capital and labour. 
In the following the concept of indirect costs will be modified, setting a 
first step towards deriving more realistic estimates of production losses due to 
disease. 
Operationalisation 
Disease may cause losses in production, but in general this loss will be 
confined to a period needed to adapt to the changed situation. This period will 
be called the friction period. To clarify this notion further, it may be helpful 
to consider the possible economic consequences of disease on the micro-
economic level. Due to illness, there are three possible outcomes for 
production and costs during the friction period. 
- Production falls; 
- Production remains equal at extra labour input and extra costs; 
- Production falls in spite of extra labour input and costs. 
The sum of production loss and possible extra costs can vary widely, 
depending on the way extra labour input is realized. Acquisition of labour 
from within the fum will often be cheaper compared with hiring exterual 
personnel. Exact data about the magnitude of losses and extra costs as well as 
the frequency of these possible outcomes are lacking. Therefore a macro-
economic approximation of the indirect costs should tackle this problem. The 
labour costs of the sick employee during the friction period may be the best 
possible estimate of the average indirect costs. Additioual costs for selecting 
and training personnel may be relevant if the sick person must be replaced 
permanently. 
In the Netherlands the current level of registered and hidden 
unemployment is substantial. Recent labour market studies indicate that with 
growing employment many yet non-participating women acquire new jobs. 
Still the participation rate for women is low, so an important part of non-
participating women can be considered as involuntarily unemployed (Dept. of 
Social Affairs and Employment, 1989; Teulings et a1., 1987). Furthermore, 
Dutch studies indicate that 15-20% of the prevalence of persons receiving 
disabjlity benefits should actually be considered as unemployed (Roodenburg 
and Wong, 1985; Vrooman and Kemp, 1990). 
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Therefore we assume that in general replacement of sick persons by 
unemployed is possible after a friction period. The production loss during the 
friction period is assumed to be equal to the labour costs of the sick person. 
For an estimate of the total indirect costs of a disease two items are to be 
analyzed: the costs per friction period and the frequency of friction periods. 
The costs per friction period are calculated for the Netherlands 1988. 
Because of insufficient data on the quantity of unpaid labour and its 
consequences for absence from work and disability the analysis yet had to be 
restricted to paid labour. 
The average value of production per labour-year has been approximated 
by combining the net domestic product, measuring the total net value added by 
all employed labour, with the number of labour years in 1988 (CPB, 1989). 
This average production value was made age- and sex-specific using data 
about the relative gross labour incomes per labour-year by age and gender 
(CBS, 1988a). We assumed a stable and linear relationship between gross 
income and the value added per labour year. 
Data on the relative amount of full time and part time labour by age 
and sex were extrapolated on the basis of a detailed study (Teulings et al., 
1987) and used to calculate the average production value per working person 
per year. Correction for the age- and sex- specific share of employed persons 
in the population yields the average production value per person per year by 
age and sex. 
The value per working person is applied to data on absence from work 
and disability. The production value per person will be used to calculate the 
indirect costs of mortality. We assumed equal mortality rates for employed 
and not-employed. 
The length of the friction period was derived from data on the average 
period necessary to fJ.J.I vacancies: 2.5 months in 1988 (not age- and sex-
specific) (CBS, 1989a). 
The production values per year are applied in calculating the potential 
indirect costs. The values per friction period lead up to the friction costs after 
combining them with the frequency of friction periods. 
We would prefer using estimates of the marginal productivity instead of 
average productivity. However, reliable data on marginal productivity are 
difficult to obtain, especially for the services sector. 
Data on absence from work, disability and mortality provide 
information about the frequency of friction periods (CBS, 1988b; CBS, 1989b; 
GMD, 1988). These databanks are not linked at the level of individuals which 
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makes some assumptions necessary. For the Netherlands a distinction must be 
made between employees and self-employed, as a consequence of differences 
in registration. 
For employees the possible flows between healthy, absent of work, 
disabled and dead are depicted in figure 7.1. In case of "immediate death" 
(flow 1) and absence from work (flow 5) a friction period is relevant. 
Premature death while one is absent of work (flow 3) can induce double 
counting of friction periods if the absence from work is longer than the 
friction period. We can't correct for this, because the number of people dying 
during absence from work and the relation with the length of absence are 
unknown. However the results in table 1 show that the maximum level of 
double counting is still small. Flows 2 and 4 don't cause friction costs because 
in the Dutch system one acquires the status of disabled only after a stay of one 
year in the absence from work insurance. In this case the friction period took 
place in a previous year. 
(l) F 
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Figure 7.1 Flows between healthy. absence from work. disabled or dead for employees. 
including the relevance of friction periods (F). 
For self-employed no absence from work register exists, so the 
frequency of friction periods must be derived from data on immediate death 
(flow 1) and incidence of disability (flow 3), see figure 7.2. Flow 1 was 
calcnlated by correcting total mortality for the number of disabled persons 
dying. 
If internal labour reserves prevail, they can further reduce the frequency 
of friction periods and the level of production losses. A study of the Dutch 
industry for the period 1975-1982 estimated the level of general internal 
labour reserves as between 5 and 15% of the existing labour volume, 
concluding that 5 % seems a minimum level of general internal labour reserve 
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of firms (de Koning, 1987), Given the heterogeneity of labour the reserve will 
be lower for each individual employee, but how much lower is unknown, 
Because of this uncertainty no further corrections are made for internal labour 
reserves, 
HEALTHY 
• 
I 
Figure 7.2 
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Flows between healthy, disabled and dead for self-employed, including the relevance 
of friction periods (F). 
As far as the internal labour reserves exist for purposes of covering for 
sickness absence, these costs are clearly related to sickness, Internal labour 
reserves can also be useful in coping with fluctuations in the volume of 
production, In that case the costs are not caused by sickness. These remarks 
illustrate the need for further investigation of the role of internal labour 
reserves. 
The assumptions for calculating the friction costs and the potential 
indirect costs can be summarized as follows. In both cases the incidence of 
absence, disability or mortality in 1988 is the viewpoint of analysis. In case of 
the friction cost method one friction period is counted per death until age 65, 
correcting for disabled persons dying. Incidence of disability is ouly relevant 
for self-employed persons. Days of absence from work are counted, but only 
within the friction period of two and a half months. 
In estimating potential indirect costs production losses caused by 
mortality are counted until age 65. The average period of disability has been 
estimated for each 10-year age group and sex and was applied to the incidence 
of disability in 1988. All registered days of absence from work are counted. 
Costs beyond 1988 were discounted by 5% yearly. 
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Results 
Table 7.1 shows the estimated indirect costs of the incidence of cardiovascular 
disease. The estimates are based on the production losses of paid labour only. 
due to insufficient data on unpaid labour. The results differ substantially 
depending on the method used. as could be expected. Total costs according to 
the human capital method are over 5 billion guilders, the friction cost methods 
results in somewhat more than 400 million. The major part of this difference 
is due to the cost of disability and mortality because of the great difference in 
the length of the period in which production losses are assumed to prevail. 
The results for the costs of absence from work differ less dramatically. The 
relative difference in costs of both methods corresponds with a Dutch study of 
the costs of traffic-accidents which used a variant of the friction cost-method 
(van Haselen, 1987). 
Considering the types of cost per method, the imporlance of the costs of 
absence from work diverges completely. More than 80 % of the friction costs 
are caused by absence from work compared with only 12 % for the human 
capital method. The opposite holds for the shares of costs induced by mortality 
and disability. The above mentioned possibility of double counting in case of 
people dying while absent of work is by definition lower than 60 min Dfl, the 
friction costs caused by mortality, see table 7.1. 
Table 7.1 
Mortality 
Disability 
Indirect costs of incidence of cardiovascular disease according to 
the friction cost method and the human capital approach (gross 
variant) for the Netherlands in 1988 in millions of Dutch 
guilders. Costs beyond 1988 were discounted by 5% per year. 
Friction cost Human capital 
(mln dfl) (mln dfI) 
60 (14%) 2,072 (39%) 
19 (4%) 2,615 (49%) 
Absence from work 353 (82%) 624 (12%) 
Total costs 421 (100%) 5,311 (100%) 
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Discussion 
Comparing both methods of estimating indirect costs the following remarks 
can be made. Both methods can provide ouly global results as they use 
aggregate data. 
In some smdies estimates of production losses according to the human 
capital theory are corrected for the chance for an individual to become 
unemployed (Muller and Caton, 1983; Berk et al., 1978). This indeed 
influences the individual income, but does not necessarily have an impact on 
society's level of production. So this won't necessarily lead to indirect costs 
according to our definition. 
A critical remark on the friction cost method may be that its credibility 
depends on the existence of substantial unemployment. However, the friction 
cost method is sensitive to the level of unemployment. If unemployment 
declines, the average period to fill vacancies will become longer, inducing 
higher costs per friction period. The situation on the Dutch labour market has 
acmally developed in this direction since 1986. The costs per friction period in 
1990 will therefore be larger than our estimates for 1988. Nevertheless, in 
parts of the labour market with serious shortages, production losses will 
certainly be higher than estimated by the friction cost method. 
The most important shortcoming of the results presented here is the lack 
of a reliable estimate of the production loss of unpaid labour, understating the 
production losses of women and elderly people to a large extent. This could 
lead to undesirable policies in favour of intensifying efforts to prevent and 
fight diseases from which predominantly men are suffering. This again shows 
the implications of calculating indirect costs for equity. Data on unpaid labour 
are very scarce. This also holds for the amount of absence from work and 
disability with respect to unpaid labour. Both are indispensable elements in 
estimating the indirect costs. 
With respect to the internal reserves of labour within firms three 
qualitative comments can be made. First, it is plausible that their size will be 
influenced by the expected sickness absence, especially if the work can't be 
postponed and the sick employee must be replaced immediately (e.g in case of 
busdrivers). This will diminish the amount of production lost by disease, but 
at extra costs for maintaining this labour reserve. The costs of this reserve are 
not necessarily high, because firms may be able to hire employees for part-
time jobs, who can be employed more hours if necessary (Reich et al., 1973). 
Secondly, the size of internal reserves and the level of unemployment may be 
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inversely related, because in times of high unemployment fmns can more 
easily acquire new personnel to replace sick employees. On the other hand, in 
the Netherlands temporary employment agencies play an important role in 
providing a flexible supply of labour which can act as a buffer, reducing 
fluctuations in the size of internal reserves. Thirdly, internal labour reserves 
can be held partly in order to cope with fluctuations in the volume of 
production. In this case not all costs are directly related to sickness. It can be 
concluded that the numerous aspects of the relation between costs of disease 
and internal labour reserves should be studied in more detail. 
In estimating production 10sses one should be careful when considering 
only the registered sickness absence, because sick people can continue 
working at a suboptimal level. The extent of this phenomenon is very difficult 
to quantify, but especially in times of high unemployment, it can be more than 
negligible. 
Further analysis will be necessary on the costs of selection and training 
if vacancies have to be fIlled permanently and the level of internal labour 
reserves for specific jobs. 
A stratification of the labour market assumptions seems useful to 
incorporate differences between parts of the labour market which are relevant 
for the level of production losses. The labour market can be split into 
educational levels, each with different production values and length of the 
friction period. This will refine the estimates of indirect costs and takes labour 
shortages in some market segments into account. For such refinement data on 
incidence and mortality by education level should be available. 
Conclusion 
In setting priorities in health care reliable estimates of direct and indirect costs 
of disease are indispensable. Thus far studies only provide estimates of the 
potential indirect costs of disease. 
The friction cost method can be considered as a promising method of 
estimating the indirect costs which may actually result from the incidence of 
disease. This approach explicitly takes into account short run and long run 
adaptation processes in the economy. The friction cost method is therefore 
highly compatible with the methodology of cost-effectiveness analysis in which 
the real resource costs (of a disease or technology) are subject of analysis. 
Because the costs per friction period depend on labour market 
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conditions the estimates of the indirect costs can vary widely over time and 
across countries. In situations with a tight labour market the differences 
between the potential costs and the ftiction costs will become much smaller 
than shown in table 7.1. The differences also depend on the type of disease. In 
case of diseases causing predominantly disability and mortality the gap will be 
much wider than for diseases merely inducing absence from work. 
The proposed methodology needs further development. Especially the 
consequences of illness in the longer run have to be considered in more detail, 
preferably by linking the analysis to a macro-economic model. Presumably, 
these consequences are minor, especially when illness occurs in more flexible 
and adaptive sectors of the economy. Furthermore, our empirical analysis is 
global and preliminary. Further refinement of the underlying labour market 
assumptions is necessary; both with respect to distinguishing different 
segments on the labour market as to a better analysis of the amount of 
sickness-related costs caused by internal labour reserves. Extension of the 
analysis to the consequences of illness in people without a paid job is needed. 
8 The friction cost method for measuring 
indirect costs of disease' 
Summary 
A new approach for estimating the indirect costs of disease, which explicitly 
considers economic circumstances that limit production losses due to disease, 
is presented (the friction cost method). For the Netherlands the short term 
friction costs in 1990 amount to 1.5-2.5% of net national income (NNI), 
depending on the extent to which short term absence from work induces 
production loss and costs. The medium term macro-economic consequences of 
absence from work and disability reduce NNI by an additional 0.8 %. These 
estimates are considerably lower than estimates based on the traditional human 
capital approach, but they better reflect the economic impact of illness. 
Introduction 
The inclusion of indirect costs of disease in economic appraisal is subject to 
considerable debate and scepticism. The disagreement on the relevance of 
indirect costs resulting from reduced productivity can be illustrated by consi-
dering recent guidelines for economic evaluations in health care, that are 
issued by Australian and Ontarian health authorities in the context of decisions 
on reimbursement of pharmaceutical products. The Australian guidelines 
suggest to exclude indirect costs, whereas the Ontarian seem to support 
inclusion (Commonwealth of Australia, 1990; Ontario Ministry of Health, 
1991). Apart from ethical objections to any form of incorporating indirect 
costs in economic evaluation, criticism concentrates on the predominating 
estimation method: the human capital approach. Defining indirect costs as the 
value of production lost, more preCisely as wealth lost, to society due to 
disease (and hence not as valuing lives per s6), the human capital method 
, Chapter based on Koopmanschap et al., J of Health Economics, 1994 
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estimates the potential production lost, which may overestimate the actual 
production lost to a considerable extent, 
We introduced an alternative approach: the so called "friction cost 
method", which takes into account several economic circumstances, that may 
reduce the estimated production losses substantially as compared with estima-
tes based on the traditional human capital approach (see chapter 7), In this 
paper we will develop this friction cost method further, focusing on the 
influence of the labour market situation on indirect costs, the impact of 
absence from work on labour productivity and the macro-economic conse-
quences of absence from work and disability, The estimation of indirect costs 
takes place in two steps, First, the short term effects of illness are considered 
by studying its possible consequences at the level of the firm. 
Second, medium term effects occur because of changes in labour costs 
per unit of output, social insurance premiums and labour supply and these will 
influence national income, the most generally used yardstiCk for society's 
wealth, as well as other economic indicators such as (un)employment, inflati-
on, the balance of payments and the government deficit, 
As an illustration total cost of absence from work, disability and 
monality respectively, will be estimated for the Netherlands in 1988 and 1990, 
using the friction cost method and the human capital approach. However, in 
this case estimates of total costs of disease represent the possible savings of 
eradicating disease and hence come down to estimating "the benefits of the 
unattainable" (Shiell et aL 1987). Therefore, the more relevant consequences 
of attainable reductions in absence from work and disability will be calculated. 
The impact of several assumptions will be investigated in a sensitivity analy-
sis. 
The friction cost method 
Indirect costs disputed 
Including indirect costs in economic appraisal of health care programs is not 
universally accepted. Opponents of inclusion state that health care programs 
directed to working people always generate more gains in production than 
programs for mentally handicapped or elderly. Even if allocation of resources 
to individuals is not driven by such considerations, this could well lead to 
priority setting enlarging existing inequalities in health. This argument shonld 
be taken seriously. Nevertheless, production losses due to illness do influence 
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the scarcity of resources and therefore the wealth of society. In this respect 
there is nO difference in assessing direct and indirect costs; both should be 
incorporated in economic evaluations of health care programs. 
There may be a trade-off between equity and efficiency: society's 
wealth will indeed gain more from programs directed to economically active 
people. Explicit estimates of the extent of the trade-off may be more helpful in 
decision making than using implicit notions. In health policy decisions, 
estimates of indirect costs should be weighed in conjunction with other criteria 
like direct costs, ethical considerations and equity. 
The "costs" of pain, suffering, discomfort etc. are sometimes included 
in the concept of indirect costs. In this paper we focus on the indirect "econo-
mic" costs of illness. 
The human capital approach and the friction cost method 
Almost all studies estimating indirect costs use the human capital approach 
(see chapter 6). This method estimates the value of potentially lost 
production (or the potentially lost income) as a consequence of disease. We 
use the word potentially because in case of permanent disablement or prema-
ture death at a specific age the total productive value (or income) from that 
age until the age of retirement is counted as indirect costs. Many authors have 
suggested that the real production losses for society may be much smaller 
(Drummond, 1992; Gerard et al., 1989; Lindgren, 1981; Williams, 1985). 
For short term absenteeism, work may be taken over by others, non-urgent 
work may be cancelled or made up for by the sick employee on his return to 
work. For long term absences, work can be taken over by someone drawn 
from the ranks of the unemployed or by reallocating employees over jobs. 
More systematically, if an employee gets ill, the following outcomes 
are possible for a firm's production and costs (assuming some form of social 
insurance for absence): 
1) Both the level of production and costs are unaffected. This situation 
may occur if work can be made up for by the sick employee on his return to 
work or if internal labour reserves exist, allowing work to be taken over by 
colleagues without extra costs. The opportunity costs of internal labour 
reserves depend on the probability for the internal labour reserve to be 
gainfully employed elsewhere. If unemployment is well above the level of fric-
tional unemployment, these costs are very low. However, the existence of 
permanent internal labour reserves raises labour costs, which may have 
medium term macro-economic implications, as described below. 
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2) Production remains unchanged, but at higher costs, due to colleagues 
working overtime or hiring temporary workers, from a firm's own pool or 
from temporary agencies. In both cases the extra costs of maintaining produc-
tion tend to be somewhat higher than average labour costs, as a result of 
higher wages paid for working overtime (reflecting the opportnnity costs of 
leisure time) or the extra costs of using temporary agencies. 
3) Production falls, while costs remain unchanged. The value of 
production lost is the relevant outcome. 
4) Production falls, despite higher costs. The consequences are a mix of 
production loss and extra costs of permanent or temporary employees, which 
may be higher (or lower, although this is not to be expected) than the value of 
production of the sick employee. 
In case of simation 1, zero costs are incurred in the short run, whereas 
the medium term consequences need to be analyzed, see below. Concerning 
the other three possible simations, the sum of production loss and extra costs 
varies from case to case, but on average it may well be approximated by the 
productive value of the sick employee during the period of absenteeism. 
Because in simation 1 no short term costs prevail, we need to know its 
probability of occurrence. Exact empirical data on this probability are non-
existent, but there is some material on the underlying determinants of the 
employment policies of firms. First, it should be known how often work can 
be made up for by the sick employee on his rerum to work. This possibility 
seems to be restricted to short term absence for jobs for which production can 
be postponed for a while and which output is not an indispensable input for 
other jobs. For example, a bus driver must be replaced in order to deliver the 
transportation services, whereas a sick health economist may make up for 
(most of) lost production a week later. Because we lack evidence on the 
magnimde of this phenomenon, we performed a sensitivity analysis regarding 
this issue. 
The occurrence of simation 1 also depends on the degree to which firms 
maintain internal labour reserves, which in mm depends on the relative costs 
and risks of keeping internal labour reserves versus flexible forms of labour 
provision, such as temporary workers, flexible contracts etc. The most 
important determinants for internal labour reserves versus flexible labour 
appear to be (Williamson, 1981; Osterman, 1987; Mitchell and Zaidi, 1990): 
- the macro-economic simation and the state of the relevant product market. 
The more uncertainty exists, the greater the employer's desire to make labour 
costs variable and execute flexible labour policies; 
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- the situation on the labour market. The tighter the labour market, the more a 
firm wants to maintain internal labour reserves, because flexible labour may 
become very scarce and expensive; 
- the technology of the production process. The more delicate and risky the 
production technology used, the more skilled employees are required and the 
more suitable internal employment is; 
- the firm-specificity of employee's skills. In a downturn market employees 
with firm-specific skills will not be laid off soon, since training new employ-
ees if the market recovers is expensive; 
- the predictability of the level of production (business cycle) and the possibili-
ty of production in advance. The less predictable production, the higher the 
costs of a permanent internal labour reserve. If stock production is not 
possible, as often in producing services, flexible labour may be very useful to 
produce the output required; 
- the heterogeneity of labour. The less homogeneous labour is, the larger the 
total amount of internal reserve required and the more expensive it is as 
compared to flexible labour reserves; 
- the predictability and variance in time of absence from work. If the absence 
pattern is unpredictable and clustered in time, flexible labour reserves seems 
more attractive; 
- the degree of competition. The more competitive a market, the larger the 
propensity to choose for less expensive, flexible labour reserves; 
- the institutional setting. A liberal labour market legislation facilitates flexible 
labour policies, for example by allowing immediate dismissal. 
In summary, choosing the appropriate mix of internal and flexible 
labour reserves depends on the trade-off between three different goals of a 
firm: - minimizing wages for any given level of output, - maximizing predicta-
bility i.e. the confidence of the availability of qualified labour at foreseeable 
prices and - flexibility with respect to staffing levels and abilities of the labour 
force (Osterman, 1987). Enhancing predictability always has a certain price in 
terms of higher labour costs and/or less flexibility and vice versa. 
Empirical research for the United Kingdom, the Netherlands and the 
U.S.A. clearly shows that during the eighties the amount of flexible labour 
used has increased, even during the upturn of 1983-1990 (Hunter et aI., 1993; 
OSA, 1987; Elfring and Kloosterman, 1993; Mitchell and Zaidi, 1990). In 
addition, Hunter et al. found that the firm's main motives for extending 
flexible labour are demands for short term cover as well as deliberate respon-
ses to increased product market uncertainty. Although these results unambigu-
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ously indicate a growing role for flexible labour, they cau not answer the 
question on the relative quantity of internal labour reserve versus the use 
flexible labour arrangements. Hence, we assume for the moment that all short 
term absence spells induce indirect costs to some extent (for long term absence 
see below). Consequently, the estimates of friction costs as described below 
should be viewed as upper bound estimaJ:es of the short term indirect 
costs of disease. The lower bound estimates are described in the sensitivity 
analysis. 
Returning to the friction cost method, its basic idea is that the amount 
of production lost due to disease depends on the time-span organisations need 
to restore' the initial production level. We assume that if unemployment, 
registered and hidden, is beyond the level of frictional unemployment, sick 
employees can be replaced, after a period necessary for adaptation. Frictional 
unemployment is an inevitable part of unemployment, since filling vacancies 
takes time and some qUalitative discrepancies between labour demand and 
supply always prevail. Production losses are assumed to be confmed to the 
period needed to replace a sick worker: the friction period. This situation 
currently applies to the Netherlands, where the level of registered and hidden 
unemployment is substantial. In 1988 and 1990 registered unemployment was 
10.2% and 8.2% respectively (CPB, 1992). In addition, several studies indica-
te that 15-20% of the persons receiving disability benefits should be conside-
red as unemployed, thus adding another 3 % unemployment (Roodenburg and 
Wong, 1985; Vrooman and Kemp, 1990). 
In order to calculate the indirect costs of disease, using the friction cost 
method, the following questions need to be answered: 
when does a friction period occur? 
how long does a friction period last? 
how can the indirect costs during a friction period be determined? 
- how can the medium term macro-economic consequences of illness be 
estimated? 
Operationalisation of concepts 
The frequency of friction periods 
The possible flows between healthy, absent from work, disabled and dead, 
which depend on the specific social security arrangements, determine when 
friction periods occur (see figure 7.1 and 7.2 for the Dutch case). Hence, in 
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order to estimate the total number of friction periods one needs data on the 
frequency and length of absence spells, the incidence of disability and mortali-
ty, correcting for the number of deaths in the disabled population. 
The length of the friction period 
The length of the friction period is based on the average vacancy duration, 
which depends on the level of unemployment and on the efficiency of the 
labour market in matching labour demand and supply. Substantial unemploy-
ment in an economy as a whole does not rule out labour scarcity in specific 
parts of the labour market. Assuming a homogeneous labour market may 
result in underestimating indirect costs, and therefore one should consider at 
least different segments of the labour market separately, preferably according 
to education level. The education level has proved to be an important determi-
nant of (un)employment (Teulings and Koopmanschap, 1989). 
As a rule, the friction period is longer than the vacancy duration, since 
time may elapse between the emergence of production loss and the decision to 
create a vacancy. In addition, time passes between filling a vacancy and the 
first working day of the new employee, especially if he or she is already 
employed. Even filling a vacancy by an employee from the same fum takes 
time. We take both circumstances into account in estimating the length of the 
friction period. 
Absence and productivity 
As noted above, short-term absence may lead to production loss andlor extra 
costs to continue production, but the extent to which this occurs depends on 
various circumstances as discussed above. Complete insight in the consequen-
ces of short term absence for indirect costs requires more detailed stndy on the 
level of the firm. However, generally speaking, absence from work reduces 
the effective labour time. Numerous stndies have demonstrated that a reducti-
on of annual labour time causes a less than proportional decrease in labour 
productivity per year. The estimated elasticity for annual labour time versus 
labour productivity is between 0.6 and 0.9. (CPB, 1987a; de Koning and 
Tuyl, 1984; WRR, 1977). In our main variant we assume the elasticity to be 
0.8. It should be noted however, that because these elasticities were estimated 
on the level of the firm, they inevitably reflect the composite result of two 
possible components: the diminishing retnrns on labour and a possible reducti-
on of the internal labour reserve. On the level of the fum, these two compo-
nents can not be disentangled. 
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The valuation of lost production 
We assume that the production level is restored after (a part of) the friction 
period. The actual indirect costs of disease consist of: the value of production 
lost and/or the extra costs to maintain production and, if an employee is to be 
replaced permanently, the costs of filling a vacancy and training new person-
nel. We assume the costs to be 80% (the aforementioned 0.8 elasticity of 
labour time versus productivity) of the average value of production per 
employee, by age-group, sex and education level. Costs of absence from work 
shorter than the friction period are calculated as being 80% of the production 
value during the period of absence. Costs of absence spells longer than the 
friction period are equal to the costs of a friction period, since we assume 
replacement after completion of the friction period. The production value per 
time period per employee is multiplied with the length of friction periods due 
to absence from work and incidence of disability. Because we assume equal 
mortality rates for employed and non-employed, the average production value 
per person (the production value per employee, corrected for participation in 
paid labour) is used to calculate the indirect costs of mortality before age 65. 
Macro-economic consequences 
The friction cost method concerns the short term indirect costs of disease. In 
addition, absence and disability may also have medium term macro-economic 
consequences. Absence from work, reducing labour productivity, directly 
affects the labour costs per unit of output, which is an important determinant 
of competitiveness on the world market. This may change the production of 
firms in the "exposed sector" of the economy: exporting firms as well as firms 
producing for the domestic market facing foreign competitors. Consequently, 
national income and other macro-economic indicators may be affected. 
The amount of insurance premiums related to absence has no separate 
economic impact in the Netherlands. A change in absence premiums paid only 
causes a redistribution between wages and sickness benefits, total labour costs 
per worker remaining equal. 
Although disability benefits themselves do not represent indirect costs, 
as they are income transfers, they may have economic consequences in two 
ways. First, insurance premiums influence the labour costs per worker and per 
unit of output, affecting the performance of the exposed sector of the econo-
my. Secondly, insurance premiums affect the net disposable income of 
employees and employers, influencing private consumption, domestic producti-
on and national income. The extent of this influence depends on the possibili-
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ties for employees and employers to pass on changes in premiums to each 
other. 
Furthermore, disability may have other economic consequences, in 
addition to the "premium-route" just described. Reducing the incidence of 
disability will raise labour supply and unemployment. High unemployment has 
a negative medium term impact on the average wage level and thus on labour 
costs, improving the competitiveness of the exposed sector. On the other hand, 
the high prevalence of disability in the Netherlands has undoubtedly raised the 
productivity of the labour force, because in the Netherlands less productive 
workers run a higher risk of becoming disabled (Aarts and de Jong, 1990). 
Policies, effective in lowering the incidence of disability, may have a small 
negative effect on average labour productivity. 
These macro-economic consequences of absence and disability can only 
be estimated by using a macro-econometric model, allowing for all interactions 
and time lags involved. 
Data and methods for the Netherlands 
Frequency of friction periods 
We used national, aggregated data on the frequency and length of absence 
from work, covering 50% of employment. We corrected for the fact that the 
absence rate for persons for whom we lack exact data is somewhat lower 
(CBS, 1989c and 1991). Data on incidence of disability and mortality by age 
and sex were available, covering the entire population (CBS, 1989b and 
1991a; GMD, 1989 and 1991a). 
The relation between absence and education level (and age and sex) for 
1988 was derived from a sample of 25,000 Dutch workers (NIA, 1993). For 
the risk of becoming disabled by education level, we used the estimates of 
Bloemhoff and de Winter (1991). Mortality rates for men by education level 
for the Netherlands were estimated by Doornbos and Kromhout (1990) and 
applied to men and women. 
Length of the friction period 
We split up the labour market into 5 education levels. This reduced heteroge-
neity considerably, because in the Netherlands unemployment is clearly higher 
for tower educated (CBS, 1991b). Van Ours' proportional hazards model 
showed that the longer the vacancy rate, the smaller the probability that a 
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vacancy is filled (van Ours and Ridder, 1991). Following van Ours' model, 
we estimated the completed vacancy durations by education level for 1988 and 
1990, based on quarterly data on the uncompleted vacancy durations and the 
number of vacancies, from a large sample of Dutch firms (CBS, 1988a and 
1990a), adding an additional period to allow for time lags indicated above. 
Absence and productivity 
The elasticity for annnal labour time versus labour productivity, found for the 
Netherlands is between 0.6 and 0.9. (WRR, 1977; de Koning and Tuyl, 1984; 
CPB, 1987a) We assume the elasticity to be 0.8 (de Koning and Tuyl, 1984), 
performing sensitivity analysis on this parameter. 
Valuation of lost production 
The average value of production per labour-year was approximated by 
combining the net national product and employment in labour years in 1988 
and 1990 (CPB, 1992). This production value was made age-, sex- and 
education level-specific using data on the relative gross labour incomes per 
labour-year by age, sex and education level (CBS, 1989a and 1991c; LTD, 
1993). We assumed a linear relationship between gross income and value 
added per labour year. Data on participation in full-time and part-time labour, 
based on the annual Dutch labour force sample (CBS, 1989d and 1991b) were 
used to calculate the average production value per employee and per 
person (age-, sex- and education-specific). 
Macro-economic consequences 
The macro-economic consequences of absence and disability were calculated, 
using the quarterly macro-econometric sectoral model FKSEC for the Nether-
lands, developed by the Dutch Central Planning Bureau (CPB, 1992a). This 
general equilibrium model has been chosen after careful comparison of several 
macro-econometric models on their overall performance as their suitability for 
estimating the macro-economic consequences of disease. The model FKSEC is 
the youngest member of a family of well known Dutch macro-econometric 
models and is currently the most frequently used" in advising the Dutch 
government and parliament on short- and medium term economic develop-
ment. 
It explicitly models the production process on the sectoral level (6 
sectors), taking account of the differences between sectors in labour intensity, 
in the degree of substitutability between capital and labour and in the speed 
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with which different sectors adjust to shocks in demand. In the capital-intensi-
ve exposed sector. the production capacity is based on a vintage production 
function. Vintages of capital goods for which the labour productivity is lower 
than the real wage have a negative return and are scrapped. Employment in 
the exposed sector is related to labour demand at full capacity and the utilizati-
on rate of capital. Because in the sheltered sector and other sectors labour is 
the main factor of production, capacity is based on the current labour force 
and the lagged trend in labour productivity. The employment level is determi-
ned by production (given production capacity), real labour costs, the ratio 
between the minimum and the average wage, working time and labour 
augmenting technical progress. 
A historical simulation for the period 1979-1988 was carried out with 
the model, showing that FKSEC is capable of reproducing the most crucial 
developments in the eighties, such as the decrease in export growth, invest-
ments and production in the beginning of the decade and the acceleration 
afterwards (CPB, I 992a). An extensive survey of the CPB macro-economic 
models is given by Bodkin (Bodkin, 1991). 
The model does not have a separate variable for absence from work, 
but absence from work primarily influences labour time per year and hence 
labour productivity per worker. A change in the number of disabled principal-
ly affects labour supply, social insurance premiums and labour productivity. 
The model simulates the rest of the consecutive chain of events including 
changes in labour costs, production, consumption, exports, national income 
etc. 
The macro-economic consequences of disease are calculated as differen-
ces between the simulation runs and the base run. The latter reflects the 
expected economic development, without serious changes in the development 
of absence and disability. The simulation period is 1991-1998, allowing all 
possible time-lags to effectuate. In the simulation runs changes in absence and 
disability are assumed to be structural. 
For the main variant in the following results we have split the 
labour market into five education levels and assume the elasticity of labour 
time versus production to be 0.8 (de Koning and Tuyl, 1984). Absence from 
work, incidence of disability and mortality are also related to sex, age and 
education level. 
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Results 
Shon term friction costs 
The average friction period was estimated to be 2.8 months in 1988 and 3.2 
months in 1990. including the vacancy duration and 3-5 weeks to allow for the 
time lags mentioned (table 8.1). In both years the friction period is considera-
bly longer for higher education levels, reflecting higher unemployment for 
lower educated and a longer period needed for hiting higher educated wor-
kers. In 1990 friction periods converged, as the labour market for higher 
educated became less tight, while at the same time lower and intermediary 
educated technicians became relatively more scarce. 
Table 8.1 
Year 
1988 
1990 
Estimated length of friction periods for the Netherlands in 
months, by education level, for 1988 and 1990. 
Education level 
Overall Basic Extended Interme- Higher University 
basic diary vocational 
2.8 2.2 2.5 2.7 3.5 3.8 
3.2 2.8 3.0 3.3 3.4 3.5 
The average production loss per employee, per friction period is higher 
for men than for women and increases sharply with education level and with 
age, levelling off at age 50 (see appendix 8). This reflects the strong positive 
relation between hourly wages and both age and education level and the 
substantial amount of part time work performed by women in the Netherlands. 
Absence from work is strongly related with education: absence rates for 
the lowest educated are about 4 times as high as for the highest education 
level. Absence increases with age and is higher for women under 45 compared 
to men, partly due to pregnancy. The lower educated also run a higher risk of 
becoming disabled: the relative risk of the lowest versus the highest education 
level is 2.3, after correction for age. The relative risk of dying before age 65 
for the lowest educated is 1.5. 
The friction costs of disease for the main variant (assuming a heteroge-
neous labour market and labour time elasticity of production = 0.8) are shown 
in table 8.2. The friction costs amount to 9.5 billion guilders in 1988 and 12 
billion guilders in 1990, about 2.5% of net national income. About half of the 
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cost increase between 1988 and 1990 is due to employment growth (raising the 
absolute number of absence days), productivity growth and inflation. The 
other half is the result of (on average) longer friction periods, mirroring a 
more tight labour market. The costs of absence from work predominate, since 
we assume production losses to be confmed to the friction period and conse-
quently disability and mortality hardly contribute to the costs. The distinction 
by education level has a small upward effect on costs. The higher costs per 
hour and longer friction period for higher educated are almost entirely 
compensated by their considerably lower rate of absence. 
Table 8.2 Indirect costs of disease in the Netherlands for 1988 and 1990 
(main variant) in billions of Dutch guilders (in parentheses as % 
of net national income). 
Cost category Friction costs 1988 Human capital Friction costs 1990 
costs 1988 
Absence from work 9.2 23.8 11.6 
Disability 0.15 49.1 0.2 
Mortality 0.15 8.0 0.2 
Total indirect costs 9.5 (2.1 %) 80.9 (18%) 12.0 (2.6%) 
without education split 9.3 11.6 
Table 8.2 also presents the indirect costs for 1988, according to the 
human capital approach, which amount to more than 80 billion guilders, 18% 
of net national income. The huge difference compared to the friction costs is 
due to the cost of disability and mortality, which are assumed to cause 
production losses in the long term. Costs of disability are very large, because 
the average duration of disability in the Netherlands is 15 years. 
The costs of absence from work differ less dramatically. As the friction 
cost method assumes production loss to be limited to the short run, the friction 
costs for diseases that cause mainly disability and mortality are much lower 
than according to the human capital approach. For diseases entailing short 
term absence, the difference is much smaller. 
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Table 8.3 Macro-economic consequences of eliminating absence from work 
and incidence of disability respectively, during 1991-1998, in % 
of net national income and other macro-economic indicators 
(differences in 1998 between the simulations and the base run). 
NNI Employ- Produc- Export Bal.of !nfla- Govern. 
ment tion pay- tion budget 
xlOOO ments % % NNI 
NNI 
I Absence +0.30% - 112 +0.9% +2.0% +0.1% -0.7% -0.2% 
from work 
II Disability +0.49% +345 +2.2% +4.0% +0.8% -4.2% -1.5% 
total effect 
ITa premium +0.07% + 71 +0.4% +1.0% +0.5% -0.9% +0.6% 
effect 
lIb labour +0.42% +271 +1.9% +3.1% +0.3% -3.3% -2.1 % 
supply 
effect 
* The sum of the partial effects ITa and lIB is not equal to the total effect fl, due to very 
small interaction effects 
Medium term macro-economic consequences 
The medium term macro-economic consequences of absence and disability are 
presented in table 8.3, as structural differences in 1998 and later years, 
between the specific variants and the base run. The average Dutch absence 
rate is 8%, so we increased working time by 9% (={100-92}192) during 
1991-1998 to illustrate the impact of eliminating absence from work. In 1998, 
overall labour productivity will be 3.3 % higher than in the base run: a 5 % 
increase in the exposed and construction sector and 2 % in the sheltered sector. 
The production of the exposed sector will increase by 1.6%. In the sheltered 
sector and the construction sector the production increase is only 0.6%, since 
it is limited by domestic demand. As a consequence, employment falls, raising 
unemployment. 
Labour costs per unit of output decrease, causing an increase in export 
(+2%) and overall production (+0.9%) from 1994 onwards. The increased 
unemployment will push down wages, so private consumption slightly falls. 
The decrease in consumption occurs almost immediately, whereas the increase 
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in production and export is lagged. As a consequence, it takes 4 years for the 
national income to increase as compared to the base run. After 8 years the 
strucrural increment in national income is 0.3%, which is considerably smaller 
than the increase in export. 
Assuming no incidence of disability implies that each year during 1991-
1997 labour supply increases by 116,000 persons, who would otherwise have 
left the labour force. As a result, disability premiums and the corresponding 
cash benefits decrease by 3.1 billion guilders per year. The second row of 
table 8.3 shows the total consequences of disability. Labour costs per worker 
decrease substantially (-16 % in 1998), due to lower premiums and increased 
labour supply (the "Phillips curve-effect"). Employment grows considerably, 
but it can ouly absorb one third of the extra labour supply, so unemployment 
rises. Production (+2.2%) and export increase (+4%), whereas private 
consumption decreases (-1.7%), due to lower wage rates. 
After 5 years, national income will be higher as compared to the base 
run, in 1998 the difference is 0.49%. The last two rows of table 8.3 show that 
the increase in labour supply is responsible for the lion's share of the effects. 
The impact of the lower disability premiums is relatively small, due to the 
trade-off between disability benefits and unemployment benefits. Since the 
total effect of disability is about equal to the sum of both effects, interaction 
effects appear not to be significant. 
Scenarios 
Table 8.4 shows the friction costs and the macro-economic consequences of 
three attainable scenarios regarding reduction in absence from work and 
disability in the Netherlands. These scenarios appear to be attainable, witnes-
sing recent trends towards more prevention and closer monitoring of absence 
from work in the Netherlands. Furthermore, there is scope for reduction as 
the level of absence from work in Belgium and Germany is lower than in the 
Netherlands (Prins, 1990). 
Reducing absence from work by 2 % (scenario 1), from 8 % to 6 % of 
labour time, will reduce friction costs by 2.3 billion guilders, about 0.5% of 
net national income. The medium term economic effects induce another 0.08% 
annual increase in NNI. Reducing the incidence of disability by 20 % (scenario 
2) hardly saves any 'friction costs, but the macro-economic consequences are 
more important: 0.1 % of NNI. Reducing both absence and disability (scenario 
3) will save 2.3 billion guilders friction costs and 0.18% of net national 
income in the medium term. The effect of scenario 3 turns out to be more or 
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less equal to the sum of the effects of scenario 1 and 2. The other macro-
economic indicators are affected in the same direction as shown in table 8.3. 
Table 8.4 Change in friction costs and macro-economic consequences of 3 
scenarios for absence from work and disability. Friction costs in 
billions of guilders (1990), in parentheses as % of net national 
income. Macro-economic consequences in % of NNI in 1998. 
Scenarios Change in friction Macro-economic conse-
costs in bIn dfl quences in % of NNI 
1 absence -2 %point -2.30 (0.5%) 0.08 % 
2 disability - 0.03 0.10 % 
incidence - 24000 
3 scenario 1 and 2 - 2.33 (0.5%) 0.18 % 
Sensitivity analysis 
The results of the sensitivity analysis are presented in table 8.5. The first two 
options represent the lower bound estimates for the friction costs of absence 
from work. 
As we lack detailed data on the consequences of short term absence, we 
assumed quite radically that half of the absence spells shorter than one week 
will not cause indirect costs, because work can be cancelled or postponed and 
made up for later. In this situation, the friction costs of absenc~ from work 
would amount to 10.2 billion guilders in 1990, which is only 12 % lower as 
compared to the main variant. 
If we alternatively assume the elasticity of labour time versus producti-
on to be very low: 0.5 instead of 0.8, (implicitly assuming an important role 
of internal labour reserves) the friction costs of absence are substantially 
lower: 7.3 billion guilders, about 1.5% of NNI, a 37% decrease as compared 
w the main variant. Hence, the friction costs are very sensitive to the level of 
this elasticity. 
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Table 8.5 Sensitivity analysis: indirect costs of absence from work (excl 
macro-econontic consequences) in billions of Dutch guilders in 
1990 and differences as compared to the main variant. 
Type of sensitivity analysis Indirect costs of absence 
(% diff.) 
Postponement of work 10.2 (-12%) 
Elasticity of production 0.5 7.3 (-37%) 
Friction period 6 months 14.7 (+27%) 
Human capital approach 23.8 (+ 105%) 
In order to show the relation berween the labour market situation and 
friction costs, we assumed a very tight labour market, entailing a long friction 
period, say 6 months. The friction costs amount to 14.7 billion guilders, a 
27 % increase as compared to the main variant. Indirect costs of absence from 
work based on the human capital approach amount to 23.8 billion guilders, 
which is considerably more than both the main variant and the variant with the 
6 months friction period. The latter difference stems from the fact that in the 
Netherlands the proportion of long term absence is quite large. More than 
20 % of all absence days are accounted for by persons who stay the maximum 
of one year in the absence insurance scheme. 
Discussion 
The friction costs and the macro-econontic consequences of absence from 
work do not overlap, but are complementary. The friction costs are restricted 
to the short term consequences of disease. After completion of the friction 
period, nO costs are considered. The influence of absence on labour time, 
productivity, labour costs and production (especially of the exposed sector) is 
a medium term economic process, which takes several years to occur. Further-
more, in the macro-econontic analysis, the negative price elasticity of demand 
ensures that lower production costs stimulate foreign demand. The friction cost 
method does not take this interaction of price and demand into account. 
Micro- and macro-econontic effects are complementary in describing 
the comprehensive effects of absence from work and disability. The macro-
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economic situation influences the length of the friction period and the relative 
importance of internal labour reserves, both determinants of friction costs. On 
the other hand, the internal labour reserves influence labour costs, which has 
clear macro-economic implications in the medium term. 
The exact consequences of short term absence from work for labour 
productivity and production need to be analyzed in more detail on the level of 
the firm. This analysis should deal with the main issues discussed: the possibi-
lities of postponing work and making up for it later, the nature and extent of 
internal labour reserves verSus flexible labour and the diminiShing returns to 
labour on the level of the individual employee. 
If unemployment is very low, the friction period is relatively long. By 
then the vacancy duration may become a less accurate proxy of labour 
scarcity, as some firms will give up hiring personnel. Consequently, the 
registered vacancy duration may underestimate the true vacancy length and the 
friction costs may underestimate the value of production losses. If an absolute 
labour shortage would occur on a particular part of the labour market, the 
friction period could become as long as it takes to educate new employees 
appropriately. For the exposed sector of the economy this situation could mean 
a loss in market share and output. Facing a tight labour market, firms tend to 
maintain more internal labour reserves, but at the same time hiring employees 
is more difficult, mitigating this tendency. 
We suggest that the true indirect costs of disease are within the range 
between the minimum estimates as provided in the sensitivity analysis and the 
estimates of the main variant. The minimum estimates are very conservative 
estimates of indirect costs, as these incorporate quite radical assumptions 
concerning the opportunity for postponing work and the impact of absence on 
productivity, respectively. This range of estimates is more useful in presenting 
the economic consequences of disease in the real world as compared to human 
capital estimates, showing the potential consequences of disease for an 
economy in a state of full employment equilibrium only found in textbooks. 
The level of friction costs in other countries depends on the labour 
market and the relation between absence and education. The macro-economic 
consequences for other countries may be somewhat smaller. The Netherlands 
is a small open economy with a large exposed sector, hence, economic growth 
is very sensitive to changes in labour costs. However, not only the exposed 
sector is affected but also firms producing intermediary supplies. Furthermore, 
the rapid international economic integration will intensify international compe-
tition for firms producing for the domestic market, enlarging the importance of 
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the exposed sector worldwide. The Dutch level of disability is relatively high. 
so reducing disability may have relatively large macro-economic effects as 
compared to other countries. 
Although our analysis is age-, sex- and education-specific, we used 
fairly aggregate data which may not reflect the indirect costs for specific 
groups of patients. For estimating indirect costs on the individual level patient-
questionnaires seem more appropriate. The latter may also be useful in 
estimating productivity loss without being absent from work (e.g. for ulcer or 
migraine) which hardly have been studied thus far. Production losses without 
absence may increase if absence from work is reduced without a decrease in 
the prevalence of the underlying disease. 
Estimates of indirect costs should incorporate production loss in relation 
to unpaid labour to prevent adverse equity implications. However, data on 
work absence and disability related to unpaid labour are extremely scarce. A 
combination of data from time-surveys and patient questionnaires, administe-
red by those carrying out unpaid work may provide reliable data. 
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9 The impact of indirect costs on 
outcomes of health care programs! 
Summary 
The impact of including indirect costs of disease (as a result of absence from 
work, disability and mortality) on outcomes of economic evaluations of 
specific health care programs is analyzed. For eight health care programs, 
changes in indirect costs are estimated using the friction cost method, that 
seeks to estimate the economic losses due to disease or the economic gains of 
health care programs. The impact of indirect costs on outcomes varies consi-
derably across programs. Indirect costs tend to play an important role if health 
care programs produce health effects in the short run, if (short term) absence 
from work is affected considerably and if a significant proportion of the target 
population is employed at the moment they benefit from the program. The 
possible induction of treatment related absence from work and disability may 
also be relevant. 
Introduction 
Health care programs may result in changes in the ability of patients to 
perform paid work and other daily activities. Production losses or -gains due 
to illness or its treatment influence the scarcity of resources, just as· health 
care costs. Consequently, indirect costs are relevant for health policy, provi-
ded that the estimates of indirect costs reflect the real economic impact of 
disease. This chapter aims at illustrating the impact of including indirect costs 
of disease on outcomes of economic evaluations of specific health care 
programs. The changes in indirect costs as a result of eight different health 
care programs are estimated using the friction cost method, that seeks to 
estimate the real amount of production losses due to disease or the production 
1 Chapter based on Koopmanschap and Rutten (submitted) 
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gains of health care programs. 
The impact of indirect costs on outcomes varies considerably across 
programs, in terms of the type of health care program, the disease category 
involved and the population aimed at. Information about the characteristics of 
those interventions where inclusion does make a difference, may help to 
decide on the resources to be devoted to estimating indirect costs in a particu-
lar evaluation study. 
Methods 
The basic idea of the friction cost method is that the amount of production lost 
due to disease depends on the time-span organisations need to restore the 
initial production level. We assume that if unemployment, registered and 
bidden, is beyond the level of frictional unemployment, sick employees can be 
replaced, after a period necessary for adaptation: the 'friction period'. The 
length of this friction period and the amount of production lost depends on the 
situation within firms and on the labour market. The estimates for the length 
of the friction period are based on the time it takes to fill vacancies (see 
chapter 7 and 8). 
The influence of including indirect costs was estimated for eight specific 
health care programs, where reliable estimates of indirect costs were available 
(table 9.1). These studies were selected as they represent a wide spectre of 
health care interventions regarding the type of service (preventive and cura-
tive), disease category (acute and chronic) and target population (young, 
middle-aged and elderly). In this chapter the estimates of indirect costs are 
restricted to paid labour. For an indication of the relevance size of indirect 
costs we used a relative indicator, the percentage change in outcome as a 
result of including indirect costs in the analysis. 
In order to calculate the friction costs three questions need to be 
answered: 
- when does a friction period occur? 
- how long does a friction period last? 
- how can the costs of lost production during a friction period be determined? 
Applying the friction cost method implies that absence from work ouly 
invokes production loss during the friction period. If the duration of absence is 
longer than the friction period, the production loss is assumed to be limited to 
the length of the friction period. 
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Table 9.1 Overview of eight health care programs by type of program, type 
of study, first author and the year the costs refer to. 
Program Type of Country First author Year 
srudy 
Breast cancer mass screening CEA Netherlands de Koning 1990 
age 50-70. each 2 years 
Cervical cancer mass screening CEA Netherlands Koopmanscbap 1988 
age 37-73. each 6 years 
Ace-inhibitors in congestive heart CUA Netherlands van Hout 1988 
failure 
Cimetidine versus surgery COl Sweden Jonsson 1983 
in peptic ulcer 
B2-agonist + Corticosteroid vs CEA Netherlands Rutten 1989 
B2-agonist +placebo in 
asthrualcopd 
Hepatitis B vaccination CEA Netherlands Eellanan- 1992 
Rooda 
Thrombolitics vs placebo after CUA Sweden Levin 1989 
myocardial infarction 
Total hip arthroplasty in osteo- Cost srudy USA Cushner 1986 
arthritis etc. 
CEA: Cost-effectiveness analysis 
CUA: Cost-utility analysis 
COl: Cost of illness analysis 
In case of mortality for persons younger than 65, we assume that the 
production loss is equal to the production loss for a complete friction period, 
taking into account the participation in paid work for the specific group of 
patients. 
Thus far, the length of the friction period has only been estimated for 
the Netherlands. For 1988 it was estimated to be 2.8 months, for 1990 3.2 
months on average. In the absence of data on the length of friction periods for 
other countries we used the Dutch estimates for all studies. 
The value of production loss is assumed to be 80 % of the average value 
of a worker's production, taking into account that absence generally causes a 
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less than proportional decrease in production (see chapter 8). The average 
value of production per worker by age and sex was estimated for the Nether-
lands for 1988 and 1990 (see appendix 8). For Sweden and the U.S.A. we 
used the estimates as reported in the original studies. 
Health care programs 
Breast cancer screening 
A national breast cancer screening program in the Netherlands was analyzed 
by de Koning et al. (1990 and 1991). They assumed that during the period 
1990-2017 all women of age 50-70 are invited every two years to be screened 
mammographically. Absence from work was assumed to occur for each 
working patient receiving primary therapy for invasive breast cancer and for 
each patient having a relapse or metastases. Becanse the treatment of these 
patients is burdensome and prolonged, all absence spells are assumed to be 3 
months or longer, implying that the period of production loss is equal to the 
length of the friction period. 
Since breast cancer screening is directed to early detection of malignan-
cies, screening will increase rather than reduce the number of patients getting 
primary therapy. A possible rednction in indirect costs may result from a 
decrease in the number of patients with recurrent or metastatic disease. 
Cervical cancer screening 
Regarding cervical cancer screening, indirect costs were calculated for a 
strategy of screening women aged 37-73 every 6 years during 1988-2015, 
which was demonstrated to be an efficient screening policy for the Netherlands 
(Koopmanschap et al., 1990). For each type of treatment a specific length of 
absence from work was assumed, based on observed length of hospital stay 
and expert opinion on the length of time for recovery at home (see appendix 
9). For each disease stage the probabilities for specific treatments (van 
Ballegooijen et a!., 1990) were combined with the number of patients and the 
length of the absence spells. For patients having recurrent or metastatic 
disease we assumed the duration of absence to be longer than the friction 
period. 
Ace-inhibitors for congestive heart failure 
In the analysis of prescribing ace-inhibitors for congestive heart failure for a 
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period of ten years versus the standard treatment, patients were classified in 
four classes of disease severity: New York Heart Association (NYHA) I-IV 
(van Hout et aI., 1993). Patients in NYHA class I were assumed not to be 
absent from work, but if a patient enters a higher NYHA-class (i.e. the heart 
function deteriorates) productivity loss of an entire ftiction period is assumed 
to occur. Consequently, production gains due to ace-inhibitors were assumed 
to arise if the health status of working patients improved significantly, imply-
ing the entrance to a lower NYHA-c1ass. 
Cimetidine versus surgery in duodenal ulcer 
The costs of cimetidine versus surgery in duodenal ulcer were compared by 
several authors (Jonsson and Carlsson, 1991; Culyer and Maynard, 1981; 
Bulthuis, 1984). Both Jonsson et aI. and Culyer et aI. found a Significant 
reduction in the length of absence from work in the first year of the therapy. 
Jonsson et aI. estimated an average reduction of 48 days, resembling the 
estimate of 5-8 weeks as found by Culyer et aI. Jonsson et al. did not report 
the total frequency distribution of the reduction in absence. However, since 48 
days is considerably shorter than the ftiction period (about 3 months) we 
assume that the entire reduction of absence represents a gain in production for 
working patients. 
AsthmalCOPD 
For 182 patients aged 18-60 years having asthma or COPD, beta-2-
agonist/corticosteroid therapy (BA +CS) was compared to beta-2-agonist/place-
bo therapy (BA + PL) during 2.5 years in a randomized controlled study 
(Kersgens et aI., 1992; Rutten-van Molken et aI., 1994». Each 3 months the 
treatment effect on lung function was measured in Forced Expiratory Volume 
in 1 second (FEV,) as a % of the predicted value. 
During the fIrst year BA + CS caused significantly more improvement in 
FEV, than BA + PL and the average number -of symptom free days per patient-
year was significantly higher for BA + CS. The mean number of restricted 
activity days per patient-year for BA+CS-patients was 5.2, compared to 10 
days for patients receiving BA + PL. However, the reduction in restricted 
activity days was not statistically significant. Since our calculations serve as an 
illustration, we used this reduction in the number of restricted activity days to 
calculate the indirect benefits of BA +CS versus BA + PL. Because it was 
unknown how many patients had a paid job, we assumed the proportion of 
paid workers to be eqnal to that in the general population aged 18 to 60. 
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Hepatitis B vaccination 
The costs and effects of several strategies concerning hepatitis B vaccination 
were estimated for the Netherlands (Eelkman Rooda et al., 1992). Vaccination 
of all newborns was compared to the current Dutch strategy: screening 
pregnant women and vaccinating babies of the HBsAG-positive mothers. Costs 
and health effects (lives and life-years) were calculated for the period 1990-
2090. For each acute and chronic disease state, the authors assumed the risk 
of being absent from work, the specific length of absence and the risk of 
getting disabled. 
Intravenous thrombolytic therapy in MI 
Costs and quality of life for intravenous thrombolytic therapy (rt-PA, n=153) 
were compared to placebo treatment (n=160) in the first year after a suspec-
ted myocardial infarction (Levin and Jonsson, 1992). The 12-month mortality 
of rt-PA patients was 8.5% as compared to 15.6% in the placebo-group 
(p=0.05). No significant difference in quality of life was observed. In the 
long run, the gain in life expectancy due to rt-PA, given an annual mortality 
rate of 6%, was 1.25 years. 
After one year 70% of the rt-PA patients and 54% of the placebo 
patients had returned to work (p = 0.06). After I and 6 months the percentage 
of rt-PA patients returning to work is also higher, but the authors don't give 
information on the statistical significance. The average time of absence from 
work was 69.7 days for rt-PA patients and 81.1 days in the placebo group. 
This difference was not statistically significant. We used the exact frequency 
distribution of absence durations for both treatment arms in calculating the 
indirect costs of rt-PA compared to placebo. 
Total hip anhroplasty 
Cushner and Friedman investigated the costs of total hip arthroplasty (THA) in 
the U.S.A. for patients having osteoarthritis, fracture-dislocation, rheumatoid 
arthritis and osteonecrosis (Cushner and Friedman, 1988). They estimate the 
annual direct costs of THA, including preoperative care, surgery and six-
month follow up to be US $ 4.6 billion. The indirect costs during hospital stay 
were US $ 20 million, including the value of household work. During the six 
month rehabilitation period indirect costs were estimated as being US $ 221 
million, using the human capital method taking into account all potential losses 
and gains in production. The authors also calculated the indirect benefits after 
rehabilitation. These are twofold: formerly disabled may resume working, 
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saving US $ 553 million and the prevention of disability would save US $ 
1300 million. The authors conclude that the total costs of THA are about US $ 
3 billion (direct costs $ 4.6 billion, indirect costs $ 0.2 billion, indirect 
benefits $ 1. 8 billion). 
Results 
For each health care program the direct costs and health effects are presented, 
followed by the impact of including indirect costs, see table 9.2. 
Table 9.2 PercentuaI impact of including indirect costs on total costs or 
cost-effectiveness of eigbt health care programs. 
Program Outcome parameter % Impact 
Breast cancer screening Cost per life·year gained +2% 
Cervical cancer screening Cost per life-year gained +2% 
Ace-inhibitors for CHF Savings + 1 % 
(and life-years gained) 
Cimetidine vs surgery Total costs - 18% 
in peptic ulcer 
BA+CS vs BA+PL Cost per 10% FEV, Savings instead of 
in asthmaiCOPD increase costs 
Hepatitis B vaccination Savings + 52 % 
Thrombolitics after MI Cost per life-year gained ·16 % 
Total hip arthroplasty Total costs +2% 
Breast cancer screening 
The total incremental direct costs of breast cancer screening over the period 
1990-2017 amount to 466 million Dutch guilders (DfI) (discount rate 5 %). In 
the long term the screening program saves 700 lives per year, reducing breast 
cancer mortality by 16% (de Koning et aI., 1990 and 1991). The costs per 
life-year gained are Dfl 7,650. Including production losses raises total costs by 
Dfl 9 million, a 2 % increase. The costs per life-year gained amount to Dfl 
7,790. The increase in costs is mainly caused by advancing the moment of 
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treatment and a slight increase in the number of patients- having primary 
therapy. On the other hand, production gains for patients not having metasta-
ses are limited, because these patients are often older than age 65, the age of 
retirement. The impact of including indirect costs is very modest. 
Cervical cancer screening 
For cervical cancer screening the story is analogous. Including production 
losses raises total incremental costs over the period 1988-2015 by Dfl 6 
million to Dfl 330 million, a 2 % increase. Again this cost increase represents 
a balance of extra costs and savings. The screening program causes Dfl 16 
million extra indirect costs for women with pre-invasive lesions, whereas the 
indirect costs for invasive cancer and metastases decrease by Dfl 10 million, a 
20% reduction. The costs per life-year gained slightly increase from Dfl 
24,400 to Dfl. 24,800. 
ACE-inhibitors for congestive heart failure 
In the first ten years of subscribing ACE-inhibitors for men having congestive 
heart failure the total number of life years gained is estimated to be almost 
7000 (van HaUl et aI., 1993). Despite the additional annual costs of prescri-
bing ACE-inhibitors of Dfl 8 mi1Iion, total costs of congestive heart failure 
(including drugs) decrease by Dfl 32 million per year. Indirect costs fall about 
Dfl 200,000, which is less than 1 % of the expected savings per year. 
Cimetidine versus surgery in duodenal ulcer 
The annual incremental direct costs of cimetidine as compared to surgery in 
duodenal ulcer amount to 28 million Swedish kronor (SEK) in 1983. The 
introduction of cimetidine induced SEK 39.6 million additional drug costs, bUl 
it saved SEK 11.6 million costs of hospital care. The savings due to a reducti-
on in absence from work amount to SEK 5 million. The total annual incre-
mental costs of cimetidine versus surgery are SEK 23 million (=28-5), thus 
including the indirect benefits makes a difference of 18 % . 
AsthmalCOPD 
For patients having asthma or COPD, the additional direct costs of BA +CS 
(versus BA + PL) were estimated to be 427 Dutch guilders per patient-year. 
The difference in lung function, measured in FEV, is 10% (Kerstjens et aI., 
1992; Rutten-van M6lken et aL, 1994). Estimating a reductlon in restricted 
activity days of 4.8 days, the indirect benefits amount to 500 guilders per 
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patient-year. Hence, including the indirect benefits of BA+CS therapy would 
result in 75 guilders net savings per patient-year. 
Hepatitis B vaccination 
Vaccination of all newborns against Hepatitis B in the Netherlands will save 
about 91000 life-years and Dfl 1325 million direct costs (not discounted) over 
the period 1990-2090, assuming that the vaccine costs 90 Dutch guilders per 
unit. Since the effects of vaccination take a long time to effectuate, the first 
savings will prevail in the year 2020. Indirect benefits, according to the 
friction cost method, make up for an additional saving of Dfl 675 million, 
resulting in total savings of Dfl 2 billion. Hence, including indirect benefits 
increases savings by 52 %. The costs of a vaccine are not known yet. If it 
would cost Dfl. 135 instead of Dfl. 90, the savings in direct costs would be 
Dfl 490 million. Including the indirect benefits of Dfl 675 million would then 
increase savings by 138 %. 
Intravenous thrombolitics in MI 
The average direct costs per patient of intravenous thrombolitics during the 
first year after myocardial infarction amount to SEK 39,400, a significant 
increase of SEK 9,880 as compared to the placebo treatment (p;0.03). The 
reduced absence from work induces an average savings in indirect costs of 
SEK 1,560 per patient. As a result, the total additional costs of thrombolitics 
per patient during the first year amount to SEK 8320. In the long run, the 
direct costs per life-year gained (discount rate 5%) are SEK 14,400, whereas 
the total costs (direct and indirect) per life-year gained amount to SEK 12,100. 
Including indirect costs improves the cost-effectiveness by 16 %. 
Total hip arthroplasty 
The costs of total hip arthroplasty would change considerably, when the 
indirect costs are calculated according to the friction cost method. The indirect 
costs during hospital stay would remain unchanged. However, since the 
rehabilitation after THA takes 6 months, this would exceed the friction period 
(2.8 months in 1988) and the indirect costs would be about half the original 
estimate: US $ 100 million. Indirect benefits in the long term would be non-
existent, using the friction cost method. Total costs of THA amount to US $ 
4.7 billion, only 2% more than Cushner and Friedman's estimate of direct 
costs ($ 4.6 billion). On the other hand, the estimate of $ 4.7 billion is about 
55% higher than Cushner's estimate of total costs ($ 3 billion), because 
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Cusbner assumed substantial savings in indirect costs. 
Analysis of impact of indirect costs 
It is interesting to see the variation across health care programs in the bnpact 
of including indirect costs. The factors underlying this variation can be 
grouped in three categories: factors related to the type of program, factors 
related to the specific disease and characteristics of the specific group aimed 
at. 
Table 9.3 presents some relevant characteristics of the eight health care 
programs. It clearly shows the special position of preventive programs. The 
(indirect) benefits of prevention take time to effectuate. For cancer screening 
this implies that future benefits are lintited due to discounting and retirement 
of patients before indirect benefits may occur. In addition, screening advances 
morbidity and absence from work due to early detection of lesions. In the 
absence of screening for cervical cancer, a part of the non-invasive lesions 
would regress spontaneously (van Ballegooijen et al,. 1990). 
In case of hepatitis B vaccination the time lag for health effects and 
savings in indirect costs is very long. Standard discounting would make the 
program worthless, but the authors defensibly argue that health benefits to be 
reaped by future generations should not be discounted in the standard way 
(Eellanan Rooda et al., 1992; Krahn and Gafui, 1993). The group to benefit 
from vaccination is fairly young, improving the scope for possible indirect 
benefits. 
For the treatment programs the bulk of effects materialises within the 
first year of the program. The indirect benefits of ACE-inhibitors are marginal 
still, since ouly a small fraction of the patients has a paid job. Total hip 
arthroplasty causes additional absence due to rehabilitation following surgery, 
reducing indirect benefits. The latter are relatively modest, since many patients 
are retired. 
The programs for ulcer, asthma and myocardial infarction cause 
instantaneous health effects, they aim at all age-groups and induce no additio-
nal absence from work, which are all favourable conditions for indirect 
benefits to be substantial. 
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Table 9.3 Main characteristics of eight health care programs and impact of 
including indirect costs on outcomes. 
Program Program Effect Group to Absence Impact 
type period benefit induced 
Breast cancer screening Secondary >5 years women yes small 
prevention age> 55 
Cervical cancer Secondary > 10 years women yes small 
screening prevention age> 45 
Ace-inhibitors in CHF Treatment < I year age> 55 no small 
Cimetidine in peptic Treatment < I year all ages no large 
ulcer 
BA +CS in astlunal Treatment < I year all ages no large 
COPD 
Hepatitis B vaccination Primary > 15 years all ages no large 
prevention 
Thrombolitics after 111 Treatment < I year age> 40 no large 
Total hip Treatment >0.5 year age> 55 yes small 
arthroplasty 
Table 9.4 summarizes the data on absence, disability and mortality for 
the relevant diseases. Following the friction cost method (short term) absence 
is the main cause of indirect costslbenefits. Absence shorter than three months 
is relatively important for ulcer, asthmaiCOPD and hepatitis B, whereas 
absence for myocardial infarction and breast cancer is predominantly long 
term absence. The relative high mortality for myocardial infarction and breast 
cancer yields only a small impact on the indirect benefits of the programs 
related to these diseases. 
136 Chapter 9 
Table 9.4 Relative number of cases registered for (short term) absence 
from work, incidence of disability and mortality in the Nether-
lands for the diseases related to eight health care programs, 
Index for number of absent cases = l, 
Disease Absence Total absence Disability Mortality 
<3 months incidence 
Breast cancer 0.13 0.38 2.96 
Cervical cancer 0.41 0.53 5.71 
Congestive 0.65 0.11 3.31 
heart failure 
Duodenal ulcer 0.75 0.03 0.08 
AstlunalCOPD 0.86 0.06 0.23 
Myocardial 0.09 0.46 4.19 
infarction 
Hepatitis B 0.87 1 NA 0.05 
Sources: absence from work (except hepatitis B) (CBS, 1989c): absence from work for 
Hepatitis B (Eelkman Rooda et a1 .. 1992): incidence of disability (GMD, 1990): mortality 
(CBS. 1989b). 
Discussion 
Some authors have objections against including indirect costs in economic 
evaluation. Inclusion may favour health care interventions directed to (well) 
paid workers, which may conflict with equity considerations, especially when 
the results of economic studies are used to support decisions at the level of 
individual patient treatment. These objections could be met by excluding 
indirect costs from economic evaluations. However, this would imply denying 
a significant part of economic reality, since indirect costs of disease do 
contribute to the scarcity of resources and hence decrease society's wealth. 
Indirect costs may be presented together with health care costs, health 
effects, consequences for equity and ethical and legal considerations, but they 
should be separately identifiable. It is up to the decision-makers to decide on 
the relative weight that they want to attach to indirect costs, compared to other 
criteria. 
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Recently, Gerard and Mooney argued that including non health care 
costs in cost-utility analysis is problematical (Gerard and Mooney, 1993). 
According to them, the opportunity costs of health care resources is defined in 
terms only of the QALY's forgone. Hence, cost utility analysis is about 
generating QAL Y's and QAL Y's foregone by opportunities sacrificed. This 
wonld preclude considering non health care costs/savings, which could only be 
considered in cost-benefit analysis. These authors interpret the concept of 
opportunity costs in a rather narrow sense. Clearly, when program A requires 
a similar health care budget as program B, but uses less resources than 
program B from a societal p~rspective, the additional resources becoming 
available when applying program A as compared to B, could be added to the 
health care budget (or added to budgets for education, housing and working 
conditions, which may also contribute to health status), and produce QAL Y's. 
Therefore, the opportunity costs in terms of QAL Y's foregone of program B 
would be larger than those of program A. So there is no specific requirement 
to use cost-benefit analysis, invoking all its valuation problems, when conside-
ring non health care costs in an economic evaluation. 
Economic evaluations should preferably also include the indirect costs 
of unpaid labour, but data on the absence and disabil:ty related to unpaid 
labour are very scarce. With respect to breast cancer screening, a rough 
calculation showed that including unpaid work implies a small increase in the 
indirect costs of Dfl 1.6 million, leaving overall results unaltered (de Koning 
et al., 1990). For other health care programs, the impact of indirect costs of 
unpaid work may be more substantial. 
With respect to the total costs of total hip arthroplasty, Cushner and 
Friedman indicated the maximum potential indirect benefits on the long term: 
after 6 months rehabilitation many formerly disabled are assumed to resume 
working. In addition, due to THA 80 % of the working patients would not 
become disabled, but would remain employed after 6 months rehabilitation. If 
unemployment is above the level of frictional unemployment, which is the 
current situation for Western Europe and North America, substantial long term 
indirect benefits of preventing disability and mortality cannot be expected. On 
the other hand, a reduction in the incidence of disability may have some 
beneficial macro-economic implications. Lower incidence may increase labour 
supply, which results in lower labour costs per unit of output, an increase in 
production, exports and national income (see chapter 8). 
The influence of including indirect costs on the results of economic 
evaluations may vary substantially. Generally speaking, a significant effort 
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should be made to estimate the indirect costs when health care programs bring 
forth health effects in the short run, when there is a major impact on (short 
term) absence from work and if a significant proportion of the target populati-
on is employed at the moment of receiving the benefits from the program, The 
possible inducement of treatment related absence from work and disability 
should also be considered, 
If health care programs have a considerable impact on permanent 
disability and mortality, estimates of indirect costs according to the human 
capital approach ouly illustrate the program's potential economic impact, 
which may overestimate the true economic consequences to a considerable 
extent (see chapter 7 and 8), 
10 Conclusions 
This chapter presents the main conclusions that can be drawn with respect to 
the key questions of this thesis: the use of detailed and more aggregate 
economic evaluations of health care and the role of indirect costs in economic 
evaluation. 
Detailed analysis 
The cost-effectiveness analysis of cervical cancer screening as described above 
illustrates the merits of a detailed economic evaluation of an individual health 
care program. The analysis permitted the selection of technically efficient 
screening policies, characterized by a broad age range for women to be invited 
(age 30-70) and a relatively large interval between invitations: at least 5 years. 
The study provided insight in the relation between cost-effectiveness 
and the size of the screening program. The costs per life-year gained are 
reasonable for efficient policies with 10 or less invitations in a lifetime. The 
marginal cost-effectiveness deteriorates sharply if women are invited more 
than 10 times, illustrating the economic 'law of diminishing returns'. 
The attendance rate is crucial for the cost-effectiveness of cervical 
cancer screening as women, who are less likely to attend, tend to carry a 
higher risk. Since the organisation of the screening program appears to influ-
ence attendance considerably, investments in a sound organisation of screening 
will produce good value for money. 
The methodology of this type of detailed cost-effectiveness analysis is 
reasonably developed and standardized. The analysis is capable of providing 
relevant information for health policy, wituess the recent decision of the Dutch 
govermnent to extend the interval between successive invitations from 3 to 5 
years and to broaden the age-range from age 35-53 to age 30-60, correspon-
ding to the study recommendations. On the other hand, the current non-
uniform screening organisation without a reminder invitation appears 
unfavourable with respect to attendance and cost-effectiveness. 
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Aggregate analysis 
The aggregate cost of illness stndy described shows that for the Netherlands 
and Sweden the health care costs of chronic non-fatal disease predominate, 
whereas in the United States this pattern is less pronounced. In addition to 
comparing costs between countries, a cost of illness stndy can provide more 
insight in the consequences of differences between countries in epidemiology, 
health care system and health policy. However, a thorough explanation of the 
differences in costs between countries requires more comparable 
epidemiological data. 
During 1988-2030, ageing will be responsible for an aunual increase in 
total health care cost of O.7%point in the Netherlands, assuming constant costs 
per caput (age- and sex-specific), as a [lIst baseline scenario. With respect to 
cancer, the estimated aunual cost increase due to ageing is 1.5%point. Health 
care costs per caput for the elderly may increase faster than for younger 
people, due to compression of disease within the last years of life, combined 
with a tendency towards more extensive diagnostic and therapeutic interven-
tions in old and very old patients. Hence, longitndinal analysis of health care 
costs for elderly appears to be the next step in refining the estimates of the 
costs of ageing. 
The future costs of cancer also depend on the expected epidemiological 
development. According to the cancer disease model, cancer costs will 
increase sharply if incidence rises, whereas improved disease-free survival has 
a moderate impact on costs. Insight in the expected epidemiological trends is 
indispensable for an accurate projection of future costs of cancer. 
The cost analyses as described are not full economic evaluations, but 
these still may be useful for health policy. Cost estimates incorporated in a 
disease model (as the cancer model described) can show the likely conse-
quences of expected trends in demography and epidemiology. The model 
should preferably take into account the cost consequences of competing 
diseases and the costs of comorbidity, especially in elderly patients. If such a 
model is supplemented with data on effectiveness of the relevant health care 
programs, it could generate an indication of the cost-effectiveness of a total set 
of health care programs directed to a particular disease or specific subsectors 
of health care. 
In sum, aggregate economic evaluation can serve several purposes. It 
may facilitate estimating the combined results of interacting programs for the 
same disease and the consequences of health care programs for the costs and 
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epidemiology of other diseases. It can produce estimates of the future costs, 
morbidity and mortality of diseases for demographic, epidemiological and 
technological scenarios. Finally, aggregate estimates of cost-effectiveness may 
select candidates for more detailed analysis in specific parts of health care that 
need closer investigation of costs and health effects. In this respect, detailed 
and aggregate economic evaluation are complementary instruments for health 
policy. 
For practical application of the aggregate analysis, a number of metho-
dological problems remain to be solved. One of the most tough issues is the 
estimation of the aggregate effectiveness of existing interventions, requiring 
knowledge about the health status of patients in the situation with and without 
the existing health care programs. 
Indirect costs 
Indirect non-medical costs of disease as an element in economic evaluation are 
controversial. According to some authors, cost-effectiveness/-utility analysis is 
restricted to generating health effects/Qaly's within a given health care budget, 
implying that indirect costs of disease should not be included in the evaluation. 
This is a rather narrow approach, since indirect costs influence the scarcity of 
resources and hence society's wealth. In addition, indirect costs may have an 
impact on the budget for health care and other budgets which may contribute 
to health status. In this respect direct and indirect costs are alike and the latter 
should therefore be included in economic evaluations. 
In order to present a balanced overview of the consequences of health 
care programs, estimates of indirect costs may be presented together with, but 
separate from, health care costs, health effects, consequences for equity and 
ethical and legal considerations. It is up to the decision-makers to decide on 
the relative weight that they want to attach to indirect costs, compared to other 
criteria. 
Given the relevance of indirect costs, it seems preferable to insist that 
indirect costs are estimated as realisticly as possible, instead of estimating the 
potential economic consequences of disease in an exceptional state of full 
employment equilibrium, according to the human capital approach. In estimat-
ing indirect costs the following issues should be analyzed: 
- the short term impact of absence from work on production and costs; 
- the time-span during which production and costs are affected directly, 
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depending on the situation within the frrm as well as on the labour market; 
- the medium term macro-econontic consequences of absence from work and 
disability . 
For the Netherlands the short term ftiction costs in 1990 amounted to 
1.5-2.5% of net national income, depending on the extent to which short term 
absence from work induces production loss and costs. The medium term 
rnacro-econontic consequences of absence from work and incidence of disabil-
ity were estimated to reduce net national income by an additional 0.8 % . 
The exact consequences of short term absence from work for produc-
tion and costs need to be analyzed in more detail on the level of the finn. 
Such analysis should focus on the possibilities of postponing work and making 
up for it later, the nature and extent of internal labour reserves versus flexible 
labour and the diminishing returns to labour for the individual employee. 
An artainable reduction of absence from work (from 8% to 6% of 
working time) and incidence of disability (-20%) will save about 0.5 % NNI 
ftiction costs and 0.18% NNI in the medium term. In order to improve the 
estimates of indirect costs, further research is necessary to estimate to what 
extent absence from work and disability can be prevented and the possible role 
of competing diseases which may decrease the potential for reduction in 
absence and disability. 
In general as well as in this thesis, estimates of indirect costs of disease 
ouly refer to paid labour. An important point for further research is the 
amount and value of indirect costs due to unpaid labour, according to the 
friction cost method. However, reliable data on the amount of absence and 
disability related to unpaid labour are rather scarce and the issue of the value 
of unpaid production needs to be analyzed further. 
In addition to the aggregate estimates of indirect costs of disease, the 
impact of indirect costs on cost-effectiveness of individual health care pro-
grams was analyzed. The influence of including indirect costs on the results of 
particular health care programs depends on the time lag between investments 
and health effects, the relative importance of (short term) absence and the 
labour participation of the population to benefit. For cervical cancer screening 
the impact is rather small. For therapeutic interventions reducing absence from 
work, like cimetidine for peptic ulcer and thrombolitics after myocardial 
infarction the savings in indirect costs appear to be substantial. 
A significant effort should be made to estimate the indirect costs when 
health care programs bring forth health effects in the short run, when there is 
a major impact on (short term) absence from work and when a Significant 
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proportion of the target population is employed at the moment of receiving the 
benefits from the program. The possible inducement of treatment related 
absence from work and disability should also be considered. 
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Summary 
The increasing conflict between limited health care budgets and the develop-
ment of medical technology has forced policy makers to reconsider the 
resource allocation in health care. Economic evaluations can support the 
decision making process. by providing information on the costs and health 
effects of health care programs. 
Health care can be analyzed on 'the detailed level': an individual 
program or, alternatively on 'the aggregate level': total health care, a specific 
sector of health care or a disease category. Either level of analysis has 
advantages and limitations. The detailed analysis is appropriate, when the 
policy decision is to choose among specific programs for a specific patient 
group. However, focusing exclusively on cost-effectiveness of individual 
programs bears the risk of overlooking interactions with other health care 
programs. In addition, it is not feasible to evaluate each possible health care 
program. 
More aggregate economic evaluations are indispensable in providing a 
consistent and complete evaluation of health care, as a starting point for more 
detailed analysis in specific parts of health care that need closer investigation 
of costs and health effects. 
The cost-effectiveness analysis of cervical cancer screening illustrates 
the merits of a detailed economic evaluation of an individual health care 
program. The costs of screening itself are dominant, the impact of screening 
on the costs of diagnosis and treatment is limited. The analysis permitted the 
selection of technically efficient screening policies (generating maximal health 
effects for a given level of costs or minimal costs for a given level of health 
effects). These efficient policies can be characterized by a broad age range for 
women to be invited: age 30-70 and at least a 5-year interval between success-
ive invitations. Given technical efficiency, the cost per life-year gained are 
reasonable for policies with 10 or less invitations in a lifetime. The marginal 
cost-effectiveness deteriorates sharply if women are invited more than· 10 
times. 
The attendance rate is crucial for the cost-effectiveness of cervical 
cancer screening, due to economies of scale related to the costs of screening 
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and the relation between risk and attendance. Additional literature research 
indicated that the way the screening program is organized may have a con-
siderable impact on attendance. Hence. investtnents in a sound organisation of 
screening appear to be worthwhile. 
The aggregate cost of illness stndy described shows that for the Nether-
lands and Sweden the health care costs of chronic non-fatal disease predomi-
nate. which is less prominent for the United States. The available data suggest 
that the differences in medical practice and health care system may explain a 
substantial part of the divergent results; demographic or epidemiologic aspects 
seem less important. Assuming constant cost per caput (age- and sex-specific), 
ageing induces a modest O.7%point annnal cost increase in the Netherlands. 
However, health care costs per caput for elderly may increase faster 
than for younger people, due to compression of disease and a tendency 
towards more extensive interventions in elderly. Further analysis of the trends 
in health care costs for elderly may refine the cost estimates related to ageing. 
The contribution of other forces in raising costs, such as the limited 
role of labour productivity growth in health care and the rapid development of 
medical technology is probably more important than ageing. A structural 
upward pressure on costs also prevails in the Netherlands and Sweden, but it 
is more prominent in the U.S.A., probably due to a large number of medical 
procedures and high administration costs. 
With respect to cancer, the estimated annual cost increase due to ageing 
is 1.5%point. The futnre costs of cancer also depend on the expected 
epidemiological development. According to the cancer disease model, the costs 
of colorectal cancer will increase sharply if incidence rises, whereas improved 
disease free survival only has a moderate impact on costs. 
Cost estimates incorporated in disease models as described, supple-
mented with data on effectiveness of the relevant health care programs, may 
give an indication of the cost-effectiveness of the total set of health care 
programs directed to a particular disease or specific subsectors of health care. 
At the moment, the relevance of the indirect non-medical costs in economic 
evaluation (further referred to as indirect costs) is subject to considerable 
debate. In this thesis, indirect costs of disease are defined as the consequences 
of absence from work, disability or death for society's production and costs. 
This definition explicitly excludes the valuation of life as such, as applied in 
cost-benefit analysis. 
Because indirect costs of disease contribute to the scarcity of resources 
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and decrease society's wealth, they should be considered in economic evalu-
ations. It seems preferable to insist that the estimated indirect costs represent 
the real economic consequences of disease, as far as possible. The friction cost 
method seeks to estimate the indirect costs realistically. Its basic idea is that 
the amount of production lost and/or extra costs incurred due to disease 
depends on the time-span organisations need to restore the initial level of 
production and costs. It is assumed that if unemployment is beyond the level 
of frictional unemployment, sick employees can be replaced, after a period 
necessary for adaptation. Indirect costs are assumed to be confined to the 
period needed to replace a sick worker: the friction period. 
For the Netherlands the shor! term friction costs in 1990 amount to 1.5-
2.5% of net national income, depending on the extent to which shor! term 
absence from work induces production loss and costs. The medium term 
macro-economic consequences of absence from work and incidence of disabil-
ity are estimated to reduce net national income by an additional 0.8 %. The 
total economic benefits of attainable reductions in absence from work (-2 
percent points) and incidence of disability (-20 %) are estimated to be about 
0.5% of net national income. 
The exact consequences of short term absence from work for produc-
tion and costs need to be analyzed in more detail on the level of the firm. 
Further smdy should deal with the possibilities of postponing work and making 
up for it later, the narnre and extent of internal labour reserves versus flexible 
labour arrangements and the dintinishing remrns to labour for the individual 
worker. 
The impact of including indirect costs on results of particular health 
care programs depends predominantly on the time lag for health effects, the 
relative imporlance of (short term) absence and the labour participation of the 
population to benefit. For cervical cancer screening the impact is rather small. 
For therapeutic interventions reducing absence from work, like cimetidine for 
peptic ulcer and thrombolytic treatment for myocardial infarction, the esti-
mated savings in indirect costs appear to be substantial. 
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Samenvatting 
De toenemende spanning tussen de beschikbare middelen voor de gezond-
heidszorg en de voortgaande ontwikkeling van medische technologie noopt 
beleidmakers steeds vaker tot heroverweging van de allocatie van middelen in 
de gezondheidszorg. Economische evaluatiestudies knnnen dit proces 
ondersteunen, door informatie te verstrekken over de kosten en gezondheids-
effecten van gezondheidszorgvoorzieningen. 
De gezondheidszorg kan op verschillende niveaus worden geanalyseerd: 
op detailniveau: de individuele voorziening, of op meer geaggregeerd niveau: 
de totale zorgsector, deelsectoren of een ziektecategorie. Beide analyseniveaus 
kennen voordelen en beperkingen. De detailanalyse is de aangewezen methode 
indien de besluitvorming gericht is op de keus tussen specifieke programma's 
voor een bepaalde patientengroep. Wanneer men aileen individuele 
voorzieningen evalueert bestaat het gevaar dat belangrijke interacties tussen 
voorzieningen worden gemist. Daarnaast is het praktisch ondoenlijk om aile 
gezondheidszorgvoorzieningen apart te evalueren. 
Geaggregeerde analyses zijn noodzakelijk om een consistent en 
compleet beeld te verkrijgen van de kosten en effecten van de 
gezondheidszorg. Dit kan dienen als startpunt voor de selectie van delen van 
de gezondheidszorg waar de kosten en effecten in meer detail knnnen worden 
geanalyseerd. 
De kosten-effectiviteitsanalyse van baarmoederhalskankerscreening toont 
de kracht van een gedetailleerde analyse van een individuele voorziening. De 
kosten van de screening zelf zijn dominant en de invloed van screening op de 
kosten van diagnostiek en behandeling zijn gering. Het bleek mogelijk 
technisch efficiente screeningpolicies te selecteren (deze leveren maximale 
gezondheidseffecten voor een gegeven kostenniveau, of een gegeven niveau 
van effecten tegen minima Ie kostenl. Deze efficiente policies hebben twee 
kenmerken gemeen: een brede leeftijdsgroep van vrouwen wordt uitgenodigd 
voor de screening (30-70 jaarl met een interval van tenminste 5 jaar tussen de 
uituodigingen. V oor de efficiente policies geldt dat de kosten per gewonneri 
levensjaar redelijk gunstig zijn bij 10 of minder uitnodigingen per vrouw. Bij 
meer' dan 10 uitnodigingen stijgen de additionele kosten per extra gewonnen 
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levensjaar sne!. 
Het percentage van de uitgenodigde vrouwen dat daadwerkelijk 
gescreend word t is van groot belang voor de kosteneffectiviteit, vanwege de 
schaalvoordelen in de kosten en de negatieve relatie tnssen risico en opkomsl, 
Aanvullende literatnurstndie wees uit dat de organisatie van het 
screeningsprogramrna van groot belang kan zijn voor het opkomstpercentage, 
zodat een goede screeningsorganisatie een waardevolle investering lijkl, 
De geaggregeerde kosten van ziektenstndie laat zien dat in Nederland en 
Zweden de kosten van niet fatale, chronische ziekten zeer belangrijk zijn, 
terwijl dit patroon in de Verenigde Staten veel minder duidelijk zichtbaar is, 
De besclllkbare data suggereren dat het uiteeniopende kostenpatroon eerder 
lijkt vOOr! te komen uit verschillen in medisch handelen en het zorgsysteem 
dan het gevolg is van verschillen in demografie en epidemiologie, Bij 
gelijkblijvende kosten per hoofd (naar leeftijd en geslacht), zorgt vergrijzing 
voor een bescheiden kostenstijging van 0.7 %punt per jaar. 
Het is echter goed mogelijk dat de kosten per hoofd voor ouderen 
sneller zuIIen stijgen dan v~~r jongeren, als gevolg van compressie van ziekten 
en een tendens tot intensivering van diagnostische en therapeutische zorg voor 
ouderen. Verdere analyse van de trend in de zorgkosten voor ouderen is 
noodzakelijk om de kostemamingen van vergrijzing te verbeteren. 
Andere factoren, zoals de beperkte groei van de arbeidsproduktiviteit in 
de zorgsector en de ontwikkeling van medische technologie zijn wellicht 
belangrijker oorzaken van kostenstijging. Nederland en Zweden kennen ook 
een permanente stijging van de zorgkosten, maar de toename is veel 
pregnanter in de Verenigde Staten, onder meer als gevolg van de grote 
omvang van dure chirurgie en de hoge administratieve kosten. 
Voor kanker bedraagt de geschatle kostenstijging als gevolg van 
vergrijzing 1.5 %punt per jaar, bij gelijkblijvende kosten per hoofd (naar 
leeftijd en geslacht). De toekomstige kosten van kanker hangen ook af van 
epidemiologische ontwikkelingen. Het beschreven ziektemodel voor kanker 
wijst uit dat de kosten van colorectnmkanker sterk zuHen stijgen bij toename 
van de incidentie, terwijl verbetering van de ziektevrije overleving een veel 
geringere invloed heeft op de kosten. 
Het koppelen van kostemamingen aan ziektemodellen, gecombineerd 
met gegevens over effectiviteil van de bijbehorende gezondheidszorg kan een 
indicatie geven van de lotale koslen-effecliviteit van de voorzieningen voor een 
bepaalde ziektecategorie of specifieke deelsectoren van de z.org. 
Het belang van indirecte niet medische kosten in economische evaluaties 
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is op dit moment niet onomstreden. In dit proefscbrift worden indirecte kosten 
gedefmieerd als de gevolgen van ziekteverzuim, arbeidsongeschiktheid en 
sterfte voor de produktie en de bijbehorende kosten op maatschappelijk niveau. 
Deze defmitie bevat geen waardering van het menselijk leven op zich, zeals 
toegepast in kosten-baten analyse. 
Omdat indirecte kosten de schaarste van goederen en diensten 
beinvloeden, dienen ze te worden geanalyseerd in economische evaluaties, 
maar de rarningen van indirecte kosten moeten zo vee! mogelijk de werkelijke 
economische gevolgen weerspiegelen. De frictiekostenmethode vonnt hiertoe 
een aanzet. Het basisidee van 'deze methode is dat de indirecte kosten bij 
ziekte afhangen van de periode die nodig is v~~r organisaties om het niveau 
van produktie en bijbehorende kosten te herstellen. Aangenomen wordt dat 
wanneer de werkIoosheid hoger is dan het niveau van de frictiewerkIoosheid, 
na een zekere periode, zieke werknemers in het algemeen knnnen worden 
vervangen. De indirecte kosten blijven beperkt tot deze periode van 
aanpassing: de frictieperiode. 
V~~r Nederland zijn de korte termijn frictiekosten voor 1990 geschat op 
1.5 -2.5% van het netto nationaal inkomen, afhankelijk van de mate waarin 
kortdurend verzuim produktieverlies en kosten veroorzaakt. De macro-
economische gevolgen op middellange termijn van verzuim en incidentie van 
arbeidsongeschiktheid worden geschat op 0.8 % van het netto nationaal 
inkomen. De totale economische voordelen van een haalbare reductie van 
·ziekteverzuim (-2 procentpunten) en incidentie van arbeidsongeschiktheid (-
20 %) komen naar schatting uit op ongeveer 0.5 % van het netto nationaal 
inkomen. 
De precieze gevolgen van korte termijn verzuim v~~r produktie en 
kosten dienen in meer detail bestndeerd te worden op bedrijfs(tak)niveau. 
Hierbij zou speciaal gelet moeten worden op de mogelijkheid om werk uit te 
stellen en later in te halen, de omvang en aard van interne en externe 
arbeidsreserves en het effect van de afnemende meeropbrengsten van de 
individuele werknemer. 
De invloed van indirecte kosten op de resultaten van zorgvoorzieningen 
hangt vooral af van de mogelijke vertraging in het optreden van de 
gezondheidseffecten, het belang van (kortdurend) verzuim en de 
arbeidsparticipatie van de doelgroep. Voor baannoederhalskankerscreening is 
de invloed beperkt. Bij therapeutische voorzieningen die leiden tot afname van 
verzuim, zoals cimetidine voor maagzweren en thrombolitica voor myocard 
infarct, zijn de geraamde besparingen op de indirecte kosten aanzienlijk. 
164 
Appendices 165 
Appendix 4 
Definition and costs of 48 disease categories. in mln of Dutch guilders. 1988. 
Disease category ICD-code ICD-Chapter Costs Co", Totti 
men women on", 
Infective dis exc AIDS 001-139 exc 
042 175 195 370 
AIDS 042 23 17 41 
Stomach cancer 151 2 46 31 77 
Colo rectal cancer 153-154 2 91 113 203 
Lung cancer 162 2 174 35 210 
Breast cancer 174 2 162 162 
Prostate cancer 185 2 77 0 77 
Other malignant dis rest 140-208 2 357 453 809 
Benign cancers 210-139 + 173 2 74 199 274 
Diabetes 250 3 153 289 442 
Other endocrin dis 240-279 exc 250 3 60 165 225 
Blood diseases 280-289 4 53 85 138 
Dementia 290 5 297 1058 1356 
Other psychiatric dis 291-316 5 1748 2059 3807 
Mental retardation 317-319 5 1562 1178 2739 
Eye diseases 360-379 6 172 242 415 
Ear diseases 380-389 6 162 153 314 
Other neurological dis 320-359 6 327 473 800 
Hypertension 401-405 7 52 9! 143 
Ischemis heart dis 410-414 7 538 278 815 
Stroke 430-438 7 443 706 1150 
Congestive heart failure 428-429 7 179 250 429 
Other card.lovascular dis rest 390459 7 477 444 921 
Acute lung diseases 460-466, 480-487 S 210 195 404 
Chromc lung dis 490-496 8 270 181 451 
Other lung dis rest 460-519 8 212 165 377 
Dental diseases 520-529 9 783 942 1724 
Duodenumulcer 531-534 9 48 46 94 
Appendicitis 540-543 9 59 67 126 
Hernias 550-553 9 160 53 213 
Biliary and liver dis 570-576 9 104 195 299 
Other dis of the gut 555-569 9 169 243 412 
Other gamo-inteSt dis rest 520-579 9 85 84 169 
N efritis/nefrosis 580-589 10 49 55 104 
Other renalJurinary dis 590-599 10 164 223 387 
Dis male genital organs 600-608 10 174 0 174 
Dis female genital organs 610-627. 629 10 0 375 375 
Fertility problems 628 10 3 18 21 
Pregnancy and delivery 630-676 11 80 1310 1389 
Dennatologic dis 680-709 12 148 223 371 
Locomotor dis exc RA 710-739 ex 714 13 1020 1587 2607 
Reumatoide artritis 714 13 37 122 159 
Congenital anomalies 740-759 14 97 76 173 
Perinatal diseases 760-779 15 191 163 354 
Symptoms 780-799 16 710 1016 1726 
Traffic accidents ESOO-E848 17 204 138 343 
Other accidents E850-E869. 
E880-E929 17 376 659 1035 
Other external causes of ES70-ES79. 
injury and death E930-E999 17 141 189 329 
Not assigned to specific diseases 4389 5629 10017 
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Appendix 5.1 
Estimation of cancer survival 
1. The survival was modelled by using the lognonnal distribution: 
f( t) = __ l_exp [ - (lnt-fl) 2] 
t..j21t (J 2 cr2 
Where t is the time after diagnosis. p. the median survival and qz the variance. 
We used a discrete approximation with a time step of one month. The proportion of 
survivors at any time ti after diagnosis to is then given by: 
where Mop is the proportion dying in hospital after fIrst admission and c is the fraction 
cured. 
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Appendix 5.2 
Average costs per patient by cancer type, phase, age and sex, x 1,000 Dutch guilders, 1988. 
Stomach cancer 
Men Women 
Age Incidence phase Last year of life Incidence phase Last year of life 
25-44 40 37 37 32 
45-49 33 30 33 27 
50-54 31 27 31 25 
55-59 32 25 34 24 
60-64 30 25 34 26 
65-{;9 30 24 32 23 
70-74 26 23 30 25 
75-79 23 21 32 29 
80-84 20 19 25 24 
85+ 15 15 14 15 
The costs during the intermediate phase are dfl 514 per patient per year. 
Colorectal cancer 
Men Women 
Age Incidence phase Last year of life Incidence phase Last year of life 
25-44 27 23 33 21 
45-49 26 23 29 23 
50-54 26 20 29 22 
55-59 27 20 28 22 
60-64 26 23 30 26 
65-69 29 22 34 26 
70-74 28 21 34 30 
75-79 25 23 34 29 
80-84 23 19 30 25 
85+ 14 12 21 18 
The costs during the intermediate phase are d:fl443 per patient per year. 
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Lung cancer 
Men Women 
Age Incidence phase Last year ofIife Incidence phase Last year of life 
25-44 27 27 38 32 
45-49 25 27 34 31 
50-54 25 27 34 33 
55-59 27 27 39 32 
60-64 25 28 37 39 
65-69 26 28 35 37 
70-74 23 24 34 36 
75-79 21 23 31 28 
80-84 15 17 23 21 
85+ 10 11 10 10 
The costs during the intennediate phase are dfl 536 per patient per year. 
Breast cancer Prostate cancer 
Women Men 
Age Incidence phase Last year of life Age Incidence phase Last year of life 
25-44 19 22 40-44 28 25 
45-49 22 24 45-49 23 25 
50-54 23 26 50-54 23 25 
55-59 23 25 55-59 22 24 
60-64 22 27 60-64 22 29 
65-69 22 25 65-69 23 28 
70-74 21 26 70-74 21 27 
75-79 21 27 75-79 20 28 
80-84 18 23 80-84 19 24 
85+ 11 15 85+ 11 13 
The costs during the intermediate phase for breast cancer (prostate cancer) are dfl 375 (435) 
per patient per year. 
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Other cancers 
Men Women 
Age Incidence phase Last year of life Incidence phase Last year of life 
0-4 55 51 54 47 
5-9 46 51 49 47 
10-14 38 45 35 35 
15-19 35 41 32 35 
20-24 33 41 33 35 
25-29 31 38 33 35 
30-34 31 38 34 35 
35-39 27 28 33 35 
40-44 27 28 32 35 
45-49 25 26 34 c 
50-54 23 24 32 36 
55-59 24 24 33 36 
60-64 22 25 34 38 
65-69 21 25 35 37 
70-74 19 23 32 39 
75-79 18 24 33 39 
80-84 15 20 31 34 
85+ 14 18 25 27 
The costs during the intermediate phase are dfl 488 per patient per year. 
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Appendix 8 
Average production value per employee per friction period, by age, sex and education level 
for the Netherlands 1990. in thousands of Dutch guilders. 
Men 
Education- > Basic Extended Intennediary Higher vocatio- University 
Age basic nal 
15-19 4.6 5.1 7.1 Not applicable Not applicable 
20-24 10.8 11.9 15.0 18.6 20.6 
25-29 13.3 15.9 20.3 23.5 26.3 
30-34 14.8 18.0 24.3 31.7 35.6 
35-39 14.4 17.9 27.9 34.7 56.9 
4044 15.2 18.7 29.3 41.6 65.9 
45-49 15.9 19.3 31.5 42.1 63.2 
50-54 15.5 18.6 32.2 44.1 58.8 
55-59 14.6 18.4 28.9 40.8 59.3 
60-64 13.0 15.2 26.8 36.6 53.3 
Women 
Education-> Basic Extended Intennediary Higher vocatio- University 
Age basic nal 
15-19 3.5 3.7 6.3 Not applicable Not applicable 
20-24 7.6 9.4 12.6 17.1 19.7 
25-29 9.1 11.2 15.6 20.1 23.6 
30-34 7.8 10.1 15.4 20.4 24.0 
35-39 8.3 10.5 17.1 22.1 32.8 
40-44 7.7 9.6 16.4 24.3 33.6 
45-49 7.8 10.2 17.8 26.5 38.0 
50-54 7.4 10.1 18.6 27.1 37.9 
55-59 6.7 9.0 16.8 24.6 33.5 
60-64 6.2 8.2 15.8 23.1 31.4 
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Average length of hospital stay and absence from work by type of treatment for cervical 
cancer; frequency of treatments by disease stage. the Netherlands. 
Type of Hospital Absence Frequency Frequency Frequency Frequency 
treatment stay in days stage stage invasive advanced 
in days eIN 1-2" CIN 3" cancer cancer 
Conserving a 14 0.94 0.25 a a 
treatments (outpatients) 
Exconisation 5 21 0.08 0.68 a a 
(clinical) 
Hysterectomy 13 50 a 0.11 0.2 a 
Radical hyste- 23 65 a a 0.6 a 
rectomy 
Radiotherapy. varying > 85 a a 0.2 
palliation etc. 
~ Sum of frequencies is greater than 1. due to exconisation as retreatment-procedure in case 
of conserving treatments as primary therapy. 
Sources: SIG (hospital length of stay) and expert opinion (absence duration). 
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